US5470974A
(en)
*
|
1985-03-15 |
1995-11-28 |
Neu-Gene Development Group |
Uncharged polynucleotide-binding polymers
|
US5521063A
(en)
*
|
1985-03-15 |
1996-05-28 |
Antivirals Inc. |
Polynucleotide reagent containing chiral subunits and methods of use
|
US5217866A
(en)
*
|
1985-03-15 |
1993-06-08 |
Anti-Gene Development Group |
Polynucleotide assay reagent and method
|
US5185444A
(en)
*
|
1985-03-15 |
1993-02-09 |
Anti-Gene Deveopment Group |
Uncharged morpolino-based polymers having phosphorous containing chiral intersubunit linkages
|
US5235033A
(en)
*
|
1985-03-15 |
1993-08-10 |
Anti-Gene Development Group |
Alpha-morpholino ribonucleoside derivatives and polymers thereof
|
US5506337A
(en)
*
|
1985-03-15 |
1996-04-09 |
Antivirals Inc. |
Morpholino-subunit combinatorial library and method
|
US5378841A
(en)
*
|
1989-12-20 |
1995-01-03 |
Antivirals Inc. |
Alpha-morpholino ribonucleoside derivatives and polymers thereof
|
US5955589A
(en)
*
|
1991-12-24 |
1999-09-21 |
Isis Pharmaceuticals Inc. |
Gapped 2' modified oligonucleotides
|
US5914396A
(en)
*
|
1990-01-11 |
1999-06-22 |
Isis Pharmaceuticals, Inc. |
2'-O-modified nucleosides and phosphoramidites
|
US5623065A
(en)
*
|
1990-08-13 |
1997-04-22 |
Isis Pharmaceuticals, Inc. |
Gapped 2' modified oligonucleotides
|
US5959096A
(en)
*
|
1992-03-16 |
1999-09-28 |
Isis Pharmaceuticals, Inc. |
Antisense oligonucleotides against human protein kinase C
|
US6753423B1
(en)
|
1990-01-11 |
2004-06-22 |
Isis Pharmaceuticals, Inc. |
Compositions and methods for enhanced biostability and altered biodistribution of oligonucleotides in mammals
|
US6399754B1
(en)
*
|
1991-12-24 |
2002-06-04 |
Isis Pharmaceuticals, Inc. |
Sugar modified oligonucleotides
|
US5514788A
(en)
*
|
1993-05-17 |
1996-05-07 |
Isis Pharmaceuticals, Inc. |
Oligonucleotide modulation of cell adhesion
|
US6339066B1
(en)
|
1990-01-11 |
2002-01-15 |
Isis Pharmaceuticals, Inc. |
Antisense oligonucleotides which have phosphorothioate linkages of high chiral purity and which modulate βI, βII, γ, δ, Ε, ζ and η isoforms of human protein kinase C
|
US20040142899A1
(en)
*
|
1990-01-11 |
2004-07-22 |
Isis Pharmaceuticals, Inc. |
Compositions and methods for enhanced biostability and altered biodistribution of oligonucleotides in mammals
|
US5591623A
(en)
*
|
1990-08-14 |
1997-01-07 |
Isis Pharmaceuticals, Inc. |
Oligonucleotide modulation of cell adhesion
|
US5514577A
(en)
*
|
1990-02-26 |
1996-05-07 |
Isis Pharmaceuticals, Inc. |
Oligonucleotide therapies for modulating the effects of herpes viruses
|
US5834607A
(en)
*
|
1990-07-27 |
1998-11-10 |
Isis Pharmaceuticals, Inc. |
Amines and methods of making and using the same
|
US5789573A
(en)
*
|
1990-08-14 |
1998-08-04 |
Isis Pharmaceuticals, Inc. |
Antisense inhibition of ICAM-1, E-selectin, and CMV IE1/IE2
|
US5442049A
(en)
*
|
1992-11-19 |
1995-08-15 |
Isis Pharmaceuticals, Inc. |
Oligonucleotides for modulating the effects of cytomegalovirus infections
|
US5595978A
(en)
*
|
1990-08-16 |
1997-01-21 |
Isis Pharmaceuticals, Inc. |
Composition and method for treatment of CMV retinites
|
US6153595A
(en)
*
|
1990-08-16 |
2000-11-28 |
Isis Pharmaceuticals Inc. |
Composition and method for treatment of CMV infections
|
US5965722A
(en)
*
|
1991-05-21 |
1999-10-12 |
Isis Pharmaceuticals, Inc. |
Antisense inhibition of ras gene with chimeric and alternating oligonucleotides
|
WO1994008003A1
(en)
*
|
1991-06-14 |
1994-04-14 |
Isis Pharmaceuticals, Inc. |
ANTISENSE OLIGONUCLEOTIDE INHIBITION OF THE ras GENE
|
US7015315B1
(en)
|
1991-12-24 |
2006-03-21 |
Isis Pharmaceuticals, Inc. |
Gapped oligonucleotides
|
US6414112B1
(en)
|
1991-05-24 |
2002-07-02 |
Ole Buchardt |
Peptide nucleic acids having 2,6-diaminopurine nucleobases
|
US6441130B1
(en)
|
1991-05-24 |
2002-08-27 |
Isis Pharmaceuticals, Inc. |
Linked peptide nucleic acids
|
US5719262A
(en)
*
|
1993-11-22 |
1998-02-17 |
Buchardt, Deceased; Ole |
Peptide nucleic acids having amino acid side chains
|
US5714331A
(en)
*
|
1991-05-24 |
1998-02-03 |
Buchardt, Deceased; Ole |
Peptide nucleic acids having enhanced binding affinity, sequence specificity and solubility
|
US6451968B1
(en)
*
|
1991-05-24 |
2002-09-17 |
Isis Pharmaceuticals, Inc. |
Peptide nucleic acids
|
US5766855A
(en)
*
|
1991-05-24 |
1998-06-16 |
Buchardt, Deceased; Ole |
Peptide nucleic acids having enhanced binding affinity and sequence specificity
|
DK51092D0
(da)
*
|
1991-05-24 |
1992-04-15 |
Ole Buchardt |
Oligonucleotid-analoge betegnet pna, monomere synthoner og fremgangsmaade til fremstilling deraf samt anvendelser deraf
|
US6713602B1
(en)
*
|
1991-05-24 |
2004-03-30 |
Ole Buchardt |
Synthetic procedures for peptide nucleic acids
|
EP0590082B1
(de)
*
|
1991-06-14 |
1999-10-27 |
Isis Pharmaceuticals, Inc. |
Antisense-oligonukleotid-inhibition des ras-gen
|
US5747253A
(en)
*
|
1991-08-23 |
1998-05-05 |
Isis Pharmaceuticals, Inc. |
Combinatorial oligomer immunoabsorbant screening assay for transcription factors and other biomolecule binding
|
US6335434B1
(en)
|
1998-06-16 |
2002-01-01 |
Isis Pharmaceuticals, Inc., |
Nucleosidic and non-nucleosidic folate conjugates
|
US8153602B1
(en)
|
1991-11-19 |
2012-04-10 |
Isis Pharmaceuticals, Inc. |
Composition and methods for the pulmonary delivery of nucleic acids
|
US6235887B1
(en)
|
1991-11-26 |
2001-05-22 |
Isis Pharmaceuticals, Inc. |
Enhanced triple-helix and double-helix formation directed by oligonucleotides containing modified pyrimidines
|
TW393513B
(en)
*
|
1991-11-26 |
2000-06-11 |
Isis Pharmaceuticals Inc |
Enhanced triple-helix and double-helix formation with oligomers containing modified pyrimidines
|
AU3250093A
(en)
|
1991-12-12 |
1993-07-19 |
Gilead Sciences, Inc. |
Nuclease stable and binding competent oligomers and methods for their use
|
US5359044A
(en)
*
|
1991-12-13 |
1994-10-25 |
Isis Pharmaceuticals |
Cyclobutyl oligonucleotide surrogates
|
US5856455A
(en)
*
|
1991-12-24 |
1999-01-05 |
Isis Pharmaceuticals, Inc. |
Gapped 2'-modified oligonucleotides
|
AU3249793A
(en)
*
|
1991-12-24 |
1993-07-28 |
Isis Pharmaceuticals, Inc. |
Compositions and methods for modulating beta -amyloid
|
US20060270624A1
(en)
*
|
1991-12-24 |
2006-11-30 |
Isis Pharmaceuticals, Inc. |
Gapped 2' modified oligonucleotides
|
EP0618925B2
(de)
*
|
1991-12-24 |
2012-04-18 |
Isis Pharmaceuticals, Inc. |
Antisense oligonukleotide
|
EP1310555A3
(de)
*
|
1992-03-16 |
2003-08-27 |
Isis Pharmaceuticals, Inc. |
Oligonukleotidemodulation von Proteinkinase C
|
US6117847A
(en)
*
|
1992-03-16 |
2000-09-12 |
Isis Pharmaceuticals, Inc. |
Oligonucleotides for enhanced modulation of protein kinase C expression
|
US5885970A
(en)
*
|
1992-03-16 |
1999-03-23 |
Isis Pharmaceuticals, Inc. |
Antisense oligonucleotides against human protein kinase C
|
US5681747A
(en)
*
|
1992-03-16 |
1997-10-28 |
Isis Pharmaceuticals, Inc. |
Nucleic acid sequences encoding protein kinase C and antisense inhibition of expression thereof
|
US6537973B1
(en)
|
1992-03-16 |
2003-03-25 |
Isis Pharmaceuticals, Inc. |
Oligonucleotide inhibition of protein kinase C
|
US5882927A
(en)
*
|
1992-03-16 |
1999-03-16 |
Isis Pharmaceuticals, Inc. |
Oligonucleotide inhibition of protein kinase C
|
US5948898A
(en)
*
|
1992-03-16 |
1999-09-07 |
Isis Pharmaceuticals, Inc. |
Methoxyethoxy oligonucleotides for modulation of protein kinase C expression
|
US6153599A
(en)
*
|
1992-03-16 |
2000-11-28 |
Isis Pharmaceuticals, Inc. |
Methoxyethoxy oligonucleotides for modulation of protein kinase C expression
|
US5922686A
(en)
*
|
1992-03-16 |
1999-07-13 |
Isis Pharmaceuticals, Inc. |
Oligonucleotide modulation of protein kinase C
|
US5916807A
(en)
*
|
1992-03-16 |
1999-06-29 |
Isis Pharmaceuticals, Inc. |
Antisense oligonucleotides against human protein kinase C
|
DE69322266T2
(de)
*
|
1992-04-03 |
1999-06-02 |
Perkin Elmer Corp |
Proben zusammensetzung und verfahren
|
US5643780A
(en)
*
|
1992-04-03 |
1997-07-01 |
Isis Pharmaceuticals, Inc. |
Compositions and methods for modulating RNA activity through modification of the 5' cap structure of RNA
|
US5434257A
(en)
*
|
1992-06-01 |
1995-07-18 |
Gilead Sciences, Inc. |
Binding compentent oligomers containing unsaturated 3',5' and 2',5' linkages
|
US5817781A
(en)
|
1992-06-01 |
1998-10-06 |
Gilead Sciences, Inc. |
Modified internucleoside linkages (II)
|
WO1994002637A1
(en)
*
|
1992-07-20 |
1994-02-03 |
Isis Pharmaceuticals, Inc. |
Pseudo-half-knot rna formation by hybridization of antisense oligonucleotides to target rna's secondary structure
|
US6391542B1
(en)
|
1992-09-10 |
2002-05-21 |
Isis Pharmaceuticals, Inc. |
Compositions and methods for treatment of Hepatitis C virus-associated diseases
|
US6995146B2
(en)
|
1992-09-10 |
2006-02-07 |
Isis Pharmaceuticals, Inc. |
Compositions and methods for treatment of hepatitis C virus-associated diseases
|
US6174868B1
(en)
|
1992-09-10 |
2001-01-16 |
Isis Pharmaceuticals, Inc. |
Compositions and methods for treatment of hepatitis C virus-associated diseases
|
EP0662157B1
(de)
*
|
1992-09-10 |
2001-06-20 |
Isis Pharmaceuticals, Inc. |
ZUSAMMENSETZUNGEN UND VERFAHREN FüR DIE BEHANDLUNG VON MIT HEPATITIS C VIREN ASSOZIIERTEN KRANKHEITEN
|
US6423489B1
(en)
|
1992-09-10 |
2002-07-23 |
Isis Pharmaceuticals, Inc. |
Compositions and methods for treatment of Hepatitis C virus-associated diseases
|
US20040049021A1
(en)
*
|
1992-09-10 |
2004-03-11 |
Anderson Kevin P. |
Compositions and mehtods for treatment of Hepatitis C virus-associated diseases
|
US6433159B1
(en)
|
1992-09-10 |
2002-08-13 |
Isis Pharmaceuticals, Inc. |
Compositions and methods for treatment of Hepatitis C virus associated diseases
|
US6235886B1
(en)
|
1993-09-03 |
2001-05-22 |
Isis Pharmaceuticals, Inc. |
Methods of synthesis and use
|
WO1994006815A1
(en)
*
|
1992-09-11 |
1994-03-31 |
Isis Pharmaceuticals, Inc. |
Oligonucleotide and nucleotide amine analogs, methods of synthesis and use
|
IL107150A0
(en)
*
|
1992-09-29 |
1993-12-28 |
Isis Pharmaceuticals Inc |
Oligonucleotides having a conserved g4 core sequence
|
US6784290B1
(en)
|
1992-10-05 |
2004-08-31 |
Isis Pharmaceuticals, Inc. |
Antisense oligonucleotide inhibition of ras
|
US5872242A
(en)
*
|
1992-10-05 |
1999-02-16 |
Isis Pharmaceuticals, Inc. |
Antisense oligonucleotide inhibition of ras
|
JP2739769B2
(ja)
*
|
1992-10-05 |
1998-04-15 |
アイシス・ファーマシューティカルス・インコーポレーテッド |
ras遺伝子のアンチセンスオリゴヌクレオチドによる阻害
|
US20030013670A1
(en)
*
|
1992-10-05 |
2003-01-16 |
Monia Brett P. |
Antisense oligonucleotide inhibition of ras
|
CA2170869C
(en)
|
1993-09-03 |
1999-09-14 |
Phillip Dan Cook |
Amine-derivatized nucleosides and oligonucleosides
|
US5510239A
(en)
*
|
1993-10-18 |
1996-04-23 |
Isis Pharmaceuticals, Inc. |
Oligonucleotide modulation of multidrug resistance-associated protein
|
US5801154A
(en)
*
|
1993-10-18 |
1998-09-01 |
Isis Pharmaceuticals, Inc. |
Antisense oligonucleotide modulation of multidrug resistance-associated protein
|
US6399376B1
(en)
|
1993-11-05 |
2002-06-04 |
Isis Pharmaceuticals, Inc. |
Modulation of vascular cell adhesive molecule expression through oligonucleotide interactions
|
US6710164B1
(en)
|
1993-11-22 |
2004-03-23 |
Peter E. Nielsen |
Peptide nucleic acids having enhanced binding affinity, sequence specificity and solubility
|
US20030119769A1
(en)
*
|
1994-05-31 |
2003-06-26 |
Monia Brett P |
Antisense oligonucleotide modulation of raf gene expression
|
US6391636B1
(en)
|
1994-05-31 |
2002-05-21 |
Isis Pharmaceuticals, Inc. |
Antisense oligonucleotide modulation of raf gene expression
|
US6410518B1
(en)
|
1994-05-31 |
2002-06-25 |
Isis Pharmaceuticals, Inc. |
Antisense oligonucleotide inhibition of raf gene expression
|
US5981731A
(en)
*
|
1994-05-31 |
1999-11-09 |
Isis Pharmaceuticals, Inc. |
Antisense oligonucleotide modulation of B-raf gene expression
|
US6090626A
(en)
*
|
1994-05-31 |
2000-07-18 |
Isis Pharmaceuticals Inc. |
Antisense oligonucleotide modulation of raf gene expression
|
US5563255A
(en)
*
|
1994-05-31 |
1996-10-08 |
Isis Pharmaceuticals, Inc. |
Antisense oligonucleotide modulation of raf gene expression
|
US20060142236A1
(en)
*
|
1994-05-31 |
2006-06-29 |
Isis Pharmaceuticals, Inc. |
Antisense oligonucleotide modulation of raf gene expression
|
KR100211178B1
(ko)
*
|
1994-05-31 |
1999-07-15 |
파샬 비. 린네 |
라프유전자 발현의 안티센스 올리고뉴클레오티드 조절
|
US5656612A
(en)
*
|
1994-05-31 |
1997-08-12 |
Isis Pharmaceuticals, Inc. |
Antisense oligonucleotide modulation of raf gene expression
|
WO1996003417A1
(en)
*
|
1994-07-25 |
1996-02-08 |
Hybridon, Inc. |
Improved methods of detritylation for oligonucleotide synthesis
|
US5665873A
(en)
*
|
1995-02-09 |
1997-09-09 |
Dana Farber Cancer Institute |
Glucocorticoid response elements
|
US6420549B1
(en)
|
1995-06-06 |
2002-07-16 |
Isis Pharmaceuticals, Inc. |
Oligonucleotide analogs having modified dimers
|
EP0843555B1
(de)
*
|
1995-08-01 |
2003-08-27 |
Isis Pharmaceuticals, Inc. |
Liposomale oligonukleotidzusammensetzungen
|
US5854033A
(en)
|
1995-11-21 |
1998-12-29 |
Yale University |
Rolling circle replication reporter systems
|
US7244622B2
(en)
*
|
1996-04-03 |
2007-07-17 |
Applera Corporation |
Device and method for multiple analyte detection
|
US20070275921A1
(en)
*
|
1996-06-06 |
2007-11-29 |
Isis Pharmaceuticals, Inc. |
Oligomeric Compounds That Facilitate Risc Loading
|
US20030044941A1
(en)
|
1996-06-06 |
2003-03-06 |
Crooke Stanley T. |
Human RNase III and compositions and uses thereof
|
US9096636B2
(en)
*
|
1996-06-06 |
2015-08-04 |
Isis Pharmaceuticals, Inc. |
Chimeric oligomeric compounds and their use in gene modulation
|
US20050118605A9
(en)
*
|
1996-06-06 |
2005-06-02 |
Baker Brenda F. |
Oligomeric compounds having modified bases for binding to adenine and guanine and their use in gene modulation
|
US5898031A
(en)
|
1996-06-06 |
1999-04-27 |
Isis Pharmaceuticals, Inc. |
Oligoribonucleotides for cleaving RNA
|
US20040266706A1
(en)
*
|
2002-11-05 |
2004-12-30 |
Muthiah Manoharan |
Cross-linked oligomeric compounds and their use in gene modulation
|
US20050032068A1
(en)
*
|
2002-11-05 |
2005-02-10 |
Prakash Thazha P. |
Sugar and backbone-surrogate-containing oligomeric compounds and compositions for use in gene modulation
|
US20040171030A1
(en)
*
|
1996-06-06 |
2004-09-02 |
Baker Brenda F. |
Oligomeric compounds having modified bases for binding to cytosine and uracil or thymine and their use in gene modulation
|
US7812149B2
(en)
|
1996-06-06 |
2010-10-12 |
Isis Pharmaceuticals, Inc. |
2′-Fluoro substituted oligomeric compounds and compositions for use in gene modulations
|
US6593305B1
(en)
*
|
1996-08-02 |
2003-07-15 |
Genesense Technologies Inc. |
Antitumor antisense sequences directed against R1 and R2 components of ribonucleotide reductase
|
US5948681A
(en)
*
|
1996-08-14 |
1999-09-07 |
Children's Hospital Of Philadelphia |
Non-viral vehicles for use in gene transfer
|
US6111085A
(en)
|
1996-09-13 |
2000-08-29 |
Isis Pharmaceuticals, Inc. |
Carbamate-derivatized nucleosides and oligonucleosides
|
WO1998014592A2
(en)
|
1996-10-01 |
1998-04-09 |
Geron Corporation |
Telomerase reverse transcriptase
|
US6001991A
(en)
*
|
1996-10-04 |
1999-12-14 |
Isis Pharmaceuticals Inc. |
Antisense oligonucleotide modulation of MDR P-glycoprotein gene expression
|
US5919638A
(en)
*
|
1996-10-08 |
1999-07-06 |
Abbott Laboratories |
Reagents and methods useful for detecting prostate tumors
|
US20050202499A1
(en)
*
|
1996-10-31 |
2005-09-15 |
Billing-Medel Patricia A. |
Reagents and methods useful for detecting diseases of the breast
|
US20030165971A1
(en)
*
|
1996-10-31 |
2003-09-04 |
Billing-Medel Patricia A. |
Reagents and methods useful for detecting diseases of the breast
|
US6319906B1
(en)
|
1996-12-31 |
2001-11-20 |
Isis Pharmaceuticals |
Oligonucleotide compositions and methods for the modulation of the expression of B7 protein
|
US20040023917A1
(en)
*
|
1996-12-31 |
2004-02-05 |
Bennett C. Frank |
Oligonucleotide compositions and methods for the modulation of the expression of B7 protein
|
US7235653B2
(en)
*
|
1996-12-31 |
2007-06-26 |
Isis Pharmaceuticals, Inc. |
Oligonucleotide compositions and methods for the modulation of the expression of B7 protein
|
US6077833A
(en)
*
|
1996-12-31 |
2000-06-20 |
Isis Pharmaceuticals, Inc. |
Oligonucleotide compositions and methods for the modulation of the expression of B7 protein
|
WO1998032467A2
(en)
*
|
1997-01-24 |
1998-07-30 |
Antivirals, Inc. |
Method and conjugate for treating h. pylori infection
|
US6576752B1
(en)
|
1997-02-14 |
2003-06-10 |
Isis Pharmaceuticals, Inc. |
Aminooxy functionalized oligomers
|
US6127533A
(en)
*
|
1997-02-14 |
2000-10-03 |
Isis Pharmaceuticals, Inc. |
2'-O-aminooxy-modified oligonucleotides
|
US6172209B1
(en)
|
1997-02-14 |
2001-01-09 |
Isis Pharmaceuticals Inc. |
Aminooxy-modified oligonucleotides and methods for making same
|
US20020137904A1
(en)
*
|
1998-03-27 |
2002-09-26 |
Patricia A. Billing-Medel |
Reagents and methods useful for detecting diseases of the gastrointestinal tract
|
US6716625B1
(en)
|
1997-04-16 |
2004-04-06 |
Claude Selitrennikoff |
Histidine kinases of Aspergillus and other fungal species, related compositions, and methods of use
|
US20050208567A1
(en)
*
|
1997-04-25 |
2005-09-22 |
Billing-Medel Patricia A |
Reagents and methods useful for detecting diseases of the prostate
|
US6528271B1
(en)
|
1997-06-05 |
2003-03-04 |
Duke University |
Inhibition of βarrestin mediated effects prolongs and potentiates opioid receptor-mediated analgesia
|
US7541151B2
(en)
|
1997-06-05 |
2009-06-02 |
Duke University |
Single-cell biosensor for the measurement of GPCR ligands in a test sample
|
US5891646A
(en)
*
|
1997-06-05 |
1999-04-06 |
Duke University |
Methods of assaying receptor activity and constructs useful in such methods
|
US5962665A
(en)
|
1997-06-16 |
1999-10-05 |
Abbott Laboratories |
Nucleic acid primers and probes for detecting HIV-1 and HIV-2
|
JP2002510319A
(ja)
|
1997-07-01 |
2002-04-02 |
アイシス・ファーマシューティカルス・インコーポレーテッド |
オリゴヌクレオチドの消化管を介したデリバリーのための組成物及び方法
|
AU8280798A
(en)
|
1997-07-03 |
1999-01-25 |
Thomas Jefferson University |
An improved method for design and selection of efficacious antisense oligonucleotides
|
US7105496B2
(en)
|
1998-07-23 |
2006-09-12 |
Northwestern University |
Methods and compositions for inhibiting angiogenesis
|
US6797691B1
(en)
*
|
1997-07-23 |
2004-09-28 |
Northwestern University |
Methods and compositions for inhibiting angiogenesis
|
US20070149472A1
(en)
*
|
1997-08-13 |
2007-06-28 |
Mckay Robert |
Antisense oligonucleotide compositions and methods for the modulation of jnk proteins
|
US6133246A
(en)
*
|
1997-08-13 |
2000-10-17 |
Isis Pharmaceuticals Inc. |
Antisense oligonucleotide compositions and methods for the modulation of JNK proteins
|
US5877309A
(en)
|
1997-08-13 |
1999-03-02 |
Isis Pharmaceuticals, Inc. |
Antisense oligonucleotides against JNK
|
US6383808B1
(en)
|
2000-09-11 |
2002-05-07 |
Isis Pharmaceuticals, Inc. |
Antisense inhibition of clusterin expression
|
US6809193B2
(en)
|
1997-08-13 |
2004-10-26 |
Isis Pharmaceuticals, Inc. |
Antisense oligonucleotide compositions and methods for the modulation of JNK proteins
|
US7252950B1
(en)
|
1997-09-04 |
2007-08-07 |
The Regents Of The University Of California |
Assays for detecting modulators of cytoskeletal function
|
US7115884B1
(en)
|
1997-10-06 |
2006-10-03 |
Trustees Of Tufts College |
Self-encoding fiber optic sensor
|
US20040171564A1
(en)
*
|
1997-11-20 |
2004-09-02 |
Honkanen Richard E. |
Antisense oligonucleotide modulation of human serine/threonine protein phosphatase gene expression
|
US5948902A
(en)
|
1997-11-20 |
1999-09-07 |
South Alabama Medical Science Foundation |
Antisense oligonucleotides to human serine/threonine protein phosphatase genes
|
JP2002500190A
(ja)
|
1998-01-08 |
2002-01-08 |
ザ リージェンツ オブ ザ ユニバーシティ オブ カリフォルニア |
海洋海綿から誘導されるキネシンモーターモジュレーター
|
US7189703B2
(en)
*
|
1998-01-09 |
2007-03-13 |
Intracell, Llc |
Treatment and diagnosis of alzheimer's disease
|
US6764830B1
(en)
|
1998-01-23 |
2004-07-20 |
The Regents Of The University Of California |
Thermomyces lanuginosus kinesin motor protein and methods of screening for modulators of kinesin proteins
|
US6326479B1
(en)
|
1998-01-27 |
2001-12-04 |
Boston Probes, Inc. |
Synthetic polymers and methods, kits or compositions for modulating the solubility of same
|
IL137177A0
(en)
|
1998-01-30 |
2001-07-24 |
Genesense Technologies Inc |
Oligonucleotide sequences complementary to thioredoxin or thioredoxin reductase genes and methods of using same to modulate cell growth
|
US5968748A
(en)
*
|
1998-03-26 |
1999-10-19 |
Isis Pharmaceuticals, Inc. |
Antisense oligonucleotide modulation of human HER-2 expression
|
US7321828B2
(en)
|
1998-04-13 |
2008-01-22 |
Isis Pharmaceuticals, Inc. |
System of components for preparing oligonucleotides
|
US20040186071A1
(en)
|
1998-04-13 |
2004-09-23 |
Bennett C. Frank |
Antisense modulation of CD40 expression
|
US6417169B1
(en)
|
1998-04-23 |
2002-07-09 |
Genesense Technologies Inc. |
Insulin-like growth factor II antisense oligonucleotide sequences and methods of using same to inhibit cell growth
|
WO1999060167A1
(en)
|
1998-05-21 |
1999-11-25 |
Isis Pharmaceuticals, Inc. |
Compositions and methods for topical delivery of oligonucleotides
|
EP1469009A2
(de)
|
1998-05-21 |
2004-10-20 |
Isis Parmaceuticals, Inc. |
Zusammensetzungen und Verfahren für nicht-parenterale Verabreichung von Oligonukleotiden
|
US6586192B1
(en)
|
1998-05-29 |
2003-07-01 |
Thomas Jefferson University |
Compositions and methods for use in affecting hematopoietic stem cell populations in mammals
|
EP2045334A1
(de)
|
1998-06-24 |
2009-04-08 |
Illumina, Inc. |
Dekodierung von Arraysensoren mit Mikrosphären
|
US6867294B1
(en)
*
|
1998-07-14 |
2005-03-15 |
Isis Pharmaceuticals, Inc. |
Gapped oligomers having site specific chiral phosphorothioate internucleoside linkages
|
US6242589B1
(en)
|
1998-07-14 |
2001-06-05 |
Isis Pharmaceuticals, Inc. |
Phosphorothioate oligonucleotides having modified internucleoside linkages
|
WO2000006696A2
(en)
|
1998-07-30 |
2000-02-10 |
University Of South Florida |
Method for the modulation of function of transcription factors
|
US20040009938A1
(en)
*
|
1998-08-07 |
2004-01-15 |
Muthiah Manoharan |
Methods of enhancing renal uptake of oligonucleotides
|
US6673912B1
(en)
|
1998-08-07 |
2004-01-06 |
Isis Pharmaceuticals, Inc. |
2′-O-aminoethyloxyethyl-modified oligonucleotides
|
US6043352A
(en)
|
1998-08-07 |
2000-03-28 |
Isis Pharmaceuticals, Inc. |
2'-O-Dimethylaminoethyloxyethyl-modified oligonucleotides
|
US20020172678A1
(en)
|
2000-06-23 |
2002-11-21 |
Napoleone Ferrara |
EG-VEGF nucleic acids and polypeptides and methods of use
|
US6175004B1
(en)
|
1998-09-01 |
2001-01-16 |
Isis Pharmaceuticals, Inc. |
Process for the synthesis of oligonucleotides incorporating 2-aminoadenosine
|
US6225293B1
(en)
|
1998-09-02 |
2001-05-01 |
Isis Pharmaceuticals, Inc. |
Methods and compounds for tracking the biodistribution of macromolecule-carrier combinations
|
US6335194B1
(en)
|
1998-09-29 |
2002-01-01 |
Isis Pharmaceuticals, Inc. |
Antisense modulation of survivin expression
|
IL142094A0
(en)
|
1998-09-29 |
2002-03-10 |
Gamida Cell Ltd |
Methods of controlling proliferation and differentiation of stem and progenitor cells
|
US6077709A
(en)
|
1998-09-29 |
2000-06-20 |
Isis Pharmaceuticals Inc. |
Antisense modulation of Survivin expression
|
US6069243A
(en)
*
|
1998-10-06 |
2000-05-30 |
Isis Pharmaceuticals, Inc. |
Process for oligonucleotide synthesis
|
US6214986B1
(en)
*
|
1998-10-07 |
2001-04-10 |
Isis Pharmaceuticals, Inc. |
Antisense modulation of bcl-x expression
|
US6172216B1
(en)
*
|
1998-10-07 |
2001-01-09 |
Isis Pharmaceuticals Inc. |
Antisense modulation of BCL-X expression
|
US20020138856A1
(en)
*
|
1998-10-23 |
2002-09-26 |
Northwestern University |
Compositions and methods useful for treatment of depressive disorder based on an animal model
|
US6429027B1
(en)
|
1998-12-28 |
2002-08-06 |
Illumina, Inc. |
Composite arrays utilizing microspheres
|
US6300320B1
(en)
|
1999-01-05 |
2001-10-09 |
Isis Pharmaceuticals, Inc. |
Modulation of c-jun using inhibitors of protein kinase C
|
US7282489B2
(en)
*
|
2000-01-19 |
2007-10-16 |
The Children's Hospital Of Philadelphia |
Compositions and methods for performing reverse gene therapy
|
US6395029B1
(en)
|
1999-01-19 |
2002-05-28 |
The Children's Hospital Of Philadelphia |
Sustained delivery of polyionic bioactive agents
|
WO2000041732A1
(en)
|
1999-01-19 |
2000-07-20 |
The Children's Hospital Of Philadelphia |
Hydrogel compositions for controlled delivery of virus vectors and methods of use thereof
|
AU2732000A
(en)
|
1999-01-19 |
2000-08-01 |
Children's Hospital Of Philadelphia, The |
Reverse gene therapy
|
US6127124A
(en)
*
|
1999-01-20 |
2000-10-03 |
Isis Pharmaceuticals, Inc. |
Fluorescence based nuclease assay
|
US6365351B1
(en)
*
|
1999-01-29 |
2002-04-02 |
Avi Biopharma, Inc. |
Non-invasive method for detecting target RNA
|
US6121000A
(en)
*
|
1999-02-11 |
2000-09-19 |
Genesense Technologies, Inc. |
Antitumor antisense sequences directed against R1 and R2 components of ribonucleotide reductase
|
EP1163333B1
(de)
*
|
1999-03-18 |
2007-11-07 |
Queen Mary And Westfield College |
Inhibitoren der endothelin-1 synthese
|
US6235891B1
(en)
|
1999-03-31 |
2001-05-22 |
South Alabama Medical Science Foundation |
Glucocorticoid receptor agonist and decreased PP5
|
EP1165787A2
(de)
|
1999-03-31 |
2002-01-02 |
The University of North Carolina at Chapel Hill |
Cullin regulatoren roc1 und roc2, dafür kodierende dna, und methoden zur ihrer verwendug
|
US7098192B2
(en)
|
1999-04-08 |
2006-08-29 |
Isis Pharmaceuticals, Inc. |
Antisense oligonucleotide modulation of STAT3 expression
|
ATE413467T1
(de)
|
1999-04-20 |
2008-11-15 |
Illumina Inc |
Detektion von nukleinsäurereaktionen auf kügelchen-arrays
|
US20060275782A1
(en)
|
1999-04-20 |
2006-12-07 |
Illumina, Inc. |
Detection of nucleic acid reactions on bead arrays
|
US20030215821A1
(en)
*
|
1999-04-20 |
2003-11-20 |
Kevin Gunderson |
Detection of nucleic acid reactions on bead arrays
|
US6331618B1
(en)
|
1999-05-13 |
2001-12-18 |
Pe Corporation (Ny) |
Compositions of solvents and high concentrations of nucleic acid analogs
|
CA2374390A1
(en)
|
1999-05-20 |
2000-12-14 |
Illumina, Inc. |
Combinatorial decoding of random nucleic acid arrays
|
US8080380B2
(en)
*
|
1999-05-21 |
2011-12-20 |
Illumina, Inc. |
Use of microfluidic systems in the detection of target analytes using microsphere arrays
|
US8481268B2
(en)
|
1999-05-21 |
2013-07-09 |
Illumina, Inc. |
Use of microfluidic systems in the detection of target analytes using microsphere arrays
|
US7534605B2
(en)
*
|
1999-06-08 |
2009-05-19 |
Yissum Research Development Company Of The Hebrew University Of Jerusalem |
CD44 polypeptides, polynucleotides encoding same, antibodies directed thereagainst and method of using same for diagnosing and treating inflammatory diseases
|
US6656730B1
(en)
|
1999-06-15 |
2003-12-02 |
Isis Pharmaceuticals, Inc. |
Oligonucleotides conjugated to protein-binding drugs
|
US6593466B1
(en)
|
1999-07-07 |
2003-07-15 |
Isis Pharmaceuticals, Inc. |
Guanidinium functionalized nucleotides and precursors thereof
|
US6147200A
(en)
*
|
1999-08-19 |
2000-11-14 |
Isis Pharmaceuticals, Inc. |
2'-O-acetamido modified monomers and oligomers
|
US20030190644A1
(en)
|
1999-10-13 |
2003-10-09 |
Andreas Braun |
Methods for generating databases and databases for identifying polymorphic genetic markers
|
US20020165188A1
(en)
*
|
1999-10-14 |
2002-11-07 |
Meenhard Herlyn |
Methods for inhibition of tumorigenic properties of melanoma cells
|
EP1244667B1
(de)
*
|
1999-12-30 |
2006-04-05 |
K.U. Leuven Research & Development |
Cyclohexennukleinsäuren
|
US20020055479A1
(en)
|
2000-01-18 |
2002-05-09 |
Cowsert Lex M. |
Antisense modulation of PTP1B expression
|
US6261840B1
(en)
|
2000-01-18 |
2001-07-17 |
Isis Pharmaceuticals, Inc. |
Antisense modulation of PTP1B expression
|
US6559128B1
(en)
|
2000-01-21 |
2003-05-06 |
Northwestern University |
Inhibitors of G protein-mediated signaling, methods of making them, and uses thereof
|
EP1257668B1
(de)
|
2000-02-16 |
2008-10-29 |
Illumina, Inc. |
Parallele genotypisierung mehrerer patientenproben
|
US6846486B1
(en)
*
|
2000-02-24 |
2005-01-25 |
Advanced Biotherapy Concepts, Inc. |
Method of treating allergy by administering an anti-histamine antibody
|
WO2001074845A2
(en)
*
|
2000-03-31 |
2001-10-11 |
Aventis Pasteur Limited |
Immunogenic peptides derived from prostate-specific membrane antigen (psma) and uses thereof
|
EP1272526A4
(de)
|
2000-04-13 |
2004-10-13 |
Univ Rockefeller |
Verstärkung von antikörpervermittelten immunantworten
|
EP1274726B1
(de)
*
|
2000-04-13 |
2009-12-23 |
Thomas N. Wight |
Therapeutische zusammenfassungen und verfahren zur modulierung von v3, eine isoform von versican
|
KR20020097241A
(ko)
*
|
2000-05-04 |
2002-12-31 |
에이브이아이 바이오파마 인코포레이티드 |
스플라이스-영역 안티센스 조성물 및 방법
|
US6680172B1
(en)
|
2000-05-16 |
2004-01-20 |
Regents Of The University Of Michigan |
Treatments and markers for cancers of the central nervous system
|
US6656700B2
(en)
|
2000-05-26 |
2003-12-02 |
Amersham Plc |
Isoforms of human pregnancy-associated protein-E
|
US6686188B2
(en)
*
|
2000-05-26 |
2004-02-03 |
Amersham Plc |
Polynucleotide encoding a human myosin-like polypeptide expressed predominantly in heart and muscle
|
EP1313880A2
(de)
*
|
2000-05-30 |
2003-05-28 |
PE Corporation (NY) |
Methoden zur detektion gewünschter nukleinsäuren mittels kombinierter ligation und amplifizierung
|
US20060166227A1
(en)
*
|
2000-06-20 |
2006-07-27 |
Stephen Kingsmore |
Protein expression profiling
|
EP3020804A1
(de)
|
2000-07-06 |
2016-05-18 |
Sarepta Therapeutics, Inc. |
Umwandlung der wachstumsfaktor-beta (tgf-beta) blockierungsmittelbehandelten stammzellenzusammensetzung und verfahren
|
FR2811323B1
(fr)
*
|
2000-07-07 |
2006-10-06 |
Fuma Tech Gmbh |
Materiau hybride, utilisation dudit materiau hybride et procede de sa fabrication
|
US6958214B2
(en)
*
|
2000-07-10 |
2005-10-25 |
Sequenom, Inc. |
Polymorphic kinase anchor proteins and nucleic acids encoding the same
|
US8044259B2
(en)
|
2000-08-03 |
2011-10-25 |
The Regents Of The University Of Michigan |
Determining the capability of a test compound to affect solid tumor stem cells
|
US20080194022A1
(en)
*
|
2000-08-03 |
2008-08-14 |
Clarke Michael F |
Isolation and use of solid tumor stem cells
|
CN1274072C
(zh)
*
|
2000-08-03 |
2006-09-06 |
松下电器产业株式会社 |
无刷电机及其制造方法
|
US6984522B2
(en)
|
2000-08-03 |
2006-01-10 |
Regents Of The University Of Michigan |
Isolation and use of solid tumor stem cells
|
US8568766B2
(en)
|
2000-08-24 |
2013-10-29 |
Gattadahalli M. Anantharamaiah |
Peptides and peptide mimetics to treat pathologies associated with eye disease
|
CA2421043C
(en)
*
|
2000-08-30 |
2012-07-31 |
Avi Biopharma, Inc. |
Method for analysis of oligonucleotide analogs
|
AU2001290629A1
(en)
*
|
2000-09-07 |
2002-03-22 |
Boehringer Ingelheim International G.M.B.H |
Heat shock response and virus replication
|
US7179614B2
(en)
*
|
2000-09-14 |
2007-02-20 |
Mount Sinai School Of Medicine |
Screening methods to identify compounds that modulate type I phosphodiesterase (PDE) activity
|
EP1191097A1
(de)
*
|
2000-09-21 |
2002-03-27 |
Leids Universitair Medisch Centrum |
Induktion von "exon-skipping" in eukaryotischen Zellen
|
US20020115058A1
(en)
*
|
2000-09-22 |
2002-08-22 |
Pedersen Finn Skou |
Methods for diagnosis and treatment of diseases associated with altered expression of Pik3r1
|
US20020164576A1
(en)
*
|
2000-09-22 |
2002-11-07 |
Pedersen Finn Skou |
Methods for diagnosis and treatment of diseases associated with altered expression of Nrf2
|
US20030044803A1
(en)
*
|
2000-09-22 |
2003-03-06 |
Pedersen Finn Skou |
Methods for diagnosis and treatment of diseases associated with altered expression of JAK1
|
US20020123474A1
(en)
*
|
2000-10-04 |
2002-09-05 |
Shannon Mark E. |
Human GTP-Rho binding protein2
|
WO2002030465A2
(en)
|
2000-10-12 |
2002-04-18 |
University Of Rochester |
Compositions that inhibit proliferation of cancer cells
|
US7045283B2
(en)
|
2000-10-18 |
2006-05-16 |
The Regents Of The University Of California |
Methods of high-throughput screening for internalizing antibodies
|
EP1736760A3
(de)
|
2000-12-11 |
2008-06-18 |
President And Fellows Of Harvard College |
Nanosensoren
|
US7645441B2
(en)
*
|
2000-12-22 |
2010-01-12 |
Sagres Discovery Inc. |
Compositions and methods in cancer associated with altered expression of PRLR
|
US20030232334A1
(en)
*
|
2000-12-22 |
2003-12-18 |
Morris David W. |
Novel compositions and methods for cancer
|
US20030099963A1
(en)
*
|
2000-12-22 |
2003-05-29 |
Morris David W. |
Novel compositions and methods in cancer associated with altered expression of TBX21
|
US20030087252A1
(en)
*
|
2000-12-22 |
2003-05-08 |
Morris David W. |
Novel compositions and methods in cancer associated with altered expression of PRDM11
|
US20030165878A1
(en)
*
|
2000-12-22 |
2003-09-04 |
Morris David W. |
Novel compositions and methods in cancer associated with altered expression of MCM3AP
|
US7700274B2
(en)
*
|
2000-12-22 |
2010-04-20 |
Sagres Discovery, Inc. |
Compositions and methods in cancer associated with altered expression of KCNJ9
|
US7892730B2
(en)
*
|
2000-12-22 |
2011-02-22 |
Sagres Discovery, Inc. |
Compositions and methods for cancer
|
US7820447B2
(en)
|
2000-12-22 |
2010-10-26 |
Sagres Discovery Inc. |
Compositions and methods for cancer
|
US7767802B2
(en)
|
2001-01-09 |
2010-08-03 |
Alnylam Pharmaceuticals, Inc. |
Compositions and methods for inhibiting expression of anti-apoptotic genes
|
US7279324B2
(en)
*
|
2001-01-23 |
2007-10-09 |
Duke University |
Nucleic acid encoding G-protein coupled receptor with modified DRY motif
|
US20030036854A1
(en)
*
|
2001-02-06 |
2003-02-20 |
The Penn State Research Foundation |
Apparatus and method for designing proteins and protein libraries
|
US6573051B2
(en)
*
|
2001-03-09 |
2003-06-03 |
Molecular Staging, Inc. |
Open circle probes with intramolecular stem structures
|
US7208279B2
(en)
*
|
2001-03-14 |
2007-04-24 |
Caden Biosciences, Inc. |
Method for identifying inhibitors of G protein coupled receptor signaling
|
WO2002072790A2
(en)
|
2001-03-14 |
2002-09-19 |
Myriad Genetics, Inc |
Tsg101-gag interaction and use thereof
|
US7294472B2
(en)
*
|
2001-03-14 |
2007-11-13 |
Caden Biosciences |
Method for identifying modulators of G protein coupled receptor signaling
|
US7803982B2
(en)
|
2001-04-20 |
2010-09-28 |
The Mount Sinai School Of Medicine Of New York University |
T1R3 transgenic animals, cells and related methods
|
IL158488A0
(en)
*
|
2001-04-20 |
2004-05-12 |
Sinai School Medicine |
Tir3 a novel taste receptor
|
US20030224365A1
(en)
*
|
2001-04-24 |
2003-12-04 |
Wood Linda Susan |
Single nucleotide polymorphisms diagnostic for schizophrenia
|
EP1392272B1
(de)
|
2001-05-11 |
2014-08-06 |
Merrion Research III Limited |
Permeationsverbesserer
|
WO2003000113A2
(en)
|
2001-06-20 |
2003-01-03 |
Genentech, Inc. |
Compositions and methods for the diagnosis and treatment of tumor
|
US7803915B2
(en)
|
2001-06-20 |
2010-09-28 |
Genentech, Inc. |
Antibody compositions for the diagnosis and treatment of tumor
|
EP2270024B1
(de)
|
2001-06-21 |
2018-10-24 |
Ionis Pharmaceuticals, Inc. |
Antisense-Modulation von Superoxid-Dismutase 1, Expression in Lösung
|
EP1925672A1
(de)
|
2001-06-22 |
2008-05-28 |
Syngeta Participations AG |
Auf abiotischen Stress ansprechende Polynukleotide und Polypeptide
|
US20040241683A1
(en)
*
|
2001-07-06 |
2004-12-02 |
Ekker Stephen C |
Hsst and angiogenesis
|
US7563584B2
(en)
|
2001-07-10 |
2009-07-21 |
The Board Of Trustees Of The Leland Stanford Junior University |
Methods and compositions for detecting the activation state of multiple proteins in single cells
|
US7393656B2
(en)
*
|
2001-07-10 |
2008-07-01 |
The Board Of Trustees Of The Leland Stanford Junior University |
Methods and compositions for risk stratification
|
US7381535B2
(en)
|
2002-07-10 |
2008-06-03 |
The Board Of Trustees Of The Leland Stanford Junior |
Methods and compositions for detecting receptor-ligand interactions in single cells
|
EP1481076A4
(de)
|
2001-07-12 |
2005-05-11 |
Illumina Inc |
Multiplex-nukleinsäurereaktionen
|
US6964950B2
(en)
|
2001-07-25 |
2005-11-15 |
Isis Pharmaceuticals, Inc. |
Antisense modulation of C-reactive protein expression
|
US7425545B2
(en)
|
2001-07-25 |
2008-09-16 |
Isis Pharmaceuticals, Inc. |
Modulation of C-reactive protein expression
|
US20030096772A1
(en)
|
2001-07-30 |
2003-05-22 |
Crooke Rosanne M. |
Antisense modulation of acyl CoA cholesterol acyltransferase-2 expression
|
US7407943B2
(en)
|
2001-08-01 |
2008-08-05 |
Isis Pharmaceuticals, Inc. |
Antisense modulation of apolipoprotein B expression
|
US7229774B2
(en)
|
2001-08-02 |
2007-06-12 |
Regents Of The University Of Michigan |
Expression profile of prostate cancer
|
CA2455424A1
(en)
*
|
2001-08-07 |
2003-02-20 |
University Of Delaware |
Compositions and methods for the prevention and treatment of huntington's disease
|
US7227014B2
(en)
|
2001-08-07 |
2007-06-05 |
Isis Pharmaceuticals, Inc. |
Antisense modulation of apolipoprotein (a) expression
|
US20040096880A1
(en)
*
|
2001-08-07 |
2004-05-20 |
Kmiec Eric B. |
Compositions and methods for the treatment of diseases exhibiting protein misassembly and aggregation
|
DE60220804D1
(de)
*
|
2001-08-20 |
2007-08-02 |
Regenesis Bioremediation Produ |
Biosensor für kleinmolekulare analyten
|
WO2003020980A2
(en)
*
|
2001-08-28 |
2003-03-13 |
Pharmacia & Upjohn Company |
Single nucleotide polymorphisms diagnostic for schizophrenia
|
US20040115699A1
(en)
*
|
2001-08-28 |
2004-06-17 |
Kaytes Paul S. |
Single nucleotide polymorphisms diagnostic for schizophrenia
|
US6852491B2
(en)
|
2001-09-04 |
2005-02-08 |
Abbott Laboratories |
Amplification and detection reagents for HIV-1
|
EP1721977A3
(de)
|
2001-09-17 |
2008-10-15 |
PDL BioPharma, Inc. |
Verfahren zur Krebsdiagnose, Zusammensetzungen und Screening-verfahren für Krebsmodulatoren
|
US7205048B2
(en)
*
|
2001-09-17 |
2007-04-17 |
Invitrogen Corporation |
Functionalized fluorescent nanocrystal compositions and methods of making
|
US7214428B2
(en)
*
|
2001-09-17 |
2007-05-08 |
Invitrogen Corporation |
Highly luminescent functionalized semiconductor nanocrystals for biological and physical applications
|
EP2159044B1
(de)
|
2001-09-17 |
2012-05-16 |
Life Technologies Corporation |
Nanokristalle
|
JP2005536439A
(ja)
|
2001-09-18 |
2005-12-02 |
ジェネンテック・インコーポレーテッド |
腫瘍の診断及び治療のための組成物と方法
|
US20070098728A1
(en)
*
|
2001-09-24 |
2007-05-03 |
Pedersen Finn S |
Novel compositions and methods in cancer
|
WO2003029422A2
(en)
|
2001-10-01 |
2003-04-10 |
Mount Sinai School Of Medicine |
Noonan syndrome gene
|
NZ577565A
(en)
|
2001-10-09 |
2010-10-29 |
Isis Pharmaceuticals Inc |
Antisense modulation of insulin-like growth factor binding protein 5 expressions
|
US6750019B2
(en)
|
2001-10-09 |
2004-06-15 |
Isis Pharmaceuticals, Inc. |
Antisense modulation of insulin-like growth factor binding protein 5 expression
|
ES2516041T3
(es)
|
2001-10-10 |
2014-10-30 |
Ratiopharm Gmbh |
Remodelación y glicoconjugación de la hormona del crecimiento humano (hGH)
|
EP2305311A3
(de)
|
2001-10-10 |
2011-07-20 |
BioGeneriX AG |
Glykokonjugation von Peptiden
|
US8323903B2
(en)
*
|
2001-10-12 |
2012-12-04 |
Life Technologies Corporation |
Antibody complexes and methods for immunolabeling
|
US20050069962A1
(en)
|
2001-10-12 |
2005-03-31 |
Archer Robert M |
Antibody complexes and methods for immunolabeling
|
WO2003088808A2
(en)
|
2002-04-16 |
2003-10-30 |
Genentech, Inc. |
Compositions and methods for the diagnosis and treatment of tumor
|
US20040166490A1
(en)
*
|
2002-12-17 |
2004-08-26 |
Morris David W. |
Novel therapeutic targets in cancer
|
US20040126762A1
(en)
*
|
2002-12-17 |
2004-07-01 |
Morris David W. |
Novel compositions and methods in cancer
|
EP1436426A4
(de)
*
|
2001-10-24 |
2005-11-02 |
Singulex Inc |
Verfahren zum nachweis genetischer haplotypen durch wechselwirkung mit sonden
|
US20030224380A1
(en)
*
|
2001-10-25 |
2003-12-04 |
The General Hospital Corporation |
Genes and polymorphisms on chromosome 10 associated with Alzheimer's disease and other neurodegenerative diseases
|
AU2002364945A1
(en)
*
|
2001-10-25 |
2003-07-09 |
Neurogenetics, Inc. |
Genes and polymorphisms on chromosome 10 associated with alzheimer's disease and other neurodegenerative diseases
|
US20030170678A1
(en)
*
|
2001-10-25 |
2003-09-11 |
Neurogenetics, Inc. |
Genetic markers for Alzheimer's disease and methods using the same
|
WO2003038111A2
(en)
*
|
2001-10-26 |
2003-05-08 |
Genencor International, Inc. |
Phytase enzymes, nucleic acid sequences encoding phytase enzymes and vectors and host cells incorporating same
|
US7510831B2
(en)
*
|
2001-10-26 |
2009-03-31 |
Genencor International, Inc. |
Trichoderma reesei phytase enzymes, nucleic acids encoding such phytase enzymes, vectors and host cells incorporating same and methods of making and using same
|
WO2003042226A2
(en)
*
|
2001-11-09 |
2003-05-22 |
Pharmacia & Upjohn Company |
Single nucleotide polymorphisms in gh-1
|
US20040180344A1
(en)
*
|
2003-03-14 |
2004-09-16 |
Morris David W. |
Novel therapeutic targets in cancer
|
US20040197778A1
(en)
*
|
2002-12-26 |
2004-10-07 |
Sagres Discovery, Inc. |
Novel compositions and methods in cancer
|
US20060040262A1
(en)
*
|
2002-12-27 |
2006-02-23 |
Morris David W |
Novel compositions and methods in cancer
|
US6965025B2
(en)
|
2001-12-10 |
2005-11-15 |
Isis Pharmaceuticals, Inc. |
Antisense modulation of connective tissue growth factor expression
|
NZ556415A
(en)
|
2002-01-02 |
2009-02-28 |
Genentech Inc |
Compositions and methods for the diagnosis and treatment of glioma tumor
|
EP1953244A1
(de)
|
2002-01-09 |
2008-08-06 |
Nakamura, Yusuke |
Krebsprofile
|
IL152904A0
(en)
|
2002-01-24 |
2003-06-24 |
Gamida Cell Ltd |
Utilization of retinoid and vitamin d receptor antagonists for expansion of renewable stem cell populations
|
EP1465982A4
(de)
*
|
2002-01-25 |
2006-06-07 |
Gamida Cell Ltd |
Verfahren zur expansion von stamm- und vorläuferzellen und damit erhaltene expandierte zellpopulationen
|
US7553619B2
(en)
|
2002-02-08 |
2009-06-30 |
Qiagen Gmbh |
Detection method using dissociated rolling circle amplification
|
WO2003069333A1
(en)
*
|
2002-02-14 |
2003-08-21 |
Illumina, Inc. |
Automated information processing in randomly ordered arrays
|
US20030191075A1
(en)
*
|
2002-02-22 |
2003-10-09 |
Cook Phillip Dan |
Method of using modified oligonucleotides for hepatic delivery
|
DK1485477T3
(da)
|
2002-02-25 |
2009-08-10 |
Genentech Inc |
Hidtil ukendt type-1-cytokinreceptor GLM-R
|
US20030182669A1
(en)
*
|
2002-03-19 |
2003-09-25 |
Rockman Howard A. |
Phosphoinositide 3-kinase mediated inhibition of GPCRs
|
US20030180712A1
(en)
|
2002-03-20 |
2003-09-25 |
Biostratum Ab |
Inhibition of the beta3 subunit of L-type Ca2+ channels
|
WO2003080808A2
(en)
|
2002-03-21 |
2003-10-02 |
Sagres Discovery, Inc. |
Novel compositions and methods in cancer
|
US7332585B2
(en)
|
2002-04-05 |
2008-02-19 |
The Regents Of The California University |
Bispecific single chain Fv antibody molecules and methods of use thereof
|
US7026120B2
(en)
|
2002-04-15 |
2006-04-11 |
Abbott Laboratories |
Probes for detecting tumor cells
|
US7622117B2
(en)
*
|
2002-04-17 |
2009-11-24 |
Dynamis Therapeutics, Inc. |
3-deoxyglucosone and skin
|
US7297484B2
(en)
|
2002-04-26 |
2007-11-20 |
Idaho Technology |
Characterization of single stranded nucleic acids by melting analysis of secondary structure using double strand-specific nucleic acid dye
|
EP1499635B8
(de)
|
2002-05-02 |
2014-04-16 |
David Lovejoy |
Teneurin c-terminal assoziierte peptide und deren verwendungen
|
US7015317B2
(en)
*
|
2002-05-02 |
2006-03-21 |
Abbott Laboratories |
Polynucleotides for the detection and quantification of hepatitis B virus nucleic acids
|
AU2003228809A1
(en)
|
2002-05-03 |
2003-11-17 |
Sequenom, Inc. |
Kinase anchor protein muteins, peptides thereof, and related methods
|
US7351542B2
(en)
|
2002-05-20 |
2008-04-01 |
The Regents Of The University Of California |
Methods of modulating tubulin deacetylase activity
|
US7176181B2
(en)
*
|
2002-05-21 |
2007-02-13 |
Yeda Research And Development Co. Ltd. |
Compositions and methods of using galectin-8 as an inhibitor of tumor cell growth
|
US7199107B2
(en)
|
2002-05-23 |
2007-04-03 |
Isis Pharmaceuticals, Inc. |
Antisense modulation of kinesin-like 1 expression
|
CA2488048A1
(en)
|
2002-05-30 |
2003-12-11 |
Memorial Sloan-Kettering Cancer Center |
Kinase suppressor of ras inactivation for therapy of ras mediated tumorigenesis
|
US7290215B2
(en)
*
|
2002-06-03 |
2007-10-30 |
Microsoft Corporation |
Dynamic wizard interface system and method
|
WO2003106617A2
(en)
*
|
2002-06-12 |
2003-12-24 |
Tel Aviv Medical Center Research Development Fund |
Oligonucleotides antibodies and kits including same for treating prostate cancer and determining predisposition thereto
|
US20040092470A1
(en)
*
|
2002-06-18 |
2004-05-13 |
Leonard Sherry A. |
Dry powder oligonucleotide formualtion, preparation and its uses
|
EP2116604A1
(de)
|
2002-08-05 |
2009-11-11 |
University of Rochester |
Proteinumwandlungsdomäne / Deaminasechimäre Proteine, zugehörige Verbindungen und Verwendungen davon
|
ATE490309T1
(de)
*
|
2002-08-12 |
2010-12-15 |
Danisco Us Inc |
Mutante e. coli-appa-phytaseenzyme und natürliche varianten davon, solche phytaseenzyme codierende nukleinsäuren, diese enthaltende vektoren und wirtszellen und verfahren zur herstellung und verwendung davon
|
AU2003270582A1
(en)
*
|
2002-09-12 |
2004-04-30 |
Massachusetts Institute Of Technology |
Rb pahtway and chromatin remodeling genes that antagonize let-60 ras signaling
|
MXPA05002791A
(es)
|
2002-09-13 |
2005-12-05 |
Replicor Inc |
Oligonucleotidos antivirales complementarios sin secuencia.
|
AU2003288906C1
(en)
|
2002-09-20 |
2010-12-09 |
Yale University |
Riboswitches, methods for their use, and compositions for use with riboswitches.
|
AU2003278957A1
(en)
|
2002-09-26 |
2004-04-23 |
Amgen, Inc. |
Modulation of forkhead box o1a expression
|
US20040235005A1
(en)
*
|
2002-10-23 |
2004-11-25 |
Ernest Friedlander |
Methods and composition for detecting targets
|
AU2003295387A1
(en)
|
2002-11-05 |
2004-06-03 |
Isis Parmaceuticals, Inc. |
Modified oligonucleotides for use in rna interference
|
EP1560839A4
(de)
|
2002-11-05 |
2008-04-23 |
Isis Pharmaceuticals Inc |
Chimäre oligomere verbindungen und derenverwendung in der genmodulation
|
US9150605B2
(en)
*
|
2002-11-05 |
2015-10-06 |
Isis Pharmaceuticals, Inc. |
Compositions comprising alternating 2′-modified nucleosides for use in gene modulation
|
US9150606B2
(en)
*
|
2002-11-05 |
2015-10-06 |
Isis Pharmaceuticals, Inc. |
Compositions comprising alternating 2'-modified nucleosides for use in gene modulation
|
CA2504694C
(en)
*
|
2002-11-05 |
2013-10-01 |
Isis Pharmaceuticals, Inc. |
Polycyclic sugar surrogate-containing oligomeric compounds and compositions for use in gene modulation
|
US7807802B2
(en)
|
2002-11-12 |
2010-10-05 |
Abbott Lab |
Polynucleotides for the amplification and detection of Chlamydia trachomatis and Neisseria gonorrhoeae
|
CA2505801A1
(en)
|
2002-11-13 |
2004-05-27 |
Rosanne Crooke |
Antisense modulation of apolipoprotein b expression
|
ES2420914T3
(es)
|
2002-11-13 |
2013-08-27 |
Genzyme Corporation |
Modulación antisentido de la expresión de la apolipoproteína B
|
US20060009378A1
(en)
|
2002-11-14 |
2006-01-12 |
Itshak Golan |
Novel galectin sequences and compositions and methods utilizing same for treating or diagnosing arthritis and other chronic inflammatory diseases
|
JP4915980B2
(ja)
|
2002-11-15 |
2012-04-11 |
エムユーエスシー ファウンデーション フォー リサーチ デベロップメント |
補体レセプター2標的化補体調節因子
|
CA2506127C
(en)
|
2002-11-15 |
2013-07-09 |
Morphotek, Inc. |
Methods of generating high-production of antibodies from hybridomas created by in vitro immunization
|
AU2003298672A1
(en)
*
|
2002-11-19 |
2005-01-28 |
Singulex, Inc. |
Detection of target molecules through interaction with probes
|
ATE542423T1
(de)
|
2002-11-21 |
2012-02-15 |
Univ Utah Res Found |
Purinerge geruchsmodulation
|
US7144999B2
(en)
|
2002-11-23 |
2006-12-05 |
Isis Pharmaceuticals, Inc. |
Modulation of hypoxia-inducible factor 1 alpha expression
|
US20070042978A1
(en)
*
|
2002-12-19 |
2007-02-22 |
Jean-Philippe Girard |
Nf-hev compositions and methods of use
|
WO2004058987A2
(en)
|
2002-12-20 |
2004-07-15 |
Qiagen Gmbh |
Nucleic acid amplification
|
US9487823B2
(en)
|
2002-12-20 |
2016-11-08 |
Qiagen Gmbh |
Nucleic acid amplification
|
US6977153B2
(en)
*
|
2002-12-31 |
2005-12-20 |
Qiagen Gmbh |
Rolling circle amplification of RNA
|
JP4177123B2
(ja)
*
|
2003-01-10 |
2008-11-05 |
富士通株式会社 |
配線図形検証方法、プログラム及び装置
|
CA2513747C
(en)
|
2003-01-24 |
2017-03-07 |
University Of Utah |
Methods of predicting mortality risk by determining telomere length
|
US7468356B2
(en)
|
2003-02-11 |
2008-12-23 |
Antisense Therapeutics Ltd. |
Modulation of insulin like growth factor I receptor expression
|
US7002006B2
(en)
*
|
2003-02-12 |
2006-02-21 |
Isis Pharmaceuticals, Inc. |
Protection of nucleosides
|
US20040170982A1
(en)
|
2003-02-14 |
2004-09-02 |
Morris David W. |
Novel therapeutic targets in cancer
|
US7767387B2
(en)
*
|
2003-06-13 |
2010-08-03 |
Sagres Discovery, Inc. |
Therapeutic targets in cancer
|
CA2516138A1
(en)
|
2003-02-14 |
2004-09-02 |
Sagres Discovery, Inc. |
Therapeutic gpcr targets in cancer
|
US6943768B2
(en)
|
2003-02-21 |
2005-09-13 |
Xtellus Inc. |
Thermal control system for liquid crystal cell
|
WO2004076621A2
(en)
|
2003-02-27 |
2004-09-10 |
Yeda Research And Development Co. Ltd. |
Compositions of nucleic acids for treating and detecting influenza virus
|
US7803781B2
(en)
|
2003-02-28 |
2010-09-28 |
Isis Pharmaceuticals, Inc. |
Modulation of growth hormone receptor expression and insulin-like growth factor expression
|
US20040185559A1
(en)
|
2003-03-21 |
2004-09-23 |
Isis Pharmaceuticals Inc. |
Modulation of diacylglycerol acyltransferase 1 expression
|
WO2004083432A1
(en)
*
|
2003-03-21 |
2004-09-30 |
Academisch Ziekenhuis Leiden |
Modulation of exon recognition in pre-mrna by interfering with the secondary rna structure
|
US8043834B2
(en)
|
2003-03-31 |
2011-10-25 |
Qiagen Gmbh |
Universal reagents for rolling circle amplification and methods of use
|
WO2004096124A2
(en)
|
2003-04-01 |
2004-11-11 |
Genentech, Inc. |
Compositions and methods for the diagnosis and treatment of tumor
|
MXPA05010773A
(es)
|
2003-04-09 |
2005-12-12 |
Neose Technologies Inc |
Metodos de glicopegilacion y proteinas/peptidos producidos por los metodos.
|
US20050043510A1
(en)
*
|
2003-04-10 |
2005-02-24 |
Moeckli Randolph A. |
Affinity purification system using troponin molecules as affinity ligands
|
US7598227B2
(en)
|
2003-04-16 |
2009-10-06 |
Isis Pharmaceuticals Inc. |
Modulation of apolipoprotein C-III expression
|
US7399853B2
(en)
|
2003-04-28 |
2008-07-15 |
Isis Pharmaceuticals |
Modulation of glucagon receptor expression
|
US20040219533A1
(en)
*
|
2003-04-29 |
2004-11-04 |
Jim Davis |
Biological bar code
|
WO2004097017A2
(en)
|
2003-04-29 |
2004-11-11 |
Avi Biopharma, Inc. |
Compositions for enhancing transport and antisense efficacy of nucleic acid analog into cells
|
US7709610B2
(en)
|
2003-05-08 |
2010-05-04 |
Facet Biotech Corporation |
Therapeutic use of anti-CS1 antibodies
|
US20050025763A1
(en)
|
2003-05-08 |
2005-02-03 |
Protein Design Laboratories, Inc. |
Therapeutic use of anti-CS1 antibodies
|
WO2004101072A1
(en)
*
|
2003-05-16 |
2004-11-25 |
Universite Laval |
Cns chloride modulation and uses thereof
|
US7897582B2
(en)
*
|
2003-05-23 |
2011-03-01 |
Isis Pharmaceuticals, Inc. |
Oligonucleotide compositions and methods for the modulation of the expression of B7 protein
|
US20060286545A1
(en)
*
|
2003-05-23 |
2006-12-21 |
Mount Sinai School Of Medicine Of New York University |
Viral vectors with improved properties
|
US7960355B2
(en)
*
|
2003-05-23 |
2011-06-14 |
Isis Pharmaceuticals, Inc. |
Compositions and methods for the modulation of the expression of B7 protein
|
EP1660512A4
(de)
*
|
2003-06-02 |
2009-12-23 |
Isis Pharmaceuticals Inc |
Oligonucleotid-synthese mit alternativen lösungsmitteln
|
BRPI0410886A
(pt)
|
2003-06-03 |
2006-07-04 |
Isis Pharmaceuticals Inc |
composto de filamento duplo, composição farmacêutica, sal farmaceuticamente aceitável, métodos de modificação do ácido nucleico que codifica a survivina humana, de inibição da expressão da suvivina em células ou tecidos, e de tratamento de uma condição associada com a expressão ou superexpressão da suvivina, e, oligonucleotìdeo de rnai de filamento único
|
US20050239089A1
(en)
*
|
2003-06-06 |
2005-10-27 |
Johnson Martin D |
Mobility cassettes
|
KR20060031809A
(ko)
|
2003-06-09 |
2006-04-13 |
더 리젠츠 오브 더 유니버시티 오브 미시간 |
암 치료 및 진단용 조성물 및 방법
|
DK3604537T3
(da)
|
2003-06-13 |
2022-02-28 |
Alnylam Europe Ag |
Dobbeltstrenget ribonukleinsyre med forøget effektivitet i en organisme
|
US20040259100A1
(en)
|
2003-06-20 |
2004-12-23 |
Illumina, Inc. |
Methods and compositions for whole genome amplification and genotyping
|
US20050019806A1
(en)
*
|
2003-06-30 |
2005-01-27 |
Horvitz H. Robert |
Nucleic acids and polypeptides required for cell survival in the absence of Rb
|
US7947817B2
(en)
*
|
2003-06-30 |
2011-05-24 |
Roche Molecular Systems, Inc. |
Synthesis and compositions of 2'-terminator nucleotides
|
US7572581B2
(en)
*
|
2003-06-30 |
2009-08-11 |
Roche Molecular Systems, Inc. |
2′-terminator nucleotide-related methods and systems
|
WO2005019419A2
(en)
*
|
2003-07-31 |
2005-03-03 |
Singulex, Inc. |
Co-detection of single polypeptide and polynucleotide molecules
|
WO2005013901A2
(en)
|
2003-07-31 |
2005-02-17 |
Isis Pharmaceuticals, Inc. |
Oligomeric compounds and compositions for use in modulation of small non-coding rnas
|
WO2005012526A1
(en)
|
2003-08-04 |
2005-02-10 |
The Hospital For Sick Children |
Lafora's disease gene
|
US7825235B2
(en)
|
2003-08-18 |
2010-11-02 |
Isis Pharmaceuticals, Inc. |
Modulation of diacylglycerol acyltransferase 2 expression
|
KR101501870B1
(ko)
|
2003-08-27 |
2015-03-12 |
옵쏘테크 코포레이션 |
안구의 혈관신생성 장애를 치료하기 위한 조합 치료법
|
US20050053981A1
(en)
*
|
2003-09-09 |
2005-03-10 |
Swayze Eric E. |
Gapped oligomeric compounds having linked bicyclic sugar moieties at the termini
|
US20070123480A1
(en)
*
|
2003-09-11 |
2007-05-31 |
Replicor Inc. |
Oligonucleotides targeting prion diseases
|
WO2005027962A1
(en)
*
|
2003-09-18 |
2005-03-31 |
Isis Pharmaceuticals, Inc. |
4’-thionucleosides and oligomeric compounds
|
NZ576775A
(en)
|
2003-09-18 |
2010-12-24 |
Isis Pharmaceuticals Inc |
Modulation of eIF4E expression
|
US7125945B2
(en)
*
|
2003-09-19 |
2006-10-24 |
Varian, Inc. |
Functionalized polymer for oligonucleotide purification
|
US20050222068A1
(en)
*
|
2003-10-23 |
2005-10-06 |
Mourich Dan V |
Method and antisense composition for selective inhibition of HIV infection in hematopoietic cells
|
US20070281896A1
(en)
*
|
2003-09-30 |
2007-12-06 |
Morris David W |
Novel compositions and methods in cancer
|
NZ546272A
(en)
|
2003-10-10 |
2009-05-31 |
Alchemia Oncology Pty Ltd |
The modulation of hyaluronan synthesis and degradation in the treatment of disease
|
US20050191653A1
(en)
|
2003-11-03 |
2005-09-01 |
Freier Susan M. |
Modulation of SGLT2 expression
|
CA2747871C
(en)
|
2003-11-17 |
2018-04-10 |
Genentech, Inc. |
Compositions and methods for the treatment of tumor of hematopoietic origin
|
KR20150006902A
(ko)
|
2003-12-03 |
2015-01-19 |
코다 테라퓨틱스 (엔지) 리미티드 |
코넥신에 표적화된 안티센스 화합물 및 그의 사용 방법
|
US7259258B2
(en)
|
2003-12-17 |
2007-08-21 |
Illumina, Inc. |
Methods of attaching biological compounds to solid supports using triazine
|
WO2005060675A2
(en)
*
|
2003-12-19 |
2005-07-07 |
Philadelphia Health And Education Corporation(D/B/A Drexel University College Of Medicine (Ducom)) |
Novel spliced 5-ht1a receptors and methods, kits, and uses relating thereto
|
US20050136414A1
(en)
*
|
2003-12-23 |
2005-06-23 |
Kevin Gunderson |
Methods and compositions for making locus-specific arrays
|
CN1910289B
(zh)
|
2004-01-07 |
2012-05-23 |
日立化成研究中心公司 |
用于检测hiv的引物和探针
|
US20080311126A1
(en)
*
|
2004-01-12 |
2008-12-18 |
Genesense Technologies, Inc |
Antisense Oligonucleotides Directed to Ribonucleotide Reducatase R2 and Uses Thereof in Combination Therapies for the Treatment of Cancer
|
US20050164271A1
(en)
|
2004-01-20 |
2005-07-28 |
Sanjay Bhanot |
Modulation of glucocorticoid receptor expression
|
US7468431B2
(en)
|
2004-01-22 |
2008-12-23 |
Isis Pharmaceuticals, Inc. |
Modulation of eIF4E-BP2 expression
|
US8778900B2
(en)
*
|
2004-01-22 |
2014-07-15 |
Isis Pharmaceuticals, Inc. |
Modulation of eIF4E-BP1 expression
|
EP1713332A4
(de)
*
|
2004-01-23 |
2010-08-18 |
Avi Biopharma Inc |
Antisense-oligomere und verfahren zur induktion von immuntoleranz und immunosuppression
|
US7842459B2
(en)
*
|
2004-01-27 |
2010-11-30 |
Compugen Ltd. |
Nucleotide and amino acid sequences, and assays and methods of use thereof for diagnosis
|
WO2005071058A2
(en)
*
|
2004-01-27 |
2005-08-04 |
Compugen Ltd. |
Methods and systems for annotating biomolecular sequences
|
JP2007526455A
(ja)
*
|
2004-02-03 |
2007-09-13 |
ザ リージェンツ オブ ザ ユニバーシティ オブ ミシガン |
癌を特徴付ける、制御する、診断する、および処置するための組成物ならびに方法
|
US7481997B1
(en)
|
2004-02-12 |
2009-01-27 |
Montana State University |
Snow mountain virus genome sequence, virus-like particles and methods of use
|
WO2005082110A2
(en)
*
|
2004-02-26 |
2005-09-09 |
Illumina Inc. |
Haplotype markers for diagnosing susceptibility to immunological conditions
|
US8569474B2
(en)
|
2004-03-09 |
2013-10-29 |
Isis Pharmaceuticals, Inc. |
Double stranded constructs comprising one or more short strands hybridized to a longer strand
|
EP2700720A3
(de)
|
2004-03-15 |
2015-01-28 |
Isis Pharmaceuticals, Inc. |
Zusammensetzungen und Verfahren zur Optimierung der Spaltung von RNA durch RNase H
|
US20050244869A1
(en)
|
2004-04-05 |
2005-11-03 |
Brown-Driver Vickie L |
Modulation of transthyretin expression
|
CA2561741C
(en)
|
2004-04-05 |
2016-09-27 |
Alnylam Pharmaceuticals, Inc. |
Processes and reagents for oligonucleotide synthesis and purification
|
US20050260755A1
(en)
*
|
2004-04-06 |
2005-11-24 |
Isis Pharmaceuticals, Inc. |
Sequential delivery of oligomeric compounds
|
US20050260652A1
(en)
*
|
2004-04-15 |
2005-11-24 |
The General Hospital Corporation |
Compositions and methods that modulate RNA interference
|
AU2005323437B2
(en)
|
2004-04-30 |
2011-10-06 |
Alnylam Pharmaceuticals, Inc. |
Oligonucleotides comprising a C5-modified pyrimidine
|
JP5697297B2
(ja)
|
2004-05-14 |
2015-04-08 |
ロゼッタ ジノミクス リミテッド |
マイクロnasおよびその使用
|
US7718382B2
(en)
*
|
2004-05-14 |
2010-05-18 |
Universite Laval |
Method for identifying compounds for treatment of pain
|
EP2322665A1
(de)
|
2004-05-14 |
2011-05-18 |
Rosetta Genomics Ltd |
Mikro-RNAs und deren Verwendung
|
EP1773872B1
(de)
|
2004-05-21 |
2017-03-15 |
The Uab Research Foundation |
Variable lymphozytenrezeptoren, verwandte polypeptide und nukleinsäuren sowie verwendung dafür
|
EP1756562A1
(de)
|
2004-05-21 |
2007-02-28 |
Atonomics A/S |
Ein hydrogel umfassender oberflächenschallwellensensor
|
EP1758937B1
(de)
*
|
2004-05-24 |
2009-09-02 |
Genvault Corporation |
Stabile lagerung von protein und stabile lagerung von nukleinsäure in wiedergewinnbarer form
|
US7498315B2
(en)
|
2004-06-01 |
2009-03-03 |
Pronai Therapeutics, Inc. |
Methods and compositions for the inhibition of gene expression
|
US20090048192A1
(en)
*
|
2004-06-03 |
2009-02-19 |
Isis Pharmaceuticals, Inc. |
Double Strand Compositions Comprising Differentially Modified Strands for Use in Gene Modulation
|
US8394947B2
(en)
|
2004-06-03 |
2013-03-12 |
Isis Pharmaceuticals, Inc. |
Positionally modified siRNA constructs
|
US7858323B2
(en)
|
2004-06-09 |
2010-12-28 |
The Regents Of The University Of Michigan |
Phage microarray profiling of the humoral response to disease
|
CA2567877A1
(en)
*
|
2004-06-09 |
2005-12-22 |
Mcgill University |
Polynucleotides encoding acetylcholine-gated chloride channel subunits of caenorhabditis elegans
|
USRE48960E1
(en)
|
2004-06-28 |
2022-03-08 |
The University Of Western Australia |
Antisense oligonucleotides for inducing exon skipping and methods of use thereof
|
US7745125B2
(en)
*
|
2004-06-28 |
2010-06-29 |
Roche Molecular Systems, Inc. |
2′-terminator related pyrophosphorolysis activated polymerization
|
DK1766010T3
(da)
|
2004-06-28 |
2011-06-06 |
Univ Western Australia |
Antisense-oligonukleotider til induktion af exon-skipping og fremgangsmåder til anvendelse deraf
|
AU2005327188C8
(en)
|
2004-07-02 |
2011-09-22 |
Avi Biopharma, Inc. |
Antisense antibacterial method and compound
|
US20060024677A1
(en)
|
2004-07-20 |
2006-02-02 |
Morris David W |
Novel therapeutic targets in cancer
|
JP2008510852A
(ja)
*
|
2004-08-17 |
2008-04-10 |
インヴィトロジェン コーポレーション |
高発光性コロイド粒子の合成
|
US7427675B2
(en)
*
|
2004-08-23 |
2008-09-23 |
Isis Pharmaceuticals, Inc. |
Compounds and methods for the characterization of oligonucleotides
|
US7884086B2
(en)
|
2004-09-08 |
2011-02-08 |
Isis Pharmaceuticals, Inc. |
Conjugates for use in hepatocyte free uptake assays
|
US8129352B2
(en)
*
|
2004-09-16 |
2012-03-06 |
Avi Biopharma, Inc. |
Antisense antiviral compound and method for treating ssRNA viral infection
|
WO2006030442A2
(en)
|
2004-09-16 |
2006-03-23 |
Gamida-Cell Ltd. |
Methods of ex vivo progenitor and stem cell expansion by co-culture with mesenchymal cells
|
CA2623471C
(en)
*
|
2004-09-23 |
2018-02-13 |
Arc Pharmaceuticals, Inc. |
Pharmaceutical compositions and methods relating to inhibiting fibrous adhesions or inflammatory disease using low sulphate fucans
|
CA2595669A1
(en)
*
|
2004-10-18 |
2006-04-27 |
Mount Sinai School Of Medicine Of New York University |
Inhibition of tumor growth and metastasis by atf2-derived peptides
|
EP1809720B1
(de)
*
|
2004-10-29 |
2012-05-02 |
Life Technologies Corporation |
Funktionalisierte fluoreszierende nanokristalle und verfahren zu deren herstellung und verwendung
|
US7524829B2
(en)
*
|
2004-11-01 |
2009-04-28 |
Avi Biopharma, Inc. |
Antisense antiviral compounds and methods for treating a filovirus infection
|
WO2006048262A2
(en)
*
|
2004-11-04 |
2006-05-11 |
Roche Diagnostics Gmbh |
Classification of acute myeloid leukemia
|
US8440610B2
(en)
|
2004-11-12 |
2013-05-14 |
Massachusetts Institute Of Technology |
Mapkap kinase-2 as a specific target for blocking proliferation of P53-defective cells
|
WO2006050999A2
(en)
*
|
2004-11-15 |
2006-05-18 |
Obe Therapy Biotechnology S.A.S |
Methods of reducing body fat
|
US20080260637A1
(en)
|
2004-11-17 |
2008-10-23 |
Dalia Dickman |
Methods of Detecting Prostate Cancer
|
US7842794B2
(en)
|
2004-12-17 |
2010-11-30 |
Roche Molecular Systems, Inc. |
Reagents and methods for detecting Neisseria gonorrhoeae
|
DE102004063599B4
(de)
*
|
2004-12-30 |
2007-07-12 |
Bayer Innovation Gmbh |
Verkürzte Wundheilungsprozesse mittels neuartiger Faservliese
|
WO2006069677A2
(en)
*
|
2004-12-30 |
2006-07-06 |
Cinvention Ag |
Combination comprising an agent providing a signal, an implant material and a drug
|
WO2006076650A2
(en)
*
|
2005-01-12 |
2006-07-20 |
Applera Corporation |
Compositions, methods, and kits for selective amplification of nucleic acids
|
KR20070101312A
(ko)
*
|
2005-01-13 |
2007-10-16 |
신벤션 아게 |
탄소 나노입자를 함유하는 복합 물질
|
EP1841520A1
(de)
*
|
2005-01-24 |
2007-10-10 |
Cinvention Ag |
Metall mit verbundwerkstoffen
|
ES2766549T3
(es)
|
2005-02-03 |
2020-06-12 |
Coda Therapeutics Ltd |
Compuestos anticonexina 43 para el tratamiento de heridas crónicas
|
ES2852549T3
(es)
*
|
2005-02-09 |
2021-09-13 |
Sarepta Therapeutics Inc |
Composición antisentido para tratamiento de la atrofia muscular
|
US20060188507A1
(en)
*
|
2005-02-11 |
2006-08-24 |
Elias Georges |
Methods for identifying chemotherapeutic resistance in non-hematopoietic tumors
|
CN101175769A
(zh)
|
2005-03-10 |
2008-05-07 |
健泰科生物技术公司 |
用于调控血管完整性的方法和组合物
|
BRPI0608506A2
(pt)
*
|
2005-03-18 |
2010-01-05 |
Cinv Ag |
processo para preparação de materiais metálicos porosos sinterizados
|
US20060256599A1
(en)
*
|
2005-03-22 |
2006-11-16 |
Malin Patricia J |
Database of electronically profiled cells and methods for generating and using same
|
US7476733B2
(en)
|
2005-03-25 |
2009-01-13 |
The United States Of America As Represented By The Department Of Health And Human Services |
Development of a real-time PCR assay for detection of pneumococcal DNA and diagnosis of pneumococccal disease
|
US20060240032A1
(en)
*
|
2005-03-31 |
2006-10-26 |
Hinrichs David J |
Immunomodulating compositions and methods for use in the treatment of human autoimmune diseases
|
US8309303B2
(en)
|
2005-04-01 |
2012-11-13 |
Qiagen Gmbh |
Reverse transcription and amplification of RNA with simultaneous degradation of DNA
|
JP2008538500A
(ja)
*
|
2005-04-22 |
2008-10-30 |
アカデミス ツィーケンホイス ライデン |
SRタンパク質の結合に対する干渉とRNA二次構造に対する干渉による、mRNA前駆体におけるエクソン認識の調節
|
US7838502B2
(en)
*
|
2005-05-06 |
2010-11-23 |
University Of Massachusetts Medical School |
Compositions and methods to modulate H. influenzae pathogenesis
|
EP2298829B1
(de)
|
2005-05-31 |
2017-09-20 |
École Polytechnique Fédérale de Lausanne (EPFL) |
Triblock-Copolymere zur zytoplasmischen Verabreichung gen-basierter Arzneimittel
|
WO2006133022A2
(en)
|
2005-06-03 |
2006-12-14 |
The Johns Hopkins University |
Compositions and methods for decreasing microrna expression for the treatment of neoplasia
|
WO2006135886A2
(en)
*
|
2005-06-13 |
2006-12-21 |
The Regents Of The University Of Michigan |
Compositions and methods for treating and diagnosing cancer
|
AU2006259583A1
(en)
*
|
2005-06-13 |
2006-12-28 |
The Regents Of The University Of Michigan |
Compositions and methods for treating and diagnosing cancer
|
WO2006138145A1
(en)
|
2005-06-14 |
2006-12-28 |
Northwestern University |
Nucleic acid functionalized nanoparticles for therapeutic applications
|
WO2006138284A2
(en)
|
2005-06-15 |
2006-12-28 |
Callida Genomics, Inc. |
Nucleic acid analysis by random mixtures of non-overlapping fragments
|
US7465561B2
(en)
|
2005-06-30 |
2008-12-16 |
Roche Molecular Systems, Inc. |
Probes and methods for hepatitis C virus typing using single probe analysis
|
MX2008000131A
(es)
*
|
2005-07-01 |
2008-04-04 |
Cinv Ag |
Dispositivos medicos que comprenden un material compuesto reticulado.
|
AU2006265193A1
(en)
*
|
2005-07-01 |
2007-01-11 |
Cinvention Ag |
Process for the production of porous reticulated composite materials
|
EP1915448B1
(de)
|
2005-07-07 |
2013-09-04 |
Yissum Research Development Company, of The Hebrew University of Jerusalem |
Nukleinsäuremittel zur herunterregulierung von h19 sowie verfahren zur verwendung davon
|
US7790694B2
(en)
*
|
2005-07-13 |
2010-09-07 |
Avi Biopharma Inc. |
Antisense antibacterial method and compound
|
WO2007009094A2
(en)
|
2005-07-13 |
2007-01-18 |
Avi Biopharma, Inc. |
Antisense antibacterial method and compound
|
US8067571B2
(en)
*
|
2005-07-13 |
2011-11-29 |
Avi Biopharma, Inc. |
Antibacterial antisense oligonucleotide and method
|
ATE483802T1
(de)
|
2005-08-11 |
2010-10-15 |
Synthetic Genomics Inc |
Verfahren zur in vitro-rekombination
|
US20100015604A1
(en)
|
2005-08-17 |
2010-01-21 |
Evriklia Lianidou |
Composition and method for determination of ck19 expression
|
ATE494372T1
(de)
|
2005-08-29 |
2011-01-15 |
Regulus Therapeutics Inc |
Verfahren für mir-122a-modulation
|
WO2007030691A2
(en)
*
|
2005-09-08 |
2007-03-15 |
Avi Biopharma, Inc. |
Antisense antiviral compound and method for treating picornavirus infection
|
AU2006287530A1
(en)
|
2005-09-08 |
2007-03-15 |
Sarepta Therapeutics, Inc. |
Antisense antiviral compound and method for treating picornavirus infection
|
EP1762627A1
(de)
|
2005-09-09 |
2007-03-14 |
Qiagen GmbH |
Verfahren zur Aktivierung einer Nukleinsäure für eine Polymerase-Reaktion
|
AU2006291054B2
(en)
|
2005-09-12 |
2011-10-13 |
The Brigham And Women's Hospital, Inc. |
Recurrent gene fusions in prostate cancer
|
US8906609B1
(en)
|
2005-09-26 |
2014-12-09 |
Arrowhead Center, Inc. |
Label-free biomolecule sensor based on surface charge modulated ionic conductance
|
IL172297A
(en)
|
2005-10-03 |
2016-03-31 |
Compugen Ltd |
Soluble vegfr-1 variants for the diagnosis of preeclampsia
|
WO2007041201A2
(en)
|
2005-10-03 |
2007-04-12 |
Applera Corporation |
Compositions, methods, and kits for amplifying nucleic acids
|
WO2007133831A2
(en)
|
2006-02-24 |
2007-11-22 |
Callida Genomics, Inc. |
High throughput genome sequencing on dna arrays
|
AU2006304321B2
(en)
|
2005-10-14 |
2012-10-04 |
Musc Foundation For Research Development |
Targeting PAX2 for the induction of DEFB1-mediated tumor immunity and cancer therapy
|
WO2007047907A2
(en)
*
|
2005-10-14 |
2007-04-26 |
The Regents Of The University Of Michigan |
Dek protein compositions and methods of using the same
|
US8080534B2
(en)
|
2005-10-14 |
2011-12-20 |
Phigenix, Inc |
Targeting PAX2 for the treatment of breast cancer
|
EA200801110A1
(ru)
*
|
2005-10-18 |
2008-10-30 |
Синвеншен Аг |
Частицы на основе термореактивных смол и способы их получения
|
US7794951B2
(en)
*
|
2005-10-18 |
2010-09-14 |
University Of Massachusetts Medical School |
SREBP2gc transcription factors and uses thereof
|
EP1948827B1
(de)
|
2005-10-21 |
2016-03-23 |
The Regents of The University of California |
C-kit-onkogenmutationen bei melanom
|
WO2007051045A2
(en)
|
2005-10-28 |
2007-05-03 |
Alnylam Pharmaceuticals, Inc. |
Compositions and methods for inhibiting expression of huntingtin gene
|
US7723477B2
(en)
|
2005-10-31 |
2010-05-25 |
Oncomed Pharmaceuticals, Inc. |
Compositions and methods for inhibiting Wnt-dependent solid tumor cell growth
|
WO2007053648A2
(en)
*
|
2005-10-31 |
2007-05-10 |
The Regents Of The University Of Michigan |
Compositions and methods for treating and diagnosing cancer
|
ES2547421T3
(es)
|
2005-10-31 |
2015-10-06 |
Oncomed Pharmaceuticals, Inc. |
Composiciones y métodos para diagnosticar y tratar el cáncer
|
WO2007056326A2
(en)
*
|
2005-11-04 |
2007-05-18 |
Alnylam Pharmaceuticals, Inc. |
Compositions and methods for inhibiting expression of nav1.8 gene
|
US8501704B2
(en)
|
2005-11-08 |
2013-08-06 |
Sarepta Therapeutics, Inc. |
Immunosuppression compound and treatment method
|
WO2007056331A2
(en)
|
2005-11-09 |
2007-05-18 |
Alnylam Pharmaceuticals, Inc. |
Compositions and methods for inhibiting expression of factor v leiden mutant gene
|
AU2006318194B2
(en)
|
2005-11-21 |
2012-08-09 |
Isis Pharmaceuticals, Inc. |
Modulation of eiF4E-BP2 expression
|
US8846393B2
(en)
|
2005-11-29 |
2014-09-30 |
Gamida-Cell Ltd. |
Methods of improving stem cell homing and engraftment
|
WO2007064945A2
(en)
|
2005-12-01 |
2007-06-07 |
Pronai Therapeutics, Inc. |
Cancer therapies and pharmaceutical compositions used therein
|
US20090215055A1
(en)
*
|
2005-12-13 |
2009-08-27 |
Erasmus University Medical Center Rotterdam |
Genetic Brain Tumor Markers
|
US10647960B2
(en)
|
2005-12-13 |
2020-05-12 |
The Trustees Of The University Of Pennsylvania |
Transcriptome transfer produces cellular phenotype conversion
|
US10646590B2
(en)
|
2005-12-13 |
2020-05-12 |
The Trustees Of The University Of Pennsylvania |
Methods for phototransfecting nucleic acids into live cells
|
US9157066B2
(en)
|
2005-12-13 |
2015-10-13 |
The Trustees Of The University Of Pennsylvania |
Transcriptome transfer produces cellular phenotype conversion
|
JP2009524411A
(ja)
*
|
2005-12-21 |
2009-07-02 |
イェール ユニバーシティー |
リボスイッチの調節に関連した方法および組成物
|
CN103301475B
(zh)
|
2005-12-28 |
2016-08-03 |
斯克里普斯研究所 |
药物组合物和表达载体以及调节基因表达的方法和核酸分子的应用
|
WO2007080597A2
(en)
|
2006-01-16 |
2007-07-19 |
Compugen Ltd. |
Polynucleotide and polypeptide sequences and methods for diagnosis
|
NZ569697A
(en)
|
2006-01-20 |
2012-01-12 |
Women S & Children S Health Res Inst |
Method of treatment, prophylaxis and diagnosis of pathologies of the bone by the modulation of GPC3
|
WO2007089584A2
(en)
|
2006-01-26 |
2007-08-09 |
Isis Pharmaceuticals, Inc. |
Compositions and their uses directed to huntingtin
|
EP2388328A1
(de)
|
2006-01-27 |
2011-11-23 |
Isis Pharmaceuticals, Inc. |
Oligomerverbindungen und Zusammensetzungen zur Verwendung bei der Modulation von microRNAs
|
KR20130042043A
(ko)
*
|
2006-01-27 |
2013-04-25 |
아이시스 파마수티컬즈 인코포레이티드 |
6-변형된 바이시클릭 핵산 유사체
|
US7569686B1
(en)
|
2006-01-27 |
2009-08-04 |
Isis Pharmaceuticals, Inc. |
Compounds and methods for synthesis of bicyclic nucleic acid analogs
|
US8229398B2
(en)
*
|
2006-01-30 |
2012-07-24 |
Qualcomm Incorporated |
GSM authentication in a CDMA network
|
US20080019961A1
(en)
*
|
2006-02-21 |
2008-01-24 |
Regents Of The University Of Michigan |
Hedgehog signaling pathway antagonist cancer treatment
|
SG10201405158QA
(en)
*
|
2006-02-24 |
2014-10-30 |
Callida Genomics Inc |
High throughput genome sequencing on dna arrays
|
EP2010677A4
(de)
*
|
2006-02-24 |
2010-04-14 |
Investigen Inc |
Verfahren und zusammensetzungen zum nachweis von polynukleotiden
|
US7582615B2
(en)
*
|
2006-03-07 |
2009-09-01 |
Avi Biopharma, Inc. |
Antisense antiviral compound and method for treating arenavirus infection
|
MX2008011323A
(es)
|
2006-03-08 |
2008-11-18 |
Archemix Corp |
Aptameros que se unen al complemento y agentes anti-c5 utiles en el tratamiento de trastornos oculares.
|
US7718629B2
(en)
|
2006-03-31 |
2010-05-18 |
Alnylam Pharmaceuticals, Inc. |
Compositions and methods for inhibiting expression of Eg5 gene
|
US7914988B1
(en)
*
|
2006-03-31 |
2011-03-29 |
Illumina, Inc. |
Gene expression profiles to predict relapse of prostate cancer
|
US8007790B2
(en)
|
2006-04-03 |
2011-08-30 |
Stowers Institute For Medical Research |
Methods for treating polycystic kidney disease (PKD) or other cyst forming diseases
|
CN101460634A
(zh)
|
2006-04-13 |
2009-06-17 |
康乃尔研究基金会有限公司 |
用于靶向c-rel的方法和组合物
|
WO2007123391A1
(en)
*
|
2006-04-20 |
2007-11-01 |
Academisch Ziekenhuis Leiden |
Therapeutic intervention in a genetic disease in an individual by modifying expression of an aberrantly expressed gene.
|
MX2008014005A
(es)
|
2006-05-03 |
2009-01-27 |
Baltic Technology Dev Ltd |
Agentes antisentido que combinan un oligonucleotido modificado con base fuertemente unida y nucleasa artificial.
|
JP5731115B2
(ja)
*
|
2006-05-05 |
2015-06-10 |
アイシス ファーマシューティカルズ, インコーポレーテッド |
遺伝子発現を調節するための化合物および方法
|
US8785407B2
(en)
*
|
2006-05-10 |
2014-07-22 |
Sarepta Therapeutics, Inc. |
Antisense antiviral agent and method for treating ssRNA viral infection
|
SI2735568T1
(en)
*
|
2006-05-10 |
2018-01-31 |
Sarepta Therapeutics, Inc. |
Analogues of the oligonucleotide, with cationic links between subunits
|
WO2007133703A2
(en)
*
|
2006-05-10 |
2007-11-22 |
Dxterity Diagnostics |
Detection of nucleic acid targets using chemically reactive oligonucleotide probes
|
WO2007134181A2
(en)
*
|
2006-05-11 |
2007-11-22 |
Isis Pharmaceuticals, Inc. |
5'-modified bicyclic nucleic acid analogs
|
US7666854B2
(en)
*
|
2006-05-11 |
2010-02-23 |
Isis Pharmaceuticals, Inc. |
Bis-modified bicyclic nucleic acid analogs
|
EP3578656B1
(de)
|
2006-05-11 |
2021-01-06 |
Alnylam Pharmaceuticals, Inc. |
Zusammensetzungen und verfahren zur hemmung der pcsk9-genexpression
|
US20070265215A1
(en)
*
|
2006-05-11 |
2007-11-15 |
Iversen Patrick L |
Antisense restenosis composition and method
|
EP1857548A1
(de)
*
|
2006-05-19 |
2007-11-21 |
Academisch Ziekenhuis Leiden |
Mittel und Verfahren zur Induktion von Exon-skipping
|
BRPI0712034A2
(pt)
|
2006-05-19 |
2012-01-10 |
Alnylam Pharmaceuticals Inc |
modulação de rnai de aha e usos terapêuticos do mesmo
|
AU2007253677B2
(en)
|
2006-05-22 |
2011-02-10 |
Alnylam Pharmaceuticals, Inc. |
Compositions and methods for inhibiting expression of IKK-B gene
|
US20090209625A1
(en)
*
|
2006-05-23 |
2009-08-20 |
Sanjay Bhanot |
Modulation of chrebp expression
|
US11001881B2
(en)
|
2006-08-24 |
2021-05-11 |
California Institute Of Technology |
Methods for detecting analytes
|
JP2009540299A
(ja)
|
2006-06-05 |
2009-11-19 |
カリフォルニア インスティテュート オブ テクノロジー |
リアルタイムマイクロアレイ
|
US8637436B2
(en)
|
2006-08-24 |
2014-01-28 |
California Institute Of Technology |
Integrated semiconductor bioarray
|
DK2038432T3
(en)
|
2006-06-30 |
2017-04-03 |
Rosetta Genomics Ltd |
METHOD OF DETECTING AND QUANTIFYING A TARGET NUCLEIC ACID GENERATED BY RT-PCR BY MIRNA
|
WO2008011473A2
(en)
|
2006-07-19 |
2008-01-24 |
Isis Pharmaceuticals, Inc. |
Compositions and their uses directed to hbxip
|
US11525156B2
(en)
|
2006-07-28 |
2022-12-13 |
California Institute Of Technology |
Multiplex Q-PCR arrays
|
CA2658786A1
(en)
|
2006-07-28 |
2008-01-31 |
Children's Memorial Hospital |
Methods of inhibiting tumor cell aggressiveness using the microenvironment of human embryonic stem cells
|
WO2008014485A2
(en)
|
2006-07-28 |
2008-01-31 |
California Institute Of Technology |
Multiplex q-pcr arrays
|
CA2660523C
(en)
|
2006-08-11 |
2019-03-19 |
Prosensa Technologies B.V. |
Methods and means for treating dna repeat instability associated genetic disorders
|
US11560588B2
(en)
|
2006-08-24 |
2023-01-24 |
California Institute Of Technology |
Multiplex Q-PCR arrays
|
US20080261216A1
(en)
*
|
2006-09-08 |
2008-10-23 |
The Regents Of The University Of Michigan |
HERV Group II Viruses In Lymphoma And Cancer
|
JP2010502752A
(ja)
*
|
2006-09-11 |
2010-01-28 |
イェール ユニバーシティー |
リシンリボスイッチ、リシンリボスイッチを用いた構造に基づく化合物設計、ならびにリシンリボスイッチを用いた使用のための方法および組成物
|
CN101679473B
(zh)
|
2006-09-14 |
2014-12-10 |
加利福尼亚大学董事会 |
用于核酸酶活性和dna足迹法的等离子分子标尺
|
US20090209478A1
(en)
|
2006-09-21 |
2009-08-20 |
Tomoko Nakayama |
Compositions and methods for inhibiting expression of the hamp gene
|
DK2068886T3
(da)
|
2006-10-03 |
2013-11-18 |
Tekmira Pharmaceuticals Corp |
Lipidholdige præparater
|
US20100166743A1
(en)
|
2006-10-06 |
2010-07-01 |
University Of Utah Research Foundation |
Method of detecting ocular diseases and pathologic conditions and treatment of same
|
EP1914303A1
(de)
*
|
2006-10-09 |
2008-04-23 |
Qiagen GmbH |
Thermus eggertssonii DNA Polymerasen
|
US20080096193A1
(en)
*
|
2006-10-24 |
2008-04-24 |
Charles Robert Bupp |
Methods and compositions for detecting polynucleotides
|
WO2008049226A1
(en)
|
2006-10-27 |
2008-05-02 |
The University Of Western Ontario |
Inhibition of sox9 function fn the treatment of proteogl ycan-associated pathophysiological conditions
|
US7910354B2
(en)
*
|
2006-10-27 |
2011-03-22 |
Complete Genomics, Inc. |
Efficient arrays of amplified polynucleotides
|
WO2008136852A2
(en)
|
2006-11-01 |
2008-11-13 |
University Of Rochester |
Methods and compositions related to the structure and function of apobec3g
|
US20090111705A1
(en)
|
2006-11-09 |
2009-04-30 |
Complete Genomics, Inc. |
Selection of dna adaptor orientation by hybrid capture
|
EP2091557A2
(de)
|
2006-11-15 |
2009-08-26 |
Coda Therapeutics, INC. |
Verbesserte verfahren und zusammensetzungen zur wundheilung
|
US20080242560A1
(en)
*
|
2006-11-21 |
2008-10-02 |
Gunderson Kevin L |
Methods for generating amplified nucleic acid arrays
|
CA2673757A1
(en)
*
|
2006-11-30 |
2008-06-05 |
Tapimmune Inc. |
Poxviridae treatment
|
WO2009024834A2
(en)
*
|
2006-12-05 |
2009-02-26 |
Rosetta Genomics Ltd |
Nucleic acids involved in viral infection
|
EP2104509A4
(de)
|
2006-12-11 |
2010-03-24 |
Univ Utah Res Found |
Zusammensetzungen und verfahren zur behandlung von pathologischer angiogenese und gefässpermeabilität
|
US9938641B2
(en)
*
|
2006-12-18 |
2018-04-10 |
Fluidigm Corporation |
Selection of aptamers based on geometry
|
US7858772B2
(en)
*
|
2006-12-22 |
2010-12-28 |
Roche Molecular Systems, Inc. |
Compounds and methods for synthesis and purification of oligonucleotides
|
WO2008094370A2
(en)
|
2006-12-22 |
2008-08-07 |
University Of Utah Research Foundation |
Method of detecting ocular diseases and pathologic conditions and treatment of same
|
US7820389B2
(en)
*
|
2007-01-10 |
2010-10-26 |
Geneohm Sciences, Inc. |
Inhibition of mismatch hybridization by a universal competitor DNA
|
US20100172882A1
(en)
*
|
2007-01-11 |
2010-07-08 |
Glazer Peter M |
Compositions and methods for targeted inactivation of hiv cell surface receptors
|
CA2675967A1
(en)
*
|
2007-01-16 |
2008-07-24 |
Yissum Research Development Company Of The Hebrew University Of Jerusale M |
Nucleic acid constructs and methods for specific silencing of h19
|
WO2008087214A1
(en)
*
|
2007-01-19 |
2008-07-24 |
Cinvention Ag |
Porous, non-degradable implant made by powder molding
|
EP2106439B1
(de)
*
|
2007-01-24 |
2014-11-12 |
The Regents of the University of Michigan |
Zusammensetzungen und verfahren zur behandlung und diagnostizierung von pankreaskrebs
|
EP2124967A4
(de)
*
|
2007-01-26 |
2011-01-05 |
Rosetta Genomics Ltd |
Zusammensetzungen und verfahren zur behandlung von hämatopoietischen malignomen
|
WO2008093331A1
(en)
*
|
2007-01-29 |
2008-08-07 |
Yissum Research Development Company Of The Hebrew University Of Jerusalem |
Antibody conjugates for circumventing multi-drug resistance
|
US8507200B2
(en)
|
2007-02-09 |
2013-08-13 |
Northwestern University |
Particles for detecting intracellular targets
|
US7771947B2
(en)
*
|
2007-02-23 |
2010-08-10 |
Investigen, Inc. |
Methods and compositions for rapid light-activated isolation and detection of analytes
|
US20100167290A1
(en)
*
|
2007-02-27 |
2010-07-01 |
Robert Elghanian |
Molecule attachment to nanoparticles
|
US9006206B2
(en)
|
2007-02-27 |
2015-04-14 |
Rosetta Genomics Ltd. |
Composition and methods for modulating cell proliferation and cell death
|
CA2699418A1
(en)
*
|
2007-02-27 |
2008-09-04 |
Moshe Oren |
Composition and methods for modulating cell proliferation and cell death
|
US20080206862A1
(en)
*
|
2007-02-28 |
2008-08-28 |
Cinvention Ag |
High surface cultivation system bag
|
US20080213742A1
(en)
*
|
2007-02-28 |
2008-09-04 |
Cinvention Ag |
High surface cultivation system
|
EP2126115A2
(de)
|
2007-03-01 |
2009-12-02 |
Rosetta Genomics Ltd |
Diagnose und prognose verschiedener krebstypen
|
WO2008116220A2
(en)
|
2007-03-22 |
2008-09-25 |
Yale University |
Methods and compositions related to riboswitches that control alternative splicing
|
PE20090064A1
(es)
|
2007-03-26 |
2009-03-02 |
Novartis Ag |
Acido ribonucleico de doble cadena para inhibir la expresion del gen e6ap humano y composicion farmaceutica que lo comprende
|
WO2012070037A2
(en)
|
2010-11-22 |
2012-05-31 |
Rosetta Genomics Ltd. |
Methods and materials for classification of tissue of origin of tumor samples
|
US20100273172A1
(en)
|
2007-03-27 |
2010-10-28 |
Rosetta Genomics Ltd. |
Micrornas expression signature for determination of tumors origin
|
EP2905336A1
(de)
|
2007-03-29 |
2015-08-12 |
Alnylam Pharmaceuticals Inc. |
Zusammensetzungen und Verfahren zur Hemmung der Expression eines Gens von Ebola
|
KR101563753B1
(ko)
*
|
2007-05-11 |
2015-10-27 |
더 트러스티스 오브 더 유니버시티 오브 펜실바니아 |
피부 궤양의 치료 방법
|
JP5277243B2
(ja)
|
2007-05-11 |
2013-08-28 |
トーマス・ジェファーソン・ユニバーシティ |
神経変性疾患および障害を治療および阻止する方法
|
CA2690281A1
(en)
|
2007-05-11 |
2008-11-20 |
The Johns Hopkins University |
Biomarkers for melanoma
|
AU2008257419B2
(en)
|
2007-05-23 |
2013-10-24 |
The Trustees Of The University Of Pennsylvania |
Targeted carriers for intracellular drug delivery
|
KR20100017893A
(ko)
*
|
2007-05-29 |
2010-02-16 |
예일 유니버시티 |
택일적 스플라이싱 및 rna 프로세싱을 조절하는 리보스위치와 관련된 방법 및 조성물
|
KR20100017905A
(ko)
|
2007-05-29 |
2010-02-16 |
예일 유니버시티 |
리보스위치, 리보스위치의 사용 방법 및 리보스위치를 함유하는 조성물
|
US8278425B2
(en)
|
2007-05-30 |
2012-10-02 |
Isis Pharmaceuticals, Inc. |
N-substituted-aminomethylene bridged bicyclic nucleic acid analogs
|
AU2008259907B2
(en)
|
2007-05-30 |
2014-12-04 |
Northwestern University |
Nucleic acid functionalized nanoparticles for therapeutic applications
|
US7807372B2
(en)
*
|
2007-06-04 |
2010-10-05 |
Northwestern University |
Screening sequence selectivity of oligonucleotide-binding molecules using nanoparticle based colorimetric assay
|
AU2008262391A1
(en)
|
2007-06-06 |
2008-12-18 |
Avi Biopharma, Inc. |
Soluble HER2 and HER3 splice variant proteins, splice-switching oligonucleotides, and their use in the treatment of disease
|
ES2386492T3
(es)
|
2007-06-08 |
2012-08-21 |
Isis Pharmaceuticals, Inc. |
Análogos de ácidos nucleicos bicíclicos carbocíclicos
|
US20090324596A1
(en)
|
2008-06-30 |
2009-12-31 |
The Trustees Of Princeton University |
Methods of identifying and treating poor-prognosis cancers
|
US10745701B2
(en)
|
2007-06-28 |
2020-08-18 |
The Trustees Of Princeton University |
Methods of identifying and treating poor-prognosis cancers
|
AU2008271050B2
(en)
|
2007-06-29 |
2014-11-06 |
Sarepta Therapeutics, Inc. |
Tissue specific peptide conjugates and methods
|
AU2008270209B2
(en)
|
2007-07-05 |
2012-05-17 |
Arrowhead Pharmaceuticals, Inc. |
dsRNA for treating viral infection
|
AU2008272918B2
(en)
*
|
2007-07-05 |
2012-09-13 |
Isis Pharmaceuticals, Inc. |
6-disubstituted bicyclic nucleic acid analogs
|
EP3018216B1
(de)
|
2007-07-06 |
2018-09-12 |
The Regents Of The University Of Michigan |
Rezidivierende genfusionen bei prostatakrebs
|
CA2693048C
(en)
*
|
2007-07-12 |
2016-10-18 |
Prosensa Technologies B.V. |
Molecules for targeting compounds to various selected organs or tissues
|
EP2167135A2
(de)
*
|
2007-07-12 |
2010-03-31 |
Prosensa Technologies B.V. |
Moleküle für targeting von verbindungen auf verschiedene ausgewählte organe, gewebe oder tumorzellen
|
WO2009023855A2
(en)
|
2007-08-15 |
2009-02-19 |
Isis Pharmaceuticals, Inc. |
Tetrahydropyran nucleic acid analogs
|
WO2009025847A2
(en)
|
2007-08-21 |
2009-02-26 |
Nodality, Inc. |
Methods for diagnosis, prognosis and methods of treatment
|
US8557767B2
(en)
|
2007-08-28 |
2013-10-15 |
Uab Research Foundation |
Synthetic apolipoprotein E mimicking polypeptides and methods of use
|
AU2008296478B9
(en)
|
2007-08-28 |
2015-03-19 |
The Uab Research Foundation |
Synthetic apolipoprotein E mimicking polypeptides and methods of use
|
LT2769729T
(lt)
|
2007-09-04 |
2019-05-10 |
Compugen Ltd. |
Polipeptidai ir polinukleotidai ir jų panaudojimas kaip vaistų taikinio vaistų ir biologinių preparatų gamybai
|
US8138318B2
(en)
|
2007-09-13 |
2012-03-20 |
Abbott Laboratories |
Hepatitis B pre-S2 nucleic acid
|
EP2348052A3
(de)
|
2007-09-17 |
2011-10-26 |
The Regents of The University of California |
Auf Prostatazellen in situ abzielende internalisierende humane monoklonale Antikörper
|
US8445217B2
(en)
|
2007-09-20 |
2013-05-21 |
Vanderbilt University |
Free solution measurement of molecular interactions by backscattering interferometry
|
WO2009039442A1
(en)
*
|
2007-09-21 |
2009-03-26 |
California Institute Of Technology |
Nfia in glial fate determination, glioma therapy and astrocytoma treatment
|
AU2008307482B2
(en)
|
2007-10-02 |
2012-07-12 |
Amgen Inc. |
Increasing erythropoietin using nucleic acids hybridizable to micro-RNA and precursors thereof
|
HUE028662T2
(en)
|
2007-10-26 |
2016-12-28 |
Academisch Ziekenhuis Leiden |
Preparations and methods for controlling muscle disorders
|
USRE48468E1
(en)
|
2007-10-26 |
2021-03-16 |
Biomarin Technologies B.V. |
Means and methods for counteracting muscle disorders
|
US7820391B2
(en)
|
2007-11-06 |
2010-10-26 |
Osmetech Molecular Diagnostics |
Baseless nucleotide analogues and uses thereof
|
US8097712B2
(en)
|
2007-11-07 |
2012-01-17 |
Beelogics Inc. |
Compositions for conferring tolerance to viral disease in social insects, and the use thereof
|
USRE47320E1
(en)
|
2007-11-20 |
2019-03-26 |
Ionis Pharmaceuticals, Inc. |
Modulation of CD40 expression
|
WO2009067647A1
(en)
*
|
2007-11-21 |
2009-05-28 |
Isis Pharmaceuticals, Inc. |
Carbocyclic alpha-l-bicyclic nucleic acid analogs
|
DK2610351T3
(en)
|
2007-12-05 |
2015-09-28 |
Complete Genomics Inc |
Base efficient provision of sequencing reactions
|
CA2707042A1
(en)
|
2007-12-10 |
2009-06-18 |
Alnylam Pharmaceuticals, Inc. |
Compositions and methods for inhibiting expression of factor vii gene
|
PL2231861T3
(pl)
|
2007-12-13 |
2015-04-30 |
Philip Morris Products Sa |
Rośliny transgeniczne modyfikowane w celu zmniejszenia transportu kadmu, produkty pochodne i metody związane
|
CA2710387A1
(en)
*
|
2007-12-21 |
2009-07-09 |
Coda Therapeutics, Inc. |
Treatment of fibrotic conditions
|
AU2008343754A1
(en)
*
|
2007-12-21 |
2009-07-09 |
Coda Therapeutics, Inc. |
Use of anti-connexin polynucleotides for the treatment of surgical adhesions
|
EP2237786A2
(de)
|
2007-12-21 |
2010-10-13 |
Coda Therapeutics, Inc. |
Verwendung von connexin43-hemmern zur behandlung fibrotischer erkrankungen
|
AU2008345033B2
(en)
*
|
2007-12-28 |
2014-04-03 |
Sarepta Therapeutics, Inc. |
Immunomodulatory agents and methods of use
|
US20110117125A1
(en)
|
2008-01-02 |
2011-05-19 |
Tekmira Pharmaceuticals Corporation |
Compositions and methods for the delivery of nucleic acids
|
EP2240583A2
(de)
*
|
2008-01-07 |
2010-10-20 |
Coda Therapeutics, Inc. |
Wundheilende zusammensetzungen und behandlungen
|
AU2009208035B2
(en)
|
2008-01-22 |
2014-04-03 |
Dogenes Inc. |
Compositions and methods for detecting Juvenile Renal Dysplasia or calcium oxalate stones in dogs
|
WO2009093254A2
(en)
*
|
2008-01-27 |
2009-07-30 |
Rosetta Genomics Ltd. |
Methods and compositions for diagnosing complications of pregnancy
|
AU2009208607B2
(en)
*
|
2008-01-31 |
2013-08-01 |
Compugen Ltd. |
Polypeptides and polynucleotides, and uses thereof as a drug target for producing drugs and biologics
|
US8530640B2
(en)
*
|
2008-02-07 |
2013-09-10 |
Isis Pharmaceuticals, Inc. |
Bicyclic cyclohexitol nucleic acid analogs
|
WO2009099326A1
(en)
*
|
2008-02-08 |
2009-08-13 |
Prosensa Holding Bv |
Methods and means for treating dna repeat instability associated genetic disorders
|
JP2011518117A
(ja)
|
2008-03-05 |
2011-06-23 |
アルナイラム ファーマシューティカルズ, インコーポレイテッド |
Eg5およびVEGF遺伝子の発現を阻害するための組成物および方法
|
EP2282744B1
(de)
|
2008-03-21 |
2018-01-17 |
Ionis Pharmaceuticals, Inc. |
Oligomere verbindungen mit trizyklischen nukleosiden und anwendungsverfahren dafür
|
US9290534B2
(en)
*
|
2008-04-04 |
2016-03-22 |
Ionis Pharmaceuticals, Inc. |
Oligomeric compounds having at least one neutrally linked terminal bicyclic nucleoside
|
US8802923B2
(en)
|
2008-04-10 |
2014-08-12 |
A.B. Seeds Ltd. |
Compositions and methods for enhancing oil content in plants
|
CN102007213B
(zh)
|
2008-04-18 |
2014-08-06 |
巴克斯特国际公司 |
用于预防和/或逆转新发作的自身免疫性糖尿病的基于微球的组合物
|
US10150990B2
(en)
|
2008-04-21 |
2018-12-11 |
Roche Molecular Systems, Inc. |
Ribonucleotide tag nucleic acid detection
|
CA2722668A1
(en)
*
|
2008-04-29 |
2009-11-05 |
Wyeth Llc |
Methods for treating inflammation
|
EP2119783A1
(de)
|
2008-05-14 |
2009-11-18 |
Prosensa Technologies B.V. |
Verfahren für effizientes Exon (44)-Skipping bei Duchenne-Muskeldystrophie und entsprechende Mittel
|
US8082730B2
(en)
*
|
2008-05-20 |
2011-12-27 |
Caterpillar Inc. |
Engine system having particulate reduction device and method
|
AU2009248971B2
(en)
|
2008-05-21 |
2015-04-30 |
Kinemed, Inc. |
Compositions and methods of treatment using modulators of motoneuron diseases
|
CA2635187A1
(en)
|
2008-06-05 |
2009-12-05 |
The Royal Institution For The Advancement Of Learning/Mcgill University |
Oligonucleotide duplexes and uses thereof
|
US20100209957A1
(en)
*
|
2008-06-20 |
2010-08-19 |
Genvault Corporation |
Biosample storage devices and methods of use thereof
|
US20110119781A1
(en)
*
|
2008-07-15 |
2011-05-19 |
Birgit Bramlage |
Compositions and Methods for Inhibiting Expression of TGF-BETA Receptor Genes
|
ES2433691T3
(es)
|
2008-07-17 |
2013-12-12 |
Ikfe Institut Für Klinische Forschung Und Entwicklung Gmbh |
Biomarcadores para la insulinorresistencia y disfunción de células beta
|
US8383585B2
(en)
|
2008-07-17 |
2013-02-26 |
Ikfe Institut Fur Klinische Forschung Und Entwicklung Gmbh |
Biomarkers for cardiodiabetes
|
WO2010017248A2
(en)
|
2008-08-04 |
2010-02-11 |
University Of Miami |
Sting (stimulator of interferon genes), a regulator of innate immune responses
|
CN103429270B
(zh)
|
2008-08-25 |
2016-11-23 |
埃克斯雷德制药有限公司 |
阻止结缔组织生长因子的反义核苷酸及其用途
|
US8318693B2
(en)
|
2008-09-02 |
2012-11-27 |
Alnylam Pharmaceuticals, Inc. |
Compositions and methods for inhibiting expression of mutant EGFR gene
|
EP3075867B1
(de)
|
2008-09-03 |
2019-03-13 |
Quantumdx Group Limited |
Wahrnehmungsstrategien und verfahren zum nukleinsäurenachweis mit biosensoren
|
US8871921B2
(en)
|
2008-09-03 |
2014-10-28 |
Quantumdx Group Ltd. |
Design, synthesis and use of synthetic nucleotides comprising charge mass tags
|
CN102177237B
(zh)
*
|
2008-09-12 |
2013-10-30 |
金沃特公司 |
用于贮存和稳定生物分子的基质和介质
|
EP3067359A1
(de)
|
2008-09-23 |
2016-09-14 |
Scott G. Petersen |
Selbstfreisetzende biolabile phosphatgeschützte pro-oligos für therapeutika auf oligonukleotidbasis und vermittlung von rna-interferenz
|
US8604192B2
(en)
*
|
2008-09-24 |
2013-12-10 |
Isis Pharmaceuticals, Inc. |
Cyclohexenyl nucleic acids analogs
|
DK2356129T3
(da)
*
|
2008-09-24 |
2013-05-13 |
Isis Pharmaceuticals Inc |
Substituerede alpha-L-bicykliske nukleosider
|
CA2739170A1
(en)
|
2008-09-25 |
2010-04-01 |
Alnylam Pharmaceuticals, Inc. |
Lipid formulated compositions and methods for inhibiting expression of serum amyloid a gene
|
NZ592338A
(en)
|
2008-09-26 |
2012-11-30 |
Oncomed Pharm Inc |
Frizzled-binding agents and uses thereof
|
WO2010037124A1
(en)
|
2008-09-29 |
2010-04-01 |
The Trustees Of The University Of Pennsylvania |
Tumor vascular marker-targeted vaccines
|
CN102239260B
(zh)
|
2008-10-03 |
2017-04-12 |
库尔纳公司 |
通过抑制针对载脂蛋白‑a1的天然反义转录物治疗载脂蛋白‑a1相关疾病
|
EP2350043B9
(de)
|
2008-10-09 |
2014-08-20 |
TEKMIRA Pharmaceuticals Corporation |
Verbesserte aminolipide und verfahren zur freisetzung von nukleinsäuren
|
WO2010042933A2
(en)
|
2008-10-10 |
2010-04-15 |
Northwestern University |
Inhibition and treatment of prostate cancer metastasis
|
NZ603603A
(en)
|
2008-10-15 |
2014-06-27 |
Isis Pharmaceuticals Inc |
Modulation of factor 11 expression
|
EP2344639B1
(de)
|
2008-10-20 |
2015-04-22 |
Alnylam Pharmaceuticals, Inc. |
Zusammensetzungen und verfahren zur hemmung der transthyretinexpression
|
TR201902952T4
(tr)
|
2008-10-24 |
2019-03-21 |
Sarepta Therapeutics Inc |
Dmd için ekson atlama bileşimleri.
|
WO2010048585A2
(en)
|
2008-10-24 |
2010-04-29 |
Isis Pharmaceuticals, Inc. |
Oligomeric compounds and methods
|
CN102264374B
(zh)
|
2008-10-24 |
2015-01-07 |
Isis制药公司 |
5′和2′双取代的核苷和由其制备的低聚化合物
|
US8309306B2
(en)
*
|
2008-11-12 |
2012-11-13 |
Nodality, Inc. |
Detection composition
|
AU2009315665A1
(en)
*
|
2008-11-17 |
2010-05-20 |
Arrowhead Research Corporation |
Compositions and methods for inhibiting expression of factor VII genes
|
WO2010060110A1
(en)
|
2008-11-24 |
2010-05-27 |
Northwestern University |
Polyvalent rna-nanoparticle compositions
|
WO2010061393A1
(en)
|
2008-11-30 |
2010-06-03 |
Compugen Ltd. |
He4 variant nucleotide and amino acid sequences, and methods of use thereof
|
AU2009323767A1
(en)
|
2008-12-04 |
2011-07-21 |
IKFE Instituit fur klinische Forschung und Entwicklung GmbH |
Biomarkers for atherosclerosis
|
MX366774B
(es)
|
2008-12-04 |
2019-07-24 |
Curna Inc |
Uso de oligonucleótidos antisentido en la inhibición de transcrito antisentido natural para sirtuina 1.
|
JP6091752B2
(ja)
|
2008-12-04 |
2017-03-08 |
クルナ・インコーポレーテッド |
Epoに対する天然アンチセンス転写物の抑制によるエリスロポエチン(epo)関連疾患の治療
|
US8927511B2
(en)
|
2008-12-04 |
2015-01-06 |
Curna, Inc. |
Treatment of vascular endothelial growth factor (VEGF) related diseases by inhibition of natural antisense transcript to VEGF
|
CA2745811C
(en)
|
2008-12-04 |
2021-07-13 |
Joseph Collard |
Treatment of tumor suppressor gene related diseases by inhibition of natural antisense transcript to the gene
|
EP2633854B1
(de)
|
2008-12-05 |
2015-09-16 |
Yeda Research And Development Co. Ltd. |
miRNA-9 or miRNA-9* zur Verwendung in der Behandlung von ALS
|
NZ593618A
(en)
|
2008-12-10 |
2013-02-22 |
Alnylam Pharmaceuticals Inc |
Gnaq targeted dsrna compositions and methods for inhibiting expression
|
AU2009325962A1
(en)
|
2008-12-11 |
2011-07-28 |
Ikfe Institut Fur Klinische Forschung Und Entwicklung Gmbh |
Biomarkers for insulin sensitizer drug response
|
WO2010080554A1
(en)
|
2008-12-17 |
2010-07-15 |
Avi Biopharma, Inc. |
Antisense compositions and methods for modulating contact hypersensitivity or contact dermatitis
|
EP2379747B1
(de)
|
2008-12-22 |
2013-07-03 |
University of Utah Research Foundation |
Monochrome quantitative multiplex-pcr
|
WO2010075441A1
(en)
|
2008-12-22 |
2010-07-01 |
Trustees Of Boston University |
Modular nucleic acid-based circuits for counters, binary operations, memory, and logic
|
EP2382467A1
(de)
|
2008-12-30 |
2011-11-02 |
IKFE GmbH |
Biomarker für fettgewebeaktivität
|
US8206929B2
(en)
|
2009-01-07 |
2012-06-26 |
Roche Molecular Systems, Inc. |
Nucleic acid amplification with allele-specific suppression of sequence variants
|
US20100210541A1
(en)
|
2009-01-07 |
2010-08-19 |
Andreas Pfuetzner |
Biomarkers for Appetite Regulation
|
US20100233270A1
(en)
|
2009-01-08 |
2010-09-16 |
Northwestern University |
Delivery of Oligonucleotide-Functionalized Nanoparticles
|
US20100294952A1
(en)
*
|
2009-01-15 |
2010-11-25 |
Northwestern University |
Controlled agent release and sequestration
|
EP3243504A1
(de)
|
2009-01-29 |
2017-11-15 |
Arbutus Biopharma Corporation |
Verbesserte lipidformulierung
|
MX2011007776A
(es)
*
|
2009-02-03 |
2011-08-12 |
Hoffmann La Roche |
Compsiciones y metodos para inhibir la expresion de genes ptp1b.
|
WO2010090762A1
(en)
|
2009-02-04 |
2010-08-12 |
Rxi Pharmaceuticals Corporation |
Rna duplexes with single stranded phosphorothioate nucleotide regions for additional functionality
|
WO2010090969A1
(en)
|
2009-02-06 |
2010-08-12 |
Isis Pharmaceuticals, Inc. |
Tetrahydropyran nucleic acid analogs
|
US20100233733A1
(en)
*
|
2009-02-10 |
2010-09-16 |
Nodality, Inc., A Delaware Corporation |
Multiple mechanisms for modulation of the pi3 kinase pathway
|
JP6066035B2
(ja)
|
2009-02-12 |
2017-01-25 |
クルナ・インコーポレーテッド |
グリア細胞由来神経栄養因子(gdnf)関連疾病の、gdnfに対する天然アンチセンス転写物の抑制による治療
|
US9074210B2
(en)
|
2009-02-12 |
2015-07-07 |
Curna, Inc. |
Treatment of brain derived neurotrophic factor (BDNF) related diseases by inhibition of natural antisense transcript to BDNF
|
US7964355B2
(en)
*
|
2009-02-17 |
2011-06-21 |
Investigen, Inc. |
Assays based on detection of photobleaching reaction products from dye catalytic complex
|
US20120041051A1
(en)
|
2009-02-26 |
2012-02-16 |
Kevin Fitzgerald |
Compositions And Methods For Inhibiting Expression Of MIG-12 Gene
|
EP2669290A1
(de)
|
2009-03-02 |
2013-12-04 |
Alnylam Pharmaceuticals Inc. |
Chemische Nukleinsäuremodifikationen
|
EP2963116B1
(de)
|
2009-03-04 |
2020-11-11 |
CuRNA, Inc. |
Behandlung von sirtuin 1 (sirt1)-bedingten erkrankungen mittels hemmung des natürlichen antisense-transkripts gegen sirt 1
|
JP6032724B2
(ja)
|
2009-03-12 |
2016-11-30 |
アルナイラム ファーマシューティカルズ, インコーポレイテッドAlnylam Pharmaceuticals, Inc. |
脂質製剤組成物およびEg5遺伝子とVEGF遺伝子の発現を阻害する方法
|
US9464287B2
(en)
|
2009-03-16 |
2016-10-11 |
Curna, Inc. |
Treatment of nuclear factor (erythroid-derived 2)-like 2 (NRF2) related diseases by inhibition of natural antisense transcript to NRF2
|
MX2011009752A
(es)
|
2009-03-17 |
2011-09-29 |
Opko Curna Llc |
Tratamiento de enfermedades relacionadas a homologo tipo delta 1(dlk1) por inhibicion de transcrito antisentido natural a homologo tipo delta (dlk1).
|
CN102449169B
(zh)
*
|
2009-04-01 |
2016-03-16 |
德克斯特里蒂诊断公司 |
化学连接依赖性的探针扩增(clpa)
|
US8309356B2
(en)
*
|
2009-04-01 |
2012-11-13 |
Yale University |
Pseudocomplementary oligonucleotides for targeted gene therapy
|
WO2010120420A1
(en)
|
2009-04-15 |
2010-10-21 |
Northwestern University |
Delivery of oligonucleotide-functionalized nanoparticles
|
EP3248618A1
(de)
|
2009-04-22 |
2017-11-29 |
Massachusetts Institute Of Technology |
Angeborene immununterdrückung mit ermöglichung der wiederholten verabreichung von langen rna-molekülen
|
WO2010123369A1
(en)
|
2009-04-24 |
2010-10-28 |
Prosensa Technologies B.V. |
Oligonucleotide comprising an inosine for treating dmd
|
US8871494B2
(en)
|
2009-04-24 |
2014-10-28 |
Wisconsin Alumni Research Foundation |
Over-production of secondary metabolites by over-expression of the VEA gene
|
CN102639151B
(zh)
|
2009-05-01 |
2017-03-22 |
库尔纳公司 |
通过针对hbf/hbg的天然反义转录物的抑制治疗血红蛋白(hbf/hbg)相关疾病
|
US20100279882A1
(en)
*
|
2009-05-01 |
2010-11-04 |
Mostafa Ronaghi |
Sequencing methods
|
JP5769701B2
(ja)
|
2009-05-05 |
2015-08-26 |
テクミラ ファーマシューティカルズ コーポレイションTekmira Pharmaceuticals Corporation |
脂質組成物
|
AU2010245933B2
(en)
|
2009-05-05 |
2016-06-16 |
Arbutus Biopharma Corporation |
Methods of delivering oligonucleotides to immune cells
|
WO2010129746A2
(en)
|
2009-05-06 |
2010-11-11 |
Curna, Inc. |
Treatment of tristetraproline (ttp) related diseases by inhibition of natural antisense transcript to ttp
|
JP5883782B2
(ja)
|
2009-05-06 |
2016-03-15 |
クルナ・インコーポレーテッド |
脂質輸送代謝遺伝子に対する天然アンチセンス転写物の抑制による脂質輸送代謝遺伝子関連疾患の治療
|
CN102459597B
(zh)
|
2009-05-08 |
2020-06-30 |
库尔纳公司 |
通过针对dmd家族的天然反义转录物的抑制治疗肌营养蛋白家族相关疾病
|
WO2010132665A1
(en)
|
2009-05-15 |
2010-11-18 |
Yale University |
Gemm riboswitches, structure-based compound design with gemm riboswitches, and methods and compositions for use of and with gemm riboswitches
|
TW201102091A
(en)
*
|
2009-05-15 |
2011-01-16 |
Hoffmann La Roche |
Compositions and methods for inhibiting expression of glucocorticoid receptor (GCR) genes
|
CA2762369C
(en)
|
2009-05-18 |
2021-12-28 |
Joseph Collard |
Treatment of reprogramming factor related diseases by inhibition of natural antisense transcript to a reprogramming factor
|
CA2682429A1
(en)
*
|
2009-05-20 |
2010-11-20 |
Gary Levy |
An assay for measuring plasma fgl-2 and methods and uses thereof
|
EP2432882B1
(de)
|
2009-05-22 |
2019-12-25 |
CuRNA, Inc. |
Behandlung von erkrankungen im zusammenhang mit dem transkriptionsfaktor e3 (tfe3) und dem insulinrezeptorsubstrat 2 (irs2) mittels hemmung des natürlichen antisense-transkripts gegen tfe3
|
CN103221541B
(zh)
|
2009-05-28 |
2017-03-01 |
库尔纳公司 |
通过抑制抗病毒基因的天然反义转录物来治疗抗病毒基因相关疾病
|
CA2764158A1
(en)
|
2009-06-01 |
2010-12-09 |
Halo-Bio Rnai Therapeutics, Inc. |
Polynucleotides for multivalent rna interference, compositions and methods of use thereof
|
AU2010259984B2
(en)
|
2009-06-10 |
2017-03-09 |
Arbutus Biopharma Corporation |
Improved lipid formulation
|
CA2765427A1
(en)
|
2009-06-15 |
2010-12-23 |
Complete Genomics, Inc. |
Methods and compositions for long fragment read sequencing
|
ES2629339T3
(es)
|
2009-06-16 |
2017-08-08 |
Curna, Inc. |
Tratamiento de enfermedades relacionadas con la paraoxonasa 1 (pon1) por inhibición de transcrito antisentido natural a pon1
|
CA2765700C
(en)
|
2009-06-16 |
2021-01-05 |
Opko Curna, Llc |
Treatment of collagen gene related diseases by inhibition of natural antisense transcript to a collagen gene
|
US8859515B2
(en)
|
2009-06-24 |
2014-10-14 |
Curna, Inc. |
Treatment of tumor necrosis factor receptor 2 (TNFR2) related diseases by inhibition of natural antisense transcript to TNFR2
|
CN102482672B
(zh)
|
2009-06-26 |
2016-11-09 |
库尔纳公司 |
通过抑制唐氏综合征基因的天然反义转录物治疗唐氏综合征基因相关疾病
|
WO2011005861A1
(en)
|
2009-07-07 |
2011-01-13 |
Alnylam Pharmaceuticals, Inc. |
Oligonucleotide end caps
|
WO2011005860A2
(en)
|
2009-07-07 |
2011-01-13 |
Alnylam Pharmaceuticals, Inc. |
5' phosphate mimics
|
CA2768947C
(en)
|
2009-07-24 |
2018-06-19 |
Opko Curna, Llc |
Treatment of sirtuin (sirt) related diseases by inhibition of natural antisense transcript to a sirtuin (sirt)
|
US9523701B2
(en)
|
2009-07-29 |
2016-12-20 |
Dynex Technologies, Inc. |
Sample plate systems and methods
|
GB0913258D0
(en)
|
2009-07-29 |
2009-09-02 |
Dynex Technologies Inc |
Reagent dispenser
|
US9234199B2
(en)
|
2009-08-05 |
2016-01-12 |
Curna, Inc. |
Treatment of insulin gene (INS) related diseases by inhibition of natural antisense transcript to an insulin gene (INS)
|
EP2462153B1
(de)
|
2009-08-06 |
2015-07-29 |
Isis Pharmaceuticals, Inc. |
Bicyclische cyclohexosenukleinsäureanaloga
|
US9624522B2
(en)
|
2009-08-07 |
2017-04-18 |
Ohmx Corporation |
Single, direct detection of hemoglobin A1c percentage using enzyme triggered redox altering chemical elimination (e-trace) immunoassay
|
JP5352742B2
(ja)
|
2009-08-07 |
2013-11-27 |
オームクス コーポレーション |
酵素による酸化還元変化化学的脱離(e−trace)免疫学的検定法
|
EP2464731B1
(de)
|
2009-08-11 |
2016-10-05 |
CuRNA, Inc. |
Behandlung von adiponectin (adipoq)-bedingten erkrankungen mittels hemmung des natürlichen antisense-transkripts gegen ein adiponectin (adipoq)
|
AP2015008874A0
(en)
|
2009-08-14 |
2015-11-30 |
Alnylam Pharmaceuticals Inc |
Lipid formulated compositions and methods for inhibiting expression of a gene from the ebola virus
|
US8409802B2
(en)
|
2009-08-14 |
2013-04-02 |
Roche Molecular Systems, Inc. |
Format of probes to detect nucleic acid differences
|
WO2011022420A1
(en)
|
2009-08-17 |
2011-02-24 |
Yale University |
Methylation biomarkers and methods of use
|
EP2467482A4
(de)
|
2009-08-21 |
2013-12-11 |
Curna Inc |
Behandlung von chip (c-terminus des hsp70-interagierenden proteins)-bedingten erkrankungen mittels hemmung des natürlichen antisense-transkripts gegen chip
|
CA2771172C
(en)
|
2009-08-25 |
2021-11-30 |
Opko Curna, Llc |
Treatment of 'iq motif containing gtpase activating protein' (iqgap) related diseases by inhibition of natural antisense transcript to iqgap
|
JP5887270B2
(ja)
|
2009-09-02 |
2016-03-16 |
ジェネンテック, インコーポレイテッド |
突然変異体smoothenedおよびその使用方法
|
US10072287B2
(en)
|
2009-09-10 |
2018-09-11 |
Centrillion Technology Holdings Corporation |
Methods of targeted sequencing
|
US10174368B2
(en)
|
2009-09-10 |
2019-01-08 |
Centrillion Technology Holdings Corporation |
Methods and systems for sequencing long nucleic acids
|
WO2011038228A1
(en)
|
2009-09-24 |
2011-03-31 |
President And Fellows Of Harvard College |
Bent nanowires and related probing of species
|
DK2480669T3
(en)
|
2009-09-25 |
2018-02-12 |
Curna Inc |
TREATMENT OF FILAGGRIN- (FLG) RELATED DISEASES BY MODULATING FLG EXPRESSION AND ACTIVITY
|
US20130079382A1
(en)
|
2009-10-12 |
2013-03-28 |
Larry J. Smith |
Methods and Compositions for Modulating Gene Expression Using Oligonucleotide Based Drugs Administered in vivo or in vitro
|
US8962584B2
(en)
|
2009-10-14 |
2015-02-24 |
Yissum Research Development Company Of The Hebrew University Of Jerusalem, Ltd. |
Compositions for controlling Varroa mites in bees
|
WO2011045796A1
(en)
|
2009-10-14 |
2011-04-21 |
Yissum Research Development Company Of The Hebrew University Of Jerusalem Ltd. |
Compositions for controlling varroa mites in bees
|
WO2011050194A1
(en)
|
2009-10-22 |
2011-04-28 |
Genentech, Inc. |
Methods and compositions for modulating hepsin activation of macrophage-stimulating protein
|
WO2011056687A2
(en)
|
2009-10-27 |
2011-05-12 |
Swift Biosciences, Inc. |
Polynucleotide primers and probes
|
MX2012004905A
(es)
|
2009-10-30 |
2012-07-23 |
Univ British Columbia |
Mutaciones gna11 en melanoma.
|
CN102666879B
(zh)
|
2009-10-30 |
2016-02-24 |
西北大学 |
模板化的纳米缀合物
|
US20110268810A1
(en)
|
2009-11-02 |
2011-11-03 |
Yale University |
Polymeric materials loaded with mutagenic and recombinagenic nucleic acids
|
KR20210149203A
(ko)
|
2009-11-02 |
2021-12-08 |
더 트러스티스 오브 더 유니버시티 오브 펜실바니아 |
구제역 바이러스(fmdv) 공통 단백질, 이를 위한 코딩 서열 및 이로부터 만들어진 백신
|
KR20120102674A
(ko)
|
2009-11-03 |
2012-09-18 |
유니버시티 오브 버지니아 페이턴트 파운데이션 |
중합체 분석물을 검출하는 다용도의 가시적인 방법
|
WO2011054939A2
(en)
|
2009-11-09 |
2011-05-12 |
F. Hoffmann-La Roche Ag |
Compositions and methods for inhibiting expression of kif10 genes
|
WO2011058555A1
(en)
|
2009-11-12 |
2011-05-19 |
Yeda Research And Development Co. Ltd. |
A method of editing dna in a cell and constructs capable of same
|
KR102366851B1
(ko)
|
2009-11-12 |
2022-02-23 |
더 유니버시티 오브 웨스턴 오스트레일리아 |
안티센스 분자 및 이를 이용한 질환 치료방법
|
US8697858B2
(en)
|
2009-11-13 |
2014-04-15 |
Sarepta Therapeutics, Inc. |
Antisense antiviral compound and method for treating influenza viral infection
|
JP2013511285A
(ja)
|
2009-11-23 |
2013-04-04 |
スイフト・バイオサイエンシズ・インコーポレイテツド |
一本鎖標的分子を伸長させるデバイス
|
MX2012006072A
(es)
|
2009-11-30 |
2012-07-23 |
Genentech Inc |
Composiciones y metodos para el diagnostico y el tratamiento de tumores.
|
US8614071B2
(en)
|
2009-12-11 |
2013-12-24 |
Roche Molecular Systems, Inc. |
Preferential amplification of mRNA over DNA using chemically modified primers
|
JP6025567B2
(ja)
|
2009-12-16 |
2016-11-16 |
カッパーアールエヌエー,インコーポレイテッド |
膜結合転写因子ペプチダーゼ、部位1(mbtps1)に対する天然アンチセンス転写物の阻害によるmbtps1関連性疾患の治療
|
US20110152349A1
(en)
|
2009-12-18 |
2011-06-23 |
Anke Geick |
Compositions and methods for inhibiting expression of il-18 genes
|
US8940708B2
(en)
|
2009-12-23 |
2015-01-27 |
Curna, Inc. |
Treatment of hepatocyte growth factor (HGF) related diseases by inhibition of natural antisense transcript to HGF
|
WO2011079263A2
(en)
|
2009-12-23 |
2011-06-30 |
Curna, Inc. |
Treatment of uncoupling protein 2 (ucp2) related diseases by inhibition of natural antisense transcript to ucp2
|
WO2011078672A1
(en)
|
2009-12-24 |
2011-06-30 |
Prosensa Technologies B.V. |
Molecule for treating an inflammatory disorder
|
RU2615450C2
(ru)
|
2009-12-29 |
2017-04-04 |
Курна, Инк. |
Лечение заболеваний, связанных с ядерным респираторным фактором 1(nrf1), путем ингибирования природного антисмыслового транскрипта к nrf1
|
RU2611186C2
(ru)
|
2009-12-29 |
2017-02-21 |
Курна, Инк. |
ЛЕЧЕНИЕ ЗАБОЛЕВАНИЙ, СВЯЗАННЫХ С ОПУХОЛЕВЫМ БЕЛКОМ 63 (р63), ПУТЕМ ИНГИБИРОВАНИЯ ПРИРОДНОГО АНТИСМЫСЛОВОГО ТРАНСКРИПТА К р63
|
CN102791862B
(zh)
|
2009-12-31 |
2017-04-05 |
库尔纳公司 |
通过抑制胰岛素受体底物2(irs2)和转录因子e3(tfe3)的天然反义转录物而治疗irs2相关疾病
|
US8946181B2
(en)
|
2010-01-04 |
2015-02-03 |
Curna, Inc. |
Treatment of interferon regulatory factor 8 (IRF8) related diseases by inhibition of natural antisense transcript to IRF8
|
WO2011085066A2
(en)
|
2010-01-06 |
2011-07-14 |
Curna, Inc. |
Treatment of pancreatic developmental gene related diseases by inhibition of natural antisense transcript to a pancreatic developmental gene
|
CA2786535C
(en)
|
2010-01-11 |
2019-03-26 |
Curna, Inc. |
Treatment of sex hormone binding globulin (shbg) related diseases by inhibition of natural antisense transcript to shbg
|
US8779118B2
(en)
|
2010-01-11 |
2014-07-15 |
Isis Pharmaceuticals, Inc. |
Base modified bicyclic nucleosides and oligomeric compounds prepared therefrom
|
TWI535445B
(zh)
|
2010-01-12 |
2016-06-01 |
安可美德藥物股份有限公司 |
Wnt拮抗劑及治療和篩選方法
|
SG182365A1
(en)
|
2010-01-12 |
2012-08-30 |
Univ Yale |
Structured rna motifs and compounds and methods for their use
|
WO2011090971A2
(en)
|
2010-01-19 |
2011-07-28 |
The Trustees Of Columbia University In The City Of New York |
Osteocalcin as a treatment for male reproductive disorders
|
EP2525905B1
(de)
|
2010-01-19 |
2020-11-04 |
Illumina, Inc. |
Verfahren und zusammensetzungen zur verarbeitung chemischer reaktionen
|
RU2611192C2
(ru)
|
2010-01-25 |
2017-02-21 |
Курна, Инк. |
ЛЕЧЕНИЕ ЗАБОЛЕВАНИЙ, СВЯЗАННЫХ С РНКазой Н1, ПУТЕМ ИНГИБИРОВАНИЯ ПРИРОДНОГО АНТИСМЫСЛОВОГО ТРАНСКРИПТА К РНКазе Н1
|
US20130028889A1
(en)
|
2010-02-04 |
2013-01-31 |
Ico Therapeutics Inc. |
Dosing regimens for treating and preventing ocular disorders using c-raf antisense
|
US20110196016A1
(en)
*
|
2010-02-05 |
2011-08-11 |
Anke Geick |
Compositions and Methods for Inhibiting Expression of IKK2 Genes
|
EP2539452B1
(de)
|
2010-02-22 |
2016-07-27 |
CuRNA, Inc. |
Behandlung von durch pyrrolin-5-carboxylat-reduktase 1 (pycr1) vermittelten erkrankungen durch hemmung des natürlichen antisense-transkripts für pycr1
|
KR20130004579A
(ko)
|
2010-02-23 |
2013-01-11 |
제넨테크, 인크. |
종양의 진단 및 치료를 위한 조성물 및 방법
|
WO2011105900A2
(en)
|
2010-02-23 |
2011-09-01 |
Academisch Ziekenhuis Bij De Universiteit Van Amsterdam |
Antagonists of complement component 8-alpha (c8-alpha) and uses thereof
|
WO2011105902A2
(en)
|
2010-02-23 |
2011-09-01 |
Academisch Ziekenhuis Bij De Universiteit Van Amsterdam |
Antagonists of complement component 8-beta (c8-beta) and uses thereof
|
WO2011105901A2
(en)
|
2010-02-23 |
2011-09-01 |
Academisch Ziekenhuis Bij De Universiteit Van Amsterdam |
Antagonists of complement component 9 (c9) and uses thereof
|
US9624491B2
(en)
|
2010-02-26 |
2017-04-18 |
Memorial Sloan Kettering Cancer Center |
Methods and compositions for the detection and treatment of cancer involving miRNAs and miRNA inhibitors and targets
|
EP2542249A4
(de)
|
2010-03-05 |
2013-08-07 |
Tissue Genesis Inc |
Verfahren und zusammensetzungen zur unterstützung von gewebeintegration und inokulation von transplantiertem gewebe und transplantiertem gezüchtetem penisgewebe mit stromazellen aus fettgewebe
|
HUE033056T2
(hu)
|
2010-03-08 |
2017-11-28 |
Monsanto Technology Llc |
Polinukleotid molekulák génszabályozáshoz növényekben
|
WO2011112516A1
(en)
|
2010-03-08 |
2011-09-15 |
Ico Therapeutics Inc. |
Treating and preventing hepatitis c virus infection using c-raf kinase antisense oligonucleotides
|
ES2743600T3
(es)
|
2010-03-12 |
2020-02-20 |
Brigham & Womens Hospital Inc |
Métodos de tratamiento de los trastornos inflamatorios vasculares
|
EP2545173A2
(de)
|
2010-03-12 |
2013-01-16 |
Sarepta Therapeutics, Inc. |
Antisense-modulation von nukleären hormonrezeptoren
|
WO2011113054A2
(en)
|
2010-03-12 |
2011-09-15 |
Aurasense Llc |
Crosslinked polynucleotide structure
|
WO2011116209A2
(en)
|
2010-03-17 |
2011-09-22 |
The Regents Of The University Of Michigan |
Using phage epitopes to profile the immune response
|
WO2011115818A1
(en)
|
2010-03-17 |
2011-09-22 |
Isis Pharmaceuticals, Inc. |
5'-substituted bicyclic nucleosides and oligomeric compounds prepared therefrom
|
WO2011120046A2
(en)
|
2010-03-26 |
2011-09-29 |
Swift Biosciences, Inc. |
Methods and compositions for isolating polynucleotides
|
JP5860029B2
(ja)
|
2010-03-29 |
2016-02-16 |
アルナイラム ファーマシューティカルズ, インコーポレイテッドAlnylam Pharmaceuticals, Inc. |
トランスチレチン(TTR)関連眼アミロイドーシスのためのsiRNA療法
|
AU2011235904B2
(en)
|
2010-04-01 |
2015-10-08 |
Oncomed Pharmaceuticals, Inc. |
Frizzled-binding agents and uses thereof
|
US9102938B2
(en)
|
2010-04-01 |
2015-08-11 |
Alnylam Pharmaceuticals, Inc. |
2′ and 5′ modified monomers and oligonucleotides
|
ES2657969T3
(es)
|
2010-04-02 |
2018-03-07 |
Curna, Inc. |
Tratamiento de enfermedades relacionadas con el Factor 3 estimulante de colonias (CSF3) por inhibición del transcrito antisentido natural a CSF3
|
EP2556160A4
(de)
|
2010-04-09 |
2013-08-21 |
Curna Inc |
Behandlung von erkrankungen im zusammenhang mit dem fibroblastenwachstumsfaktor 21 (fgf21) mittels hemmung des natürlichen antisense-transkripts gegen fgf21
|
US20110269194A1
(en)
|
2010-04-20 |
2011-11-03 |
Swift Biosciences, Inc. |
Materials and methods for nucleic acid fractionation by solid phase entrapment and enzyme-mediated detachment
|
US20110262406A1
(en)
|
2010-04-21 |
2011-10-27 |
Yale University |
Compositions and methods for targeted inactivation of hiv cell surface receptors
|
WO2011133802A1
(en)
|
2010-04-21 |
2011-10-27 |
Helix Therapeutics, Inc. |
Compositions and methods for treatment of lysosomal storage disorders
|
US9725479B2
(en)
|
2010-04-22 |
2017-08-08 |
Ionis Pharmaceuticals, Inc. |
5′-end derivatives
|
EP2563380B1
(de)
|
2010-04-26 |
2018-05-30 |
aTyr Pharma, Inc. |
Innovative entdeckung therapeutischer, diagnostischer und antikörperhaltiger zusammensetzungen im zusammenhang mit proteinfragmenten der cysteinyl-trna-synthetase
|
JP6294074B2
(ja)
|
2010-04-27 |
2018-03-14 |
エータイアー ファーマ, インコーポレイテッド |
イソロイシルtRNA合成酵素のタンパク質フラグメントに関連した治療用、診断用および抗体組成物の革新的発見
|
AU2011248489B2
(en)
|
2010-04-28 |
2016-10-06 |
Pangu Biopharma Limited |
Innovative discovery of therapeutic, diagnostic, and antibody compositions related to protein fragments of alanyl tRNA synthetases
|
EP2625186B1
(de)
|
2010-04-28 |
2016-07-27 |
Ionis Pharmaceuticals, Inc. |
5'-modifizierte nukleoside und daraus hergestellte oligomere verbindungen
|
CN103154014B
(zh)
|
2010-04-28 |
2015-03-25 |
Isis制药公司 |
修饰核苷、其类似物以及由它们制备的寡聚化合物
|
DK2563920T3
(en)
|
2010-04-29 |
2017-05-22 |
Ionis Pharmaceuticals Inc |
Modulation of transthyretin expression
|
AU2011248490B2
(en)
|
2010-04-29 |
2016-11-10 |
Pangu Biopharma Limited |
Innovative discovery of therapeutic, diagnostic, and antibody compositions related to protein fragments of Asparaginyl tRNA synthetases
|
JP5991963B2
(ja)
|
2010-04-29 |
2016-09-14 |
エータイアー ファーマ, インコーポレイテッド |
バリルtRNA合成酵素のタンパク質フラグメントに関連した治療用、診断用および抗体組成物の革新的発見
|
JP6008841B2
(ja)
|
2010-05-03 |
2016-10-19 |
エータイアー ファーマ, インコーポレイテッド |
メチオニルtRNA合成酵素のタンパク質フラグメントに関連した治療用、診断用および抗体組成物の革新的発見
|
CN103096912A
(zh)
|
2010-05-03 |
2013-05-08 |
Atyr医药公司 |
与苯丙氨酰-α-tRNA合成酶的蛋白片段相关的治疗、诊断和抗体组合物的创新发现
|
EP2566515B1
(de)
|
2010-05-03 |
2017-08-02 |
aTyr Pharma, Inc. |
Innovative entdeckung von therapeutischen und diagnostischen mitteln sowie antikörperzusammensetzungen im zusammenhang mit proteinfragmenten von arginyl-trna-synthetasen
|
BR112012028010A2
(pt)
|
2010-05-03 |
2017-09-26 |
Genentech Inc |
anticorpo isolado, célula, ácido nucleíco isolado, método de identificação de um primeiro anticorpo que se liga a um epítopo antigênico tat425 ligado or um anticorpo, métodos de inibir o crescimento de uma célula, de tratamento terapêutico de determinação da presença de uma proteína de tat425 e de diagnóstico da presença de um tumor em um mamífero
|
RU2018110642A
(ru)
|
2010-05-03 |
2019-02-27 |
Курна, Инк. |
Лечение заболеваний, связанных с сиртуином (sirt), путем ингибирования природного антисмыслового транскрипта к сиртуину (sirt)
|
CA2798139C
(en)
|
2010-05-04 |
2019-09-24 |
Atyr Pharma, Inc. |
Innovative discovery of therapeutic, diagnostic, and antibody compositions related to protein fragments of p38 multi-trna synthetase complex
|
WO2011137533A1
(en)
|
2010-05-05 |
2011-11-10 |
The Governing Council Of The University Of Toronto |
Method of processing dried samples using digital microfluidic device
|
EP3078753B1
(de)
|
2010-05-10 |
2018-04-18 |
The Regents of The University of California |
Verfahren unter verwendung von endoribonukleasezusammensetzungen
|
EP2569430B1
(de)
|
2010-05-12 |
2018-10-17 |
The Trustees of Columbia University in the City of New York |
Verfahren zur herstellung enteroendokriner zellen zur produktion und abgabe von insulin
|
US9050373B2
(en)
|
2010-05-13 |
2015-06-09 |
The Charlotte-Mecklenburg Hospital Authority |
Pharmaceutical compositions comprising antisense oligonucleotides and methods of using same
|
ES2816898T3
(es)
|
2010-05-13 |
2021-04-06 |
Sarepta Therapeutics Inc |
Compuestos que modulan la actividad de señalización de las interleucinas 17 y 23
|
TWI531370B
(zh)
|
2010-05-14 |
2016-05-01 |
可娜公司 |
藉由抑制par4天然反股轉錄本治療par4相關疾病
|
WO2011143482A2
(en)
|
2010-05-14 |
2011-11-17 |
Atyr Pharma, Inc. |
Innovative discovery of therapeutic, diagnostic, and antibody compositions related to protein fragments of phenylalanyl-beta-trna synthetases
|
US9034598B2
(en)
|
2010-05-17 |
2015-05-19 |
Atyr Pharma, Inc. |
Innovative discovery of therapeutic, diagnostic, and antibody compositions related to protein fragments of leucyl-tRNA synthetases
|
EP3299464B1
(de)
|
2010-05-26 |
2019-10-02 |
CuRNA, Inc. |
Behandlung von durch atonal homolog 1 (atoh1) vermittelten erkrankungen durch hemmung des natürlichen antisense-transkripts für atoh1
|
NO2576784T3
(de)
|
2010-05-26 |
2018-04-14 |
|
|
US20130203045A1
(en)
|
2010-05-26 |
2013-08-08 |
University Of Virginia Patent Foundation |
Method for detecting nucleic acids based on aggregate formation
|
CA2800375C
(en)
|
2010-05-27 |
2021-03-09 |
Atyr Pharma, Inc. |
Innovative discovery of therapeutic, diagnostic, and antibody compositions related to protein fragments of glutaminyl-trna synthetases
|
NZ603606A
(en)
|
2010-05-28 |
2015-06-26 |
Sarepta Therapeutics Inc |
Oligonucleotide analogues having modified intersubunit linkages and/or terminal groups
|
AU2011261434B2
(en)
|
2010-06-02 |
2015-11-26 |
Alnylam Pharmaceuticals, Inc. |
Compositions and methods directed to treating liver fibrosis
|
US9228240B2
(en)
|
2010-06-03 |
2016-01-05 |
California Institute Of Technology |
Methods for detecting and quantifying viable bacterial endo-spores
|
US8957200B2
(en)
|
2010-06-07 |
2015-02-17 |
Isis Pharmaceuticals, Inc. |
Bicyclic nucleosides and oligomeric compounds prepared therefrom
|
WO2011156202A1
(en)
|
2010-06-08 |
2011-12-15 |
Isis Pharmaceuticals, Inc. |
Substituted 2 '-amino and 2 '-thio-bicyclic nucleosides and oligomeric compounds prepared therefrom
|
WO2011156713A1
(en)
|
2010-06-11 |
2011-12-15 |
Vanderbilt University |
Multiplexed interferometric detection system and method
|
CN109112126A
(zh)
|
2010-06-23 |
2019-01-01 |
库尔纳公司 |
通过抑制电压门控钠通道α亚基(SCNA)的天然反义转录物而治疗SCNA相关疾病
|
US9168297B2
(en)
|
2010-06-23 |
2015-10-27 |
The United States Of America, As Represented By The Secretary, Department Of Health And Human Services |
Regulation of skin pigmentation by neuregulin-1 (NRG-1)
|
EP2588123A2
(de)
|
2010-06-30 |
2013-05-08 |
Compugen Ltd. |
C1orf32 zur behandlung von multipler sklerose, rheumatoider arthritis und anderen autoimmunerkrankungen
|
EP2593125B1
(de)
|
2010-07-12 |
2017-11-01 |
aTyr Pharma, Inc. |
Innovative erkennung therapeutischer, diagnostischer und antikörperhaltiger zusammensetzungen in zusammenhang mit proteinfragmenten von glycyl-trna-synthetasen
|
NO2593547T3
(de)
|
2010-07-14 |
2018-04-14 |
|
|
NZ605438A
(en)
|
2010-07-22 |
2015-02-27 |
Harvard College |
Multiple input biologic classifier circuits for cells
|
US8198429B2
(en)
|
2010-08-09 |
2012-06-12 |
Avi Biopharma, Inc. |
Antisense antiviral compounds and methods for treating a filovirus infection
|
US20130143955A1
(en)
|
2010-08-09 |
2013-06-06 |
Yale University |
Cyclic di-GMP-II Riboswitches, Motifs, and Compounds, and Methods for Their Use
|
CN103228796B
(zh)
|
2010-08-11 |
2016-06-01 |
赛路拉公司 |
基因分型dna
|
WO2012027611A2
(en)
|
2010-08-25 |
2012-03-01 |
Atyr Pharma, Inc. |
INNOVATIVE DISCOVERY OF THERAPEUTIC, DIAGNOSTIC, AND ANTIBODY COMPOSITIONS RELATED TO PROTEIN FRAGMENTS OF TYROSYL-tRNA SYNTHETASES
|
WO2012028697A1
(en)
|
2010-09-01 |
2012-03-08 |
Eth Zürich, Institute Of Molecular Biology And Biophysics |
Affinity purification system based on donor strand complementation
|
US10017763B2
(en)
|
2010-09-03 |
2018-07-10 |
Sarepta Therapeutics, Inc. |
dsRNA molecules comprising oligonucleotide analogs having modified intersubunit linkages and/or terminal groups
|
JP5917519B2
(ja)
|
2010-09-10 |
2016-05-18 |
バイオ−ラッド ラボラトリーズ インコーポレーティッド |
クロマチン分析のためのdnaのサイズ選択
|
US8483969B2
(en)
|
2010-09-17 |
2013-07-09 |
Illuminia, Inc. |
Variation analysis for multiple templates on a solid support
|
US20130210901A1
(en)
|
2010-09-20 |
2013-08-15 |
Yissum Research Development Company Of The Hebrew University Of Jerusalem Ltd. |
Method of treating neurodegenerative diseases
|
DK2625197T3
(en)
|
2010-10-05 |
2016-10-03 |
Genentech Inc |
Smoothened MUTANT AND METHODS OF USING THE SAME
|
CA2813901C
(en)
|
2010-10-06 |
2019-11-12 |
Curna, Inc. |
Treatment of sialidase 4 (neu4) related diseases by inhibition of natural antisense transcript to neu4
|
WO2012048113A2
(en)
|
2010-10-07 |
2012-04-12 |
The General Hospital Corporation |
Biomarkers of cancer
|
US8951983B2
(en)
|
2010-10-17 |
2015-02-10 |
Yeda Research And Development Co. Ltd. |
Methods and compositions for the treatment of insulin-associated medical conditions
|
EP2630240A1
(de)
|
2010-10-18 |
2013-08-28 |
Arrowhead Research Corporation |
Zusammensetzungen und verfahren zur hemmung der expression von rrm2-genen
|
US8648053B2
(en)
|
2010-10-20 |
2014-02-11 |
Rosalind Franklin University Of Medicine And Science |
Antisense oligonucleotides that target a cryptic splice site in Ush1c as a therapeutic for Usher syndrome
|
US9222088B2
(en)
|
2010-10-22 |
2015-12-29 |
Curna, Inc. |
Treatment of alpha-L-iduronidase (IDUA) related diseases by inhibition of natural antisense transcript to IDUA
|
EP2633069B1
(de)
|
2010-10-26 |
2015-07-01 |
Illumina, Inc. |
Sequenzierungsverfahren
|
DK2633052T3
(en)
|
2010-10-27 |
2018-07-16 |
Curna Inc |
TREATMENT OF INTERFERON-RELATED DEVELOPMENT REGULATOR 1 (IFRD1) -RELATED DISEASES BY INHIBITION OF NATURAL ANTISENCE TRANSCRIPT TO IFRD1
|
CN106399472A
(zh)
|
2010-10-28 |
2017-02-15 |
生命技术公司 |
化学增强型引物组合物、方法和试剂盒
|
EP2635679B1
(de)
|
2010-11-05 |
2017-04-19 |
Illumina, Inc. |
Verknüpfung von sequenzstücken mit gepaarten code-tags
|
CN103370054A
(zh)
|
2010-11-09 |
2013-10-23 |
阿尔尼拉姆医药品有限公司 |
用于抑制Eg5和VEGF基因的表达的脂质配制的组合物和方法
|
WO2012065143A1
(en)
|
2010-11-12 |
2012-05-18 |
The General Hospital Corporation |
Polycomb-associated non-coding rnas
|
EP2638161A1
(de)
|
2010-11-12 |
2013-09-18 |
Sarepta Therapeutics, Inc. |
Antibakterielle antisense-verbindungen und verfahren
|
US9663783B2
(en)
|
2010-11-17 |
2017-05-30 |
Ionis Pharmaceuticals, Inc. |
Modulation of alpha synuclein expression
|
US10000752B2
(en)
|
2010-11-18 |
2018-06-19 |
Curna, Inc. |
Antagonat compositions and methods of use
|
CN103459599B
(zh)
|
2010-11-23 |
2017-06-16 |
库尔纳公司 |
通过抑制nanog的天然反义转录物而治疗nanog相关疾病
|
US9150926B2
(en)
|
2010-12-06 |
2015-10-06 |
The United States Of America, As Represented By The Secretary, Department Of Health And Human Services |
Diagnosis and treatment of adrenocortical tumors using human microRNA-483
|
WO2012078967A2
(en)
|
2010-12-10 |
2012-06-14 |
Alnylam Pharmaceuticals, Inc. |
Compositions and methods for increasing erythropoietin (epo) production
|
EP2648763A4
(de)
|
2010-12-10 |
2014-05-14 |
Alnylam Pharmaceuticals Inc |
Zusammensetzungen und verfahren zur expressionshemmung der gene klf-1 und bcl11a
|
US20120208189A1
(en)
|
2011-01-14 |
2012-08-16 |
Life Technologies Corporation |
Methods for isolation, identification, and quantification of mirnas
|
US9045749B2
(en)
|
2011-01-14 |
2015-06-02 |
The General Hospital Corporation |
Methods targeting miR-128 for regulating cholesterol/lipid metabolism
|
WO2012100078A1
(en)
|
2011-01-19 |
2012-07-26 |
Ohmx Corporation |
Enzyme triggered redox altering chemical elimination (e-trace) immmunoassay
|
CA2821559C
(en)
|
2011-01-28 |
2017-01-31 |
Illumina, Inc. |
Oligonucleotide replacement for di-tagged and directional libraries
|
EP2670864B1
(de)
|
2011-01-31 |
2017-03-08 |
Illumina, Inc. |
Verfahren zur reduzierung von nukleinsäureschäden
|
SI2670411T1
(sl)
|
2011-02-02 |
2019-06-28 |
Excaliard Pharmaceuticals, Inc. |
Protismiselne spojine, ki so usmerjene na rastni faktor veznega tkiva (CTGF), za uporabo v postopku zdravljenja keloidov ali hipertrofnih brazgotin
|
CN103391777A
(zh)
|
2011-02-02 |
2013-11-13 |
普林斯顿大学理事会 |
作为病毒产生调节剂的去乙酰化酶调节剂
|
US9327037B2
(en)
|
2011-02-08 |
2016-05-03 |
The Johns Hopkins University |
Mucus penetrating gene carriers
|
WO2012109296A1
(en)
|
2011-02-08 |
2012-08-16 |
The Charlotte-Mecklenburg Hospital Authority D/B/A Carolinas Medical Center |
Antisense oligonucleotides
|
US9365897B2
(en)
|
2011-02-08 |
2016-06-14 |
Illumina, Inc. |
Selective enrichment of nucleic acids
|
EP3483285B1
(de)
|
2011-02-09 |
2021-07-14 |
Bio-Rad Laboratories, Inc. |
Analyse von nukleinsäuren
|
WO2012109495A1
(en)
|
2011-02-09 |
2012-08-16 |
Metabolic Solutions Development Company, Llc |
Cellular targets of thiazolidinediones
|
WO2012112606A1
(en)
|
2011-02-15 |
2012-08-23 |
Bio-Rad Laboratories, Inc. |
Detecting methylati0n in a subpopulation of genomic dna
|
US9562853B2
(en)
|
2011-02-22 |
2017-02-07 |
Vanderbilt University |
Nonaqueous backscattering interferometric methods
|
WO2012129242A2
(en)
|
2011-03-23 |
2012-09-27 |
Pacific Biosciences Of California, Inc. |
Isolation of polymerase-nucleic acid complexes and loading onto substrates
|
EP3406267A1
(de)
|
2011-03-25 |
2018-11-28 |
Children's Medical Center Corporation |
Lin28-vermittelte steuerung der let-7-biogenese
|
SG193923A1
(en)
|
2011-03-29 |
2013-11-29 |
Alnylam Pharmaceuticals Inc |
Compositions and methods for inhibiting expression of tmprss6 gene
|
CA2831613A1
(en)
|
2011-03-31 |
2012-10-04 |
Moderna Therapeutics, Inc. |
Delivery and formulation of engineered nucleic acids
|
US20120252682A1
(en)
|
2011-04-01 |
2012-10-04 |
Maples Corporate Services Limited |
Methods and systems for sequencing nucleic acids
|
JP2014511694A
(ja)
|
2011-04-03 |
2014-05-19 |
ザ ジェネラル ホスピタル コーポレーション ドゥーイング ビジネス アズ マサチューセッツ ジェネラル ホスピタル |
修飾型rna(mod−rna)を使用する効率的なインビボタンパク質発現
|
RU2016147206A
(ru)
|
2011-04-15 |
2018-10-19 |
Компуджен Лтд. |
Полипептиды и полинуклеотиды и их применение для лечения иммунологических нарушений и рака
|
AU2012249759A1
(en)
|
2011-04-25 |
2013-11-07 |
Bio-Rad Laboratories, Inc. |
Methods and compositions for nucleic acid analysis
|
WO2012149154A1
(en)
|
2011-04-26 |
2012-11-01 |
Swift Biosciences, Inc. |
Polynucleotide primers and probes
|
WO2012151289A2
(en)
|
2011-05-02 |
2012-11-08 |
University Of Virginia Patent Foundation |
Method and system to detect aggregate formation on a substrate
|
WO2012151268A1
(en)
|
2011-05-02 |
2012-11-08 |
University Of Virginia Patent Foundation |
Method and system for high throughput optical and label free detection of analytes
|
WO2012151324A1
(en)
|
2011-05-02 |
2012-11-08 |
Isis Pharmaceuticals, Inc. |
Antisense compounds targeting genes associated with usher syndrome
|
CN103619356B
(zh)
|
2011-05-05 |
2017-09-12 |
萨勒普塔医疗公司 |
肽寡核苷酸缀合物
|
CN105132284B
(zh)
|
2011-05-13 |
2018-04-03 |
加利福尼亚大学董事会 |
用于选择性转染细胞的光热衬底
|
CN106434871B
(zh)
|
2011-05-17 |
2020-08-18 |
德克斯特里蒂诊断公司 |
用于检测目标核酸的方法与组合物
|
BR112013029857A2
(pt)
|
2011-05-24 |
2017-11-28 |
Mor Research Applic Ltd |
métodos e composições para determinação de insuficiência cardíaca ou risco de insuficiência cardíaca
|
RU2620980C2
(ru)
|
2011-06-09 |
2017-05-30 |
Курна, Инк. |
Лечение заболеваний, связанных с фратаксином (fxn), путем ингибирования природного антисмыслового транскрипта fxn
|
WO2012170347A1
(en)
|
2011-06-09 |
2012-12-13 |
Isis Pharmaceuticals, Inc. |
Bicyclic nucleosides and oligomeric compounds prepared therefrom
|
EP2717923B1
(de)
|
2011-06-10 |
2017-09-27 |
Ionis Pharmaceuticals, Inc. |
Verfahren zur modulierung der kallikrein (klkb1)-expression
|
MX360782B
(es)
|
2011-06-21 |
2018-11-16 |
Alnylam Pharmaceuticals Inc |
Composiciones de arni similares a angiopoyetina 3 (angptl3) y metodos para su uso.
|
US9068184B2
(en)
|
2011-06-21 |
2015-06-30 |
Alnylam Pharmaceuticals, Inc. |
Compositions and methods for inhibition of expression of protein C (PROC) genes
|
MX344807B
(es)
|
2011-06-21 |
2017-01-09 |
Alnylam Pharmaceuticals Inc |
Composiciones y metodos para inhibicion de genes para alipoproteina c-iii (apoc3).
|
EP3366312A1
(de)
|
2011-06-23 |
2018-08-29 |
Alnylam Pharmaceuticals, Inc. |
Serpina 1 sirnas: materialzusammensetzungen und verfahren zur behandlung
|
CA2840614A1
(en)
|
2011-06-29 |
2013-01-03 |
Isis Pharmaceuticals, Inc. |
Methods for modulating kallikrein (klkb1) expression
|
EP2726503B1
(de)
|
2011-06-30 |
2019-09-04 |
Compugen Ltd. |
Polypetide und ihre verwendung zur behandlung von autoimmunerkrankungen und infektionen
|
WO2013001372A2
(en)
|
2011-06-30 |
2013-01-03 |
University Of Oslo |
Methods and compositions for inhibition of activation of regulatory t cells
|
JP6165723B2
(ja)
|
2011-06-30 |
2017-07-19 |
アローヘッド ファーマシューティカルズ インコーポレイテッド |
B型肝炎ウイルスの遺伝子発現を阻害するための組成物および方法
|
JP6109165B2
(ja)
|
2011-07-01 |
2017-04-05 |
ザ リージェンツ オブ ザ ユニバーシティ オブ カリフォルニア |
ヘルペスウイルスワクチンおよび使用方法
|
US10100305B2
(en)
|
2011-07-15 |
2018-10-16 |
Sarepta Therapeutics, Inc. |
Methods and compositions for manipulating translation of protein isoforms from alternative initiation of start sites
|
US20140328811A1
(en)
|
2011-08-01 |
2014-11-06 |
Alnylam Pharmaceuticals, Inc. |
Method for improving the success rate of hematopoietic stem cell transplants
|
EP2739752B1
(de)
|
2011-08-03 |
2017-07-19 |
Bio-Rad Laboratories, Inc. |
Filterung von kleinen nukleinsäuren anhand von permeabilisierten zellen
|
EP3524679B1
(de)
|
2011-08-04 |
2021-10-06 |
Yeda Research and Development Co., Ltd. |
Mikro-rna mir-19 und zusammensetzungen damit zur behandlung medizinischer zustände, bei denen ein niedriger adrenalin- oder noradrenalinspiegel therapeutisch sinnvoll ist
|
US9040678B2
(en)
|
2011-08-05 |
2015-05-26 |
Illumina, Inc. |
Functionalization and purification of molecules by reversible group exchange
|
WO2013036403A1
(en)
|
2011-09-06 |
2013-03-14 |
Curna, Inc. |
TREATMENT OF DISEASES RELATED TO ALPHA SUBUNITS OF SODIUM CHANNELS, VOLTAGE-GATED (SCNxA) WITH SMALL MOLECULES
|
US9840715B1
(en)
|
2011-09-13 |
2017-12-12 |
Monsanto Technology Llc |
Methods and compositions for delaying senescence and improving disease tolerance and yield in plants
|
MX343071B
(es)
|
2011-09-13 |
2016-10-21 |
Monsanto Technology Llc |
Metodos y composiciones para el control de malezas.
|
US10760086B2
(en)
|
2011-09-13 |
2020-09-01 |
Monsanto Technology Llc |
Methods and compositions for weed control
|
CA2848689A1
(en)
|
2011-09-13 |
2013-03-21 |
Monsanto Technology Llc |
Methods and compositions for weed control targeting pds
|
ES2645927T3
(es)
|
2011-09-13 |
2017-12-11 |
Monsanto Technology Llc |
Procedimientos y composiciones para el control de malezas
|
WO2013040033A1
(en)
|
2011-09-13 |
2013-03-21 |
Monsanto Technology Llc |
Methods and compositions for weed control
|
US10829828B2
(en)
|
2011-09-13 |
2020-11-10 |
Monsanto Technology Llc |
Methods and compositions for weed control
|
US10806146B2
(en)
|
2011-09-13 |
2020-10-20 |
Monsanto Technology Llc |
Methods and compositions for weed control
|
US9580708B2
(en)
|
2011-09-14 |
2017-02-28 |
Rana Therapeutics, Inc. |
Multimeric oligonucleotides compounds
|
WO2013040499A1
(en)
|
2011-09-14 |
2013-03-21 |
Northwestern University |
Nanoconjugates able to cross the blood-brain barrier
|
US9920326B1
(en)
|
2011-09-14 |
2018-03-20 |
Monsanto Technology Llc |
Methods and compositions for increasing invertase activity in plants
|
US20140234373A1
(en)
|
2011-09-16 |
2014-08-21 |
Georfia Regents University |
Methods of Promoting Immune Tolerance
|
WO2013040548A2
(en)
|
2011-09-17 |
2013-03-21 |
Yale University |
Fluoride-responsive riboswitchs, fluoride transporters, and methods of use
|
US9801948B2
(en)
|
2011-09-21 |
2017-10-31 |
Yale University |
Antimicrobial compositions and methods of use thereof
|
WO2013041194A1
(en)
|
2011-09-23 |
2013-03-28 |
Roche Diagnostics Gmbh |
Use of g-clamp for improved allele-specific pcr
|
US20130085139A1
(en)
|
2011-10-04 |
2013-04-04 |
Royal Holloway And Bedford New College |
Oligomers
|
US10184151B2
(en)
|
2011-10-11 |
2019-01-22 |
The Brigham And Women's Hospital, Inc. |
Micrornas in neurodegenerative disorders
|
EA201490778A1
(ru)
|
2011-10-14 |
2014-09-30 |
Дженентек, Инк. |
АНТИТЕЛА ПРОТИВ HtrA1 И СПОСОБЫ ПРИМЕНЕНИЯ
|
ES2660228T3
(es)
|
2011-10-14 |
2018-03-21 |
Becton Dickinson & Company |
Ciclado térmico de onda cuadrada
|
US9206418B2
(en)
|
2011-10-19 |
2015-12-08 |
Nugen Technologies, Inc. |
Compositions and methods for directional nucleic acid amplification and sequencing
|
WO2013061328A2
(en)
|
2011-10-27 |
2013-05-02 |
Yeda Research And Development Co. Ltd. |
Method of treating cancer
|
ES2791830T3
(es)
|
2011-10-28 |
2020-11-06 |
Univ California |
Mutaciones de FLT3 asociadas a resistencia a fármacos en pacientes con aml que tienen mutaciones activadoras en FLT3
|
EP2771341A4
(de)
|
2011-10-28 |
2015-09-23 |
Univ Texas |
Neue zusammensetzungen und verfahren zur behandlung von krebs
|
US10837879B2
(en)
|
2011-11-02 |
2020-11-17 |
Complete Genomics, Inc. |
Treatment for stabilizing nucleic acid arrays
|
JP2014532720A
(ja)
|
2011-11-04 |
2014-12-08 |
オームクス コーポレイション |
バイオセンサーにおいて使用される新規化学
|
KR20140097398A
(ko)
|
2011-11-18 |
2014-08-06 |
사렙타 쎄러퓨틱스, 인코퍼레이티드 |
기능적으로-변형된 올리고뉴클레오티드 및 이의 서브유니트
|
EP2785840B8
(de)
|
2011-11-30 |
2019-05-22 |
Sarepta Therapeutics, Inc. |
Induzierte exon-inklusion in spinaler muskelatrophie
|
US10066228B2
(en)
|
2011-11-30 |
2018-09-04 |
Sarepta Therapeutics, Inc. |
Oligonucleotides for treating expanded repeat diseases
|
US10465042B2
(en)
|
2011-12-02 |
2019-11-05 |
Yale University |
Poly(amine-co-ester) nanoparticles and methods of use thereof
|
US9895451B2
(en)
|
2011-12-02 |
2018-02-20 |
Yale University |
Formulations for targeted release of agents to low pH tissue environments or cellular compartments and methods of use thereof
|
WO2013082529A1
(en)
|
2011-12-02 |
2013-06-06 |
Yale University |
Enzymatic synthesis of poly(amine-co-esters) and methods of use thereof for gene delivery
|
LT2788487T
(lt)
|
2011-12-08 |
2018-09-10 |
Sarepta Therapeutics, Inc. |
Oligonukleotido analogai, nukreipti į žmogaus lmna
|
US10557136B2
(en)
|
2011-12-12 |
2020-02-11 |
Oncolmmunin Inc. |
In vivo delivery of oligonucleotides
|
AU2012351994B2
(en)
|
2011-12-14 |
2015-11-05 |
The Johns Hopkins University |
Nanoparticles with enhanced mucosal penetration or decreased inflammation
|
IN2014MN00974A
(de)
|
2011-12-16 |
2015-04-24 |
Targetgene Biotechnologies Ltd |
|
ES2923757T3
(es)
|
2011-12-16 |
2022-09-30 |
Modernatx Inc |
Composiciones de ARNm modificado
|
WO2013096455A1
(en)
|
2011-12-20 |
2013-06-27 |
Dana-Farber Cancer Institute, Inc. |
Methods for diagnosing and treating oncogenic kras-associated cancer
|
JP6280045B2
(ja)
|
2011-12-22 |
2018-02-14 |
アイオーニス ファーマシューティカルズ, インコーポレーテッドIonis Pharmaceuticals,Inc. |
肺腺癌内転移関連性転写物1(metastasis−associated−in−lung−adenocarcinoma−transcript−1:malat−1)の発現調節法
|
US9115394B2
(en)
|
2011-12-22 |
2015-08-25 |
Roche Molecular Systems, Inc. |
Methods and reagents for reducing non-specific amplification
|
WO2013101783A2
(en)
|
2011-12-30 |
2013-07-04 |
Bio-Rad Laboratories, Inc. |
Methods and compositions for performing nucleic acid amplification reactions
|
GB201122458D0
(en)
|
2011-12-30 |
2012-02-08 |
Univ Wageningen |
Modified cascade ribonucleoproteins and uses thereof
|
CA2860739A1
(en)
|
2012-01-09 |
2013-07-18 |
Ohmx Corporation |
Enzyme cascade methods for e-trace assay signal amplification
|
US20150025231A1
(en)
|
2012-01-11 |
2015-01-22 |
Cold Spring Harbor Laboratory |
Compositions and methods for modulation of ikbkap splicing
|
CA2863632C
(en)
|
2012-01-19 |
2017-07-11 |
The Johns Hopkins University |
Nanoparticle formulations with enhanced mucosal penetration
|
CA2862552A1
(en)
|
2012-01-26 |
2013-08-01 |
Nugen Technologies, Inc. |
Compositions and methods for targeted nucleic acid sequence enrichment and high efficiency library generation
|
CA2862628C
(en)
|
2012-01-27 |
2021-08-24 |
Prosensa Technologies B.V. |
Rna modulating oligonucleotides with improved characteristics for the treatment of duchenne and becker muscular dystrophy
|
KR20140126357A
(ko)
|
2012-02-01 |
2014-10-30 |
컴퓨젠 엘티디. |
C1orf32 항체 및 이의 암 치료를 위한 용도
|
US20140378533A1
(en)
|
2012-02-08 |
2014-12-25 |
Isis Pharmaceuticals, Inc. |
Modulation of rna by repeat targeting
|
US9862994B2
(en)
|
2012-02-09 |
2018-01-09 |
Dana-Farber Cancer Institute, Inc. |
Selective nucleic acid amplification from nucleic acid pools
|
EP2814951B1
(de)
|
2012-02-13 |
2019-04-03 |
Gamida-Cell Ltd. |
Kultivierung mesenchymaler stammzellen
|
EP2814953B1
(de)
|
2012-02-15 |
2017-06-07 |
Pacific Biosciences Of California, Inc. |
Polymeraseenzymsubstrate mit proteinabschirmung
|
JP2015509366A
(ja)
|
2012-02-22 |
2015-03-30 |
ブレインステム バイオテック リミテッド |
神経幹細胞および運動ニューロンの生成
|
US10034902B2
(en)
|
2012-02-22 |
2018-07-31 |
Exostem Biotec Ltd. |
MicroRNAs for the generation of astrocytes
|
EP2825672B1
(de)
|
2012-03-13 |
2019-02-13 |
Swift Biosciences, Inc. |
Verfahren und zusammensetzungen für grössenkontrolliertes homopolymer-tailing von substratpolynucleotiden mittels einer nucleinsäurepolymerase
|
EP2639238A1
(de)
|
2012-03-15 |
2013-09-18 |
Universität Bern |
Tricyclische Nukleoside und daraus hergestellte oligomere Verbindungen
|
JP2015511494A
(ja)
|
2012-03-15 |
2015-04-20 |
キュアナ,インク. |
脳由来神経栄養因子(bdnf)に対する天然アンチセンス転写物の阻害によるbdnf関連の疾患の処置
|
WO2013138662A1
(en)
|
2012-03-16 |
2013-09-19 |
4S3 Bioscience, Inc. |
Antisense conjugates for decreasing expression of dmpk
|
WO2013142514A1
(en)
|
2012-03-19 |
2013-09-26 |
Isis Pharmaceuticals, Inc. |
Methods and compositions for modulating alpha-1-antitrypsin expression
|
US9920085B2
(en)
|
2012-03-20 |
2018-03-20 |
Sarepta Therapeutics, Inc. |
Boronic acid conjugates of oligonucleotide analogues
|
WO2013142255A2
(en)
|
2012-03-22 |
2013-09-26 |
University Of Miami |
Multi-specific binding agents
|
AU2013203395A1
(en)
|
2012-03-30 |
2013-10-17 |
Isis Pharmaceuticals, Inc. |
Compositions and methods for modulating TAU expression for reducing seizure and modifying a neurodegenerative syndrome
|
AU2013243953A1
(en)
|
2012-04-02 |
2014-10-30 |
Modernatx, Inc. |
Modified polynucleotides for the production of nuclear proteins
|
WO2013151666A2
(en)
|
2012-04-02 |
2013-10-10 |
modeRNA Therapeutics |
Modified polynucleotides for the production of biologics and proteins associated with human disease
|
JP6375289B2
(ja)
|
2012-04-05 |
2018-08-15 |
マサチューセッツ インスティテュート オブ テクノロジー |
免疫刺激組成物およびその使用方法
|
WO2013154799A1
(en)
|
2012-04-09 |
2013-10-17 |
Isis Pharmaceuticals, Inc. |
Tricyclic nucleosides and oligomeric compounds prepared therefrom
|
EP2850092B1
(de)
|
2012-04-09 |
2017-03-01 |
Ionis Pharmaceuticals, Inc. |
Tricyclische nukleinsäureanaloga
|
US9133461B2
(en)
|
2012-04-10 |
2015-09-15 |
Alnylam Pharmaceuticals, Inc. |
Compositions and methods for inhibiting expression of the ALAS1 gene
|
US20150087055A1
(en)
|
2012-04-13 |
2015-03-26 |
Massachusetts Institute Of Technology |
Analog and mixed-signal computation and circuits in living cells
|
CA2871073A1
(en)
|
2012-04-20 |
2013-10-24 |
Aptamir Therapeutics, Inc. |
Mirna modulators of thermogenesis
|
US9127274B2
(en)
|
2012-04-26 |
2015-09-08 |
Alnylam Pharmaceuticals, Inc. |
Serpinc1 iRNA compositions and methods of use thereof
|
WO2013163628A2
(en)
|
2012-04-27 |
2013-10-31 |
Duke University |
Genetic correction of mutated genes
|
US9533068B2
(en)
|
2012-05-04 |
2017-01-03 |
The Johns Hopkins University |
Drug loaded microfiber sutures for ophthalmic application
|
JP6392209B2
(ja)
|
2012-05-04 |
2018-09-19 |
ザ・ジョンズ・ホプキンス・ユニバーシティー |
粘液内層を通過する迅速な透過のための脂質ベース薬物キャリア
|
US9273949B2
(en)
|
2012-05-11 |
2016-03-01 |
Vanderbilt University |
Backscattering interferometric methods
|
AU2013262649A1
(en)
|
2012-05-16 |
2015-01-22 |
Rana Therapeutics, Inc. |
Compositions and methods for modulating smn gene family expression
|
EP3511416A1
(de)
|
2012-05-16 |
2019-07-17 |
Translate Bio MA, Inc. |
Zusammensetzungen und verfahren zur modulation von genexpression
|
EA201492116A1
(ru)
|
2012-05-16 |
2015-05-29 |
Рана Терапьютикс, Инк. |
Композиции и способы для модулирования экспрессии mecp2
|
US9574193B2
(en)
|
2012-05-17 |
2017-02-21 |
Ionis Pharmaceuticals, Inc. |
Methods and compositions for modulating apolipoprotein (a) expression
|
US20160002624A1
(en)
|
2012-05-17 |
2016-01-07 |
Isis Pharmaceuticals, Inc. |
Antisense oligonucleotide compositions
|
US9518261B2
(en)
|
2012-05-22 |
2016-12-13 |
Ionis Pharmaceuticals, Inc. |
Modulation of enhancer RNA mediated gene expression
|
EP2855698A4
(de)
|
2012-05-24 |
2016-03-30 |
Dana Farber Cancer Inst Inc |
Abzielung auf den glutamin-zu-pyruvat-signalweg zur behandlung von mit dem kras-onkogen assoziierten krebs
|
UY34822A
(es)
|
2012-05-24 |
2013-12-31 |
Seeds Ltd Ab |
Composiciones y métodos para silenciar la expresión genética
|
PE20150336A1
(es)
|
2012-05-25 |
2015-03-25 |
Univ California |
Metodos y composiciones para la modificacion de adn objetivo dirigida por arn y para la modulacion de la transcripcion dirigida por arn
|
US9487780B2
(en)
|
2012-06-01 |
2016-11-08 |
Ionis Pharmaceuticals, Inc. |
Antisense compounds targeting genes associated with fibronectin
|
US9828602B2
(en)
|
2012-06-01 |
2017-11-28 |
Ionis Pharmaceuticals, Inc. |
Antisense compounds targeting genes associated with fibronectin
|
WO2013184209A1
(en)
|
2012-06-04 |
2013-12-12 |
Ludwig Institute For Cancer Research Ltd. |
Mif for use in methods of treating subjects with a neurodegenerative disorder
|
CN104619894B
(zh)
|
2012-06-18 |
2017-06-06 |
纽亘技术公司 |
用于非期望核酸序列的阴性选择的组合物和方法
|
CA2877905A1
(en)
|
2012-06-25 |
2014-01-03 |
Isis Pharmaceuticals, Inc. |
Modulation of ube3a-ats expression
|
US20150011396A1
(en)
|
2012-07-09 |
2015-01-08 |
Benjamin G. Schroeder |
Methods for creating directional bisulfite-converted nucleic acid libraries for next generation sequencing
|
US20140038182A1
(en)
|
2012-07-17 |
2014-02-06 |
Dna Logix, Inc. |
Cooperative primers, probes, and applications thereof
|
US20150285802A1
(en)
|
2012-07-18 |
2015-10-08 |
Dana-Farber Cancer Institute, Inc. |
Methods for treating, preventing and predicting risk of developing breast cancer
|
US9567569B2
(en)
|
2012-07-23 |
2017-02-14 |
Gamida Cell Ltd. |
Methods of culturing and expanding mesenchymal stem cells
|
US9175266B2
(en)
|
2012-07-23 |
2015-11-03 |
Gamida Cell Ltd. |
Enhancement of natural killer (NK) cell proliferation and activity
|
ES2817897T3
(es)
|
2012-07-23 |
2021-04-08 |
La Jolla Inst Allergy & Immunology |
PTPRS y proteoglicanos en enfermedad autoinmune
|
EP2877593B1
(de)
|
2012-07-26 |
2018-07-18 |
Illumina, Inc. |
Zusammensetzungen und verfahren zur amplifikation von nukleinsäuren
|
EP2877579B1
(de)
|
2012-07-27 |
2019-12-18 |
Ionis Pharmaceuticals, Inc. |
Modulation von mit dem reninangiotensinsystem (ras) assoziierten erkrankungen durch angiotensinogen
|
US20150216892A1
(en)
|
2012-08-03 |
2015-08-06 |
Aptamir Therapeutics, Inc. |
Cell-specific delivery of mirna modulators for the treatment of obesity and related disorders
|
US8603470B1
(en)
|
2012-08-07 |
2013-12-10 |
National Cheng Kung University |
Use of IL-20 antagonists for treating liver diseases
|
US9403865B2
(en)
|
2012-08-15 |
2016-08-02 |
Ionis Pharmaceuticals, Inc. |
Method of preparing oligomeric compounds using modified capping protocols
|
US9950001B2
(en)
|
2012-08-20 |
2018-04-24 |
The Regents Of The University Of California |
Polynucleotides having bioreversible groups
|
SG10201700751XA
(en)
|
2012-09-25 |
2017-03-30 |
Genzyme Corp |
Peptide-linked morpholino antisense oligonucleotides for treatment of myotonic dystrophy
|
ES2907254T3
(es)
|
2012-10-11 |
2022-04-22 |
Ionis Pharmaceuticals Inc |
Un compuesto antisentido modificado para su uso en el tratamiento de la enfermedad de Kennedy
|
US9175291B2
(en)
|
2012-10-11 |
2015-11-03 |
Isis Pharmaceuticals Inc. |
Modulation of androgen receptor expression
|
EP2906255B1
(de)
|
2012-10-12 |
2023-02-22 |
Ionis Pharmaceuticals, Inc. |
Antisense-verbindungen und verwendungen davon
|
WO2014059356A2
(en)
|
2012-10-12 |
2014-04-17 |
Isis Pharmaceuticals, Inc. |
Selective antisense compounds and uses thereof
|
US9029335B2
(en)
|
2012-10-16 |
2015-05-12 |
Isis Pharmaceuticals, Inc. |
Substituted 2′-thio-bicyclic nucleosides and oligomeric compounds prepared therefrom
|
US10077451B2
(en)
|
2012-10-18 |
2018-09-18 |
Monsanto Technology Llc |
Methods and compositions for plant pest control
|
US10548962B2
(en)
|
2012-10-22 |
2020-02-04 |
The Board Of Regents For Oklahoma State University |
Use of the salmonella SPP type III secretion proteins as a protective vaccination
|
US9266959B2
(en)
|
2012-10-23 |
2016-02-23 |
Oncomed Pharmaceuticals, Inc. |
Methods of treating neuroendocrine tumors using frizzled-binding agents
|
US20140322706A1
(en)
|
2012-10-24 |
2014-10-30 |
Jon Faiz Kayyem |
Integrated multipelx target analysis
|
EP2965817B1
(de)
|
2012-10-24 |
2017-09-27 |
Genmark Diagnostics Inc. |
Integrierte multiplex-zielanalyse
|
US20150299803A1
(en)
|
2012-11-05 |
2015-10-22 |
Pronai Therapeutics, Inc. |
Methods of Using Biomarkers for the Treatment of Cancer by Modulation of BCL2 Expression
|
EP2914621B1
(de)
|
2012-11-05 |
2023-06-07 |
Foundation Medicine, Inc. |
Neuartige ntrk1-fusionsmoleküle und verwendungen davon
|
DK2922554T3
(en)
|
2012-11-26 |
2022-05-23 |
Modernatx Inc |
Terminalt modificeret rna
|
WO2014093305A2
(en)
|
2012-12-13 |
2014-06-19 |
Ymir Genomics, Llc |
Micrornas and uses thereof
|
JP2016502858A
(ja)
|
2012-12-20 |
2016-02-01 |
サレプタ セラピューティクス, インコーポレイテッド |
筋ジストロフィを処置するための改善されたエキソンスキッピング組成物
|
US10683505B2
(en)
|
2013-01-01 |
2020-06-16 |
Monsanto Technology Llc |
Methods of introducing dsRNA to plant seeds for modulating gene expression
|
EP2941488B1
(de)
|
2013-01-01 |
2023-03-22 |
Monsanto Technology LLC |
Verfahren zur einfügung von dsrna in pflanzensamen zur modulation der genexpression
|
WO2014113540A1
(en)
|
2013-01-16 |
2014-07-24 |
Iowa State University Research Foundation, Inc. |
A deep intronic target for splicing correction on spinal muscular atrophy gene
|
EP2946014A2
(de)
|
2013-01-17 |
2015-11-25 |
Moderna Therapeutics, Inc. |
Signal-sensor-polynukleotide zur veränderung zellulärer phänotypen
|
WO2014113729A2
(en)
|
2013-01-18 |
2014-07-24 |
Foundation Mecicine, Inc. |
Methods of treating cholangiocarcinoma
|
WO2014113802A1
(en)
|
2013-01-18 |
2014-07-24 |
H. Lee Moffitt Cancer Center And Research Institute, Inc. |
TARGETED SENSITIZATION OF NON-DEL(5q) MALIGNANT CELLS
|
US10000767B2
(en)
|
2013-01-28 |
2018-06-19 |
Monsanto Technology Llc |
Methods and compositions for plant pest control
|
KR102190852B1
(ko)
|
2013-01-31 |
2020-12-14 |
아이오니스 파마수티컬즈, 인코포레이티드 |
변형된 커플링 프로토콜을 이용하는 올리고머 화합물의 제조 방법
|
US9359444B2
(en)
|
2013-02-04 |
2016-06-07 |
Oncomed Pharmaceuticals Inc. |
Methods and monitoring of treatment with a Wnt pathway inhibitor
|
US10568975B2
(en)
|
2013-02-05 |
2020-02-25 |
The Johns Hopkins University |
Nanoparticles for magnetic resonance imaging tracking and methods of making and using thereof
|
MX368155B
(es)
|
2013-02-14 |
2019-09-20 |
Ionis Pharmaceuticals Inc |
Modulación de la expresión de apolipoproteína c-iii (apociii) en poblaciones con deficiencia de lipoproteína lipasa (lpld).
|
US20150366890A1
(en)
|
2013-02-25 |
2015-12-24 |
Trustees Of Boston University |
Compositions and methods for treating fungal infections
|
CN105163755A
(zh)
|
2013-03-12 |
2015-12-16 |
犹他大学研究基金会 |
用于诱导细胞凋亡的组合物和方法
|
CN105263329B
(zh)
|
2013-03-13 |
2020-09-18 |
孟山都技术公司 |
用于杂草控制的方法和组合物
|
EP2968391A1
(de)
|
2013-03-13 |
2016-01-20 |
Moderna Therapeutics, Inc. |
Langlebige polynukleotidmoleküle
|
CA2898456C
(en)
|
2013-03-13 |
2020-11-10 |
Illumina, Inc. |
Methods and compositions for nucleic acid sequencing
|
US10609930B2
(en)
|
2013-03-13 |
2020-04-07 |
Monsanto Technology Llc |
Methods and compositions for weed control
|
ES2901396T3
(es)
|
2013-03-14 |
2022-03-22 |
Caribou Biosciences Inc |
Composiciones y métodos de ácidos nucleicos dirigidos a ácido nucleico
|
US9168300B2
(en)
|
2013-03-14 |
2015-10-27 |
Oncomed Pharmaceuticals, Inc. |
MET-binding agents and uses thereof
|
CA2906119A1
(en)
|
2013-03-14 |
2014-09-25 |
Isis Pharmaceuticals, Inc. |
Compositions and methods for modulating tau expression
|
LT2970964T
(lt)
|
2013-03-14 |
2019-04-25 |
Sarepta Therapeutics, Inc. |
Kompozicijos su egzono praleidimu, skirtos raumenų distrofijos gydymui
|
US20140283211A1
(en)
|
2013-03-14 |
2014-09-18 |
Monsanto Technology Llc |
Methods and Compositions for Plant Pest Control
|
WO2014153220A2
(en)
|
2013-03-14 |
2014-09-25 |
Sarepta Therapeutics, Inc. |
Exon skipping compositions for treating muscular dystrophy
|
WO2014152211A1
(en)
|
2013-03-14 |
2014-09-25 |
Moderna Therapeutics, Inc. |
Formulation and delivery of modified nucleoside, nucleotide, and nucleic acid compositions
|
AU2014244116B9
(en)
|
2013-03-14 |
2020-08-13 |
Alnylam Pharmaceuticals, Inc. |
Complement component C5 iRNA compositions and methods of use thereof
|
US9822408B2
(en)
|
2013-03-15 |
2017-11-21 |
Nugen Technologies, Inc. |
Sequential sequencing
|
EP2971287B1
(de)
|
2013-03-15 |
2019-08-14 |
GPB Scientific, LLC |
Mikrofluidische on-chip-verarbeitung von partikeln
|
EP3608022A1
(de)
|
2013-03-15 |
2020-02-12 |
The Trustees of Princeton University |
Verfahren und vorrichtungen für reinigung mit hohem durchsatz
|
US9347095B2
(en)
|
2013-03-15 |
2016-05-24 |
Bio-Rad Laboratories, Inc. |
Digital assays for mutation detection
|
BR112015022582B1
(pt)
|
2013-03-15 |
2024-01-09 |
The Trustees Of The University Of Pennsylvania |
Molécula de ácido nucleico, plasmídeo, vacina, e, uso de um plasmídeo
|
EP2972392A4
(de)
|
2013-03-15 |
2017-03-22 |
Intermune, Inc. |
Proteomische ipf marker
|
EP2971165A4
(de)
|
2013-03-15 |
2016-11-23 |
Moderna Therapeutics Inc |
Entfernung von dna-fragmenten in mrna-herstellungsverfahren
|
US10052364B2
(en)
|
2013-03-15 |
2018-08-21 |
The Trustees Of Columbia University In The City Of New York |
Osteocalcin as a treatment for cognitive disorders
|
US20140329762A1
(en)
|
2013-03-15 |
2014-11-06 |
Sarepta Therapeutics, Inc. |
Compositions for treating muscular dystrophy
|
US10568328B2
(en)
|
2013-03-15 |
2020-02-25 |
Monsanto Technology Llc |
Methods and compositions for weed control
|
EP2972329A2
(de)
|
2013-03-15 |
2016-01-20 |
Kinemed, Inc. |
Biomarker
|
AU2014235532B2
(en)
|
2013-03-15 |
2018-08-09 |
Genmark Diagnostics, Inc. |
Systems, methods, and apparatus for manipulating deformable fluid vessels
|
US8980864B2
(en)
|
2013-03-15 |
2015-03-17 |
Moderna Therapeutics, Inc. |
Compositions and methods of altering cholesterol levels
|
WO2014165825A2
(en)
|
2013-04-04 |
2014-10-09 |
President And Fellows Of Harvard College |
Therapeutic uses of genome editing with crispr/cas systems
|
US10544461B2
(en)
|
2013-04-16 |
2020-01-28 |
The Johns Hopkins University |
Diagnostic and prognostic test for sturge-weber syndrome, klippel-trenaunay-weber syndrome, and port-wine stains (PWSS)
|
JP6387084B2
(ja)
|
2013-05-01 |
2018-09-05 |
アイオーニス ファーマシューティカルズ, インコーポレーテッドIonis Pharmaceuticals,Inc. |
アポリポタンパク質c−iiiの発現を調節するための組成物および方法
|
EP2994167B1
(de)
|
2013-05-06 |
2020-05-06 |
Alnylam Pharmaceuticals, Inc. |
Dosierungen und verfahren zur abgabe von lipidformulierten nukleinsäuremolekülen
|
WO2014182630A1
(en)
|
2013-05-06 |
2014-11-13 |
Pacific Biosciences Of California , Inc. |
Real-time electronic sequencing
|
US10316366B2
(en)
|
2013-05-22 |
2019-06-11 |
Telomere Diagnostics, Inc. |
Measures of short telomere abundance
|
TWI664187B
(zh)
|
2013-05-22 |
2019-07-01 |
阿尼拉製藥公司 |
絲胺酸蛋白酶抑制因子A1 iRNA組成物及其使用方法
|
AP2015008862A0
(en)
|
2013-05-22 |
2015-11-30 |
Alnylam Pharmaceuticals Inc |
Tmprss6 irna compositions and methods of use thereof
|
WO2014197835A2
(en)
|
2013-06-06 |
2014-12-11 |
The General Hospital Corporation |
Methods and compositions for the treatment of cancer
|
WO2014197938A1
(en)
|
2013-06-13 |
2014-12-18 |
Antisense Therapeutics Ltd |
Combination therapy
|
WO2014203189A1
(en)
|
2013-06-18 |
2014-12-24 |
Rosetta Genomics Ltd. |
Nanocarrier system for micrornas and uses thereof
|
ES2778462T3
(es)
|
2013-06-21 |
2020-08-10 |
Ionis Pharmaceuticals Inc |
Compuestos y métodos para modular expresión de C-III de apolipoproteína para mejorar un perfil diabético
|
ES2787600T3
(es)
|
2013-07-02 |
2020-10-16 |
Ionis Pharmaceuticals Inc |
Moduladores del receptor de la hormona del crecimiento
|
CA2917348A1
(en)
|
2013-07-11 |
2015-01-15 |
Moderna Therapeutics, Inc. |
Compositions comprising synthetic polynucleotides encoding crispr related proteins and synthetic sgrnas and methods of use
|
WO2015009731A2
(en)
|
2013-07-15 |
2015-01-22 |
The Regents Of The University Of California |
Azacyclic constrained analogs of fty720
|
EP3608412A3
(de)
|
2013-07-19 |
2020-04-08 |
Monsanto Technology LLC |
Zusammensetzungen und verfahren zur bekämpfung von leptinotarsa
|
US9850496B2
(en)
|
2013-07-19 |
2017-12-26 |
Monsanto Technology Llc |
Compositions and methods for controlling Leptinotarsa
|
TW202246503A
(zh)
|
2013-07-19 |
2022-12-01 |
美商百健Ma公司 |
用於調節τ蛋白表現之組合物
|
US9944998B2
(en)
|
2013-07-25 |
2018-04-17 |
Bio-Rad Laboratories, Inc. |
Genetic assays
|
JP2016531122A
(ja)
|
2013-08-08 |
2016-10-06 |
ザ スクリップス リサーチ インスティテュートThe Scripps Research Institute |
非天然ヌクレオチドの取り込みによるインビトロの核酸の部位特異的な酵素標識のための方法
|
TW201536329A
(zh)
|
2013-08-09 |
2015-10-01 |
Isis Pharmaceuticals Inc |
用於調節失養性肌強直蛋白質激酶(dmpk)表現之化合物及方法
|
EP3033625B1
(de)
|
2013-08-13 |
2020-01-22 |
The Scripps Research Institute |
Nachweis zystein-reaktiver liganden in proteomen
|
US9670492B2
(en)
|
2013-08-28 |
2017-06-06 |
Ionis Pharmaceuticals, Inc. |
Modulation of prekallikrein (PKK) expression
|
CA2922698C
(en)
|
2013-08-29 |
2023-01-03 |
City Of Hope |
Cell penetrating conjugates comprising non-cell penetrating antibodies covalently attached to one or more phosphorothioate nucleic acids
|
CA2923029A1
(en)
|
2013-09-03 |
2015-03-12 |
Moderna Therapeutics, Inc. |
Chimeric polynucleotides
|
WO2015034925A1
(en)
|
2013-09-03 |
2015-03-12 |
Moderna Therapeutics, Inc. |
Circular polynucleotides
|
AU2014317961B2
(en)
|
2013-09-05 |
2020-07-30 |
Murdoch University |
Antisense-induced exon2 inclusion in acid alpha-glucosidase
|
RU2675824C2
(ru)
|
2013-09-11 |
2018-12-25 |
Игл Байолоджикс, Инк. |
Жидкие белковые составы, содержащие ионные жидкости
|
ES2739850T3
(es)
|
2013-09-11 |
2020-02-04 |
Synthena Ag |
Acidos nucleicos y procedimientos para el tratamiento de la enfermedad de Pompe
|
HUE045109T2
(hu)
|
2013-09-13 |
2019-12-30 |
Ionis Pharmaceuticals Inc |
A B-komplementfaktor modulátorai
|
EP3052512A4
(de)
|
2013-09-30 |
2017-02-22 |
Geron Corporation |
Phosphorodiamidat-rückgratverbindung für oligonukleotide
|
TW202003849A
(zh)
|
2013-10-02 |
2020-01-16 |
美商艾爾妮蘭製藥公司 |
抑制lect2基因表現之組合物及方法
|
EP3052511A4
(de)
|
2013-10-02 |
2017-05-31 |
Moderna Therapeutics, Inc. |
Polynukleotidmoleküle und verwendungen davon
|
WO2015051214A1
(en)
|
2013-10-03 |
2015-04-09 |
Moderna Therapeutics, Inc. |
Polynucleotides encoding low density lipoprotein receptor
|
MY197646A
(en)
|
2013-10-04 |
2023-06-30 |
Alnylam Pharmaceuticals Inc |
Compositions and methods for inhibiting expression of the alas1 gene
|
KR102298475B1
(ko)
|
2013-10-04 |
2021-09-06 |
노파르티스 아게 |
RNA 간섭에 사용하기 위한 RNAi 작용제를 위한 3' 말단 캡
|
JP6546161B2
(ja)
|
2013-10-04 |
2019-07-17 |
ノバルティス アーゲー |
B型肝炎ウイルスを治療するための有機化合物
|
US9988627B2
(en)
|
2013-10-04 |
2018-06-05 |
Novartis Ag |
Formats for organic compounds for use in RNA interference
|
WO2015054451A1
(en)
|
2013-10-09 |
2015-04-16 |
The United States Of America As Represented By The Secretary Department Of Health And Human Services |
Detection of hepatitis delta virus (hdv) for the diagnosis and treatment of sjögren's syndrome and lymphoma
|
US11162096B2
(en)
|
2013-10-14 |
2021-11-02 |
Ionis Pharmaceuticals, Inc |
Methods for modulating expression of C9ORF72 antisense transcript
|
US10159652B2
(en)
|
2013-10-16 |
2018-12-25 |
The University Of British Columbia |
Device for formulating particles at small volumes
|
US9758546B2
(en)
|
2013-10-21 |
2017-09-12 |
Ionis Pharmaceuticals, Inc. |
Method for solution phase detritylation of oligomeric compounds
|
EP3060680B1
(de)
|
2013-10-21 |
2019-02-27 |
The General Hospital Corporation |
Verfahren im zusammenhang mit zirkulierenden tumorzellclustern und krebsbehandlung
|
USD881409S1
(en)
|
2013-10-24 |
2020-04-14 |
Genmark Diagnostics, Inc. |
Biochip cartridge
|
US9498778B2
(en)
|
2014-11-11 |
2016-11-22 |
Genmark Diagnostics, Inc. |
Instrument for processing cartridge for performing assays in a closed sample preparation and reaction system
|
JP2016538882A
(ja)
|
2013-10-30 |
2016-12-15 |
グリーン ライフ バイオテック,エルエルシー |
カンキツグリーニング病のための病因定量システム及び治療方法
|
CA2929533C
(en)
|
2013-11-04 |
2023-06-06 |
Monsanto Technology Llc |
Compositions and methods for controlling arthropod parasite and pest infestations
|
WO2015066708A1
(en)
|
2013-11-04 |
2015-05-07 |
Northwestern University |
Quantification and spatio-temporal tracking of a target using a spherical nucleic acid (sna)
|
WO2015073711A1
(en)
|
2013-11-13 |
2015-05-21 |
Nugen Technologies, Inc. |
Compositions and methods for identification of a duplicate sequencing read
|
CA2930877A1
(en)
|
2013-11-18 |
2015-05-21 |
Crispr Therapeutics Ag |
Crispr-cas system materials and methods
|
CN105934522B
(zh)
|
2013-11-26 |
2021-07-20 |
伊鲁米那股份有限公司 |
用于多核苷酸测序的组合物和方法
|
EP3077510B1
(de)
|
2013-12-02 |
2020-05-06 |
Ionis Pharmaceuticals, Inc. |
Antisense-verbindungen und verwendungen davon
|
JP6527516B2
(ja)
|
2013-12-03 |
2019-06-05 |
ノースウェスタン ユニバーシティ |
リポソーム粒子、前述のものを作製する方法及びその使用
|
EP3077545B1
(de)
|
2013-12-05 |
2020-09-16 |
Centrillion Technology Holdings Corporation |
Verfahren zur sequenzierung von nukleinsäuren
|
US10385335B2
(en)
|
2013-12-05 |
2019-08-20 |
Centrillion Technology Holdings Corporation |
Modified surfaces
|
EP3077543B1
(de)
|
2013-12-05 |
2019-09-25 |
Centrillion Technology Holdings Corporation |
Herstellung von gemusterten anordnungen
|
CA2844640A1
(en)
|
2013-12-06 |
2015-06-06 |
The University Of British Columbia |
Method for treatment of castration-resistant prostate cancer
|
WO2015085183A2
(en)
|
2013-12-06 |
2015-06-11 |
Swift Biosciences, Inc. |
Cleavable competitor polynucleotides
|
WO2015085350A1
(en)
|
2013-12-10 |
2015-06-18 |
Conexio Genomics Pty Ltd |
Methods and probes for identifying gene alleles
|
UA119253C2
(uk)
|
2013-12-10 |
2019-05-27 |
Біолоджикс, Інк. |
Спосіб боротьби із вірусом у кліща varroa та у бджіл
|
US9994831B2
(en)
|
2013-12-12 |
2018-06-12 |
The Regents Of The University Of California |
Methods and compositions for modifying a single stranded target nucleic acid
|
AU2014362262B2
(en)
|
2013-12-12 |
2021-05-13 |
Alnylam Pharmaceuticals, Inc. |
Complement component iRNA compositions and methods of use thereof
|
EP3865144A1
(de)
|
2013-12-20 |
2021-08-18 |
The General Hospital Corporation |
Verfahren und tests im zusammenhang mit zirkulierenden tumorzellen
|
EP3984537B1
(de)
|
2013-12-20 |
2024-03-20 |
Biomed Valley Discoveries, Inc. |
Krebsbehandlungen unter verwendung von kombinationen aus typ-2-mek- und erk-hemmern
|
US9243289B2
(en)
|
2013-12-23 |
2016-01-26 |
Roche Molecular Systems, Inc. |
Method for screening reagents used in PCR assays
|
US20170037409A1
(en)
|
2013-12-24 |
2017-02-09 |
Ionis Pharmaceuticals, Inc. |
Modulation of angiopoietin-like 3 expression
|
CN105979770B
(zh)
|
2014-01-15 |
2019-07-05 |
孟山都技术公司 |
用于使用epsps多核苷酸的杂草控制的方法和组合物
|
WO2015109234A1
(en)
|
2014-01-16 |
2015-07-23 |
Illumina, Inc. |
Gene expression panel for prognosis of prostate cancer recurrence
|
ES2838804T3
(es)
|
2014-01-31 |
2021-07-02 |
Univ Temple |
BAG3 como diana para el tratamiento de la insuficiencia cardíaca
|
WO2015120075A2
(en)
|
2014-02-04 |
2015-08-13 |
Genentech, Inc. |
Mutant smoothened and methods of using the same
|
CN111733231A
(zh)
|
2014-02-05 |
2020-10-02 |
耶达研究及发展有限公司 |
用于治疗和诊断的微rna和包含所述微rna的组合物
|
KR102592370B1
(ko)
|
2014-02-11 |
2023-10-25 |
알닐람 파마슈티칼스 인코포레이티드 |
케토헥소키나제(KHK) iRNA 조성물 및 그의 사용 방법
|
WO2015127389A1
(en)
|
2014-02-23 |
2015-08-27 |
The Johns Hopkins University |
Hypotonic enema formulations and methods of use
|
US9745614B2
(en)
|
2014-02-28 |
2017-08-29 |
Nugen Technologies, Inc. |
Reduced representation bisulfite sequencing with diversity adaptors
|
US10036019B2
(en)
|
2014-03-17 |
2018-07-31 |
Ionis Pharmaceuticals, Inc. |
Bicyclic carbocyclic nucleosides and oligomeric compounds prepared therefrom
|
RU2019130898A
(ru)
|
2014-03-19 |
2019-11-11 |
Ионис Фармасьютикалз, Инк. |
Композиции для модуляции экспрессии атаксина 2
|
US10006027B2
(en)
|
2014-03-19 |
2018-06-26 |
Ionis Pharmaceuticals, Inc. |
Methods for modulating Ataxin 2 expression
|
WO2015149006A2
(en)
|
2014-03-27 |
2015-10-01 |
Dana-Farber Cancer Institute, Inc. |
Compositions and methods for modulating ncoa4-mediated autophagic targeting of ferritin
|
US11060139B2
(en)
|
2014-03-28 |
2021-07-13 |
Centrillion Technology Holdings Corporation |
Methods for sequencing nucleic acids
|
ES2868305T3
(es)
|
2014-03-28 |
2021-10-21 |
Univ Washington Through Its Center For Commercialization |
Vacunas contra el cáncer de mama y de ovario
|
EP3126372B1
(de)
|
2014-03-30 |
2019-02-06 |
Cepheid |
Modifizierte thyminpolynukleotidoligomere und verfahren
|
US10385341B2
(en)
|
2014-04-01 |
2019-08-20 |
Biogen Ma Inc. |
Compositions for modulating SOD-1 expression
|
US11091770B2
(en)
|
2014-04-01 |
2021-08-17 |
Monsanto Technology Llc |
Compositions and methods for controlling insect pests
|
EP3129493B1
(de)
|
2014-04-09 |
2021-07-07 |
The Scripps Research Institute |
Import von unnatürlichen oder modifizierten nukleosid-triphosphaten in zellen mittels nukleinsäure-triphosphattransportern
|
US10221416B2
(en)
|
2014-04-24 |
2019-03-05 |
Ionis Pharmaceuticals, Inc. |
Oligomeric compounds comprising alpha-beta-constrained nucleic acid
|
DK3137091T3
(da)
|
2014-05-01 |
2021-01-25 |
Ionis Pharmaceuticals Inc |
Konjugater af modificerede antisense-oligonukleotider og anvendelse deraf til modulation af pkk-ekspression
|
PL3137596T3
(pl)
|
2014-05-01 |
2019-11-29 |
Ionis Pharmaceuticals Inc |
Kompozycja i sposoby modulowania ekspresji czynnika b dopełniacza
|
WO2015168589A2
(en)
|
2014-05-01 |
2015-11-05 |
Isis Pharmaceuticals, Inc. |
Compositions and methods for modulating angiopoietin-like 3 expression
|
EP3137115B1
(de)
|
2014-05-01 |
2020-10-14 |
Ionis Pharmaceuticals, Inc. |
Verfahren zur synthese von reaktiven konjugatclustern
|
RU2724527C2
(ru)
|
2014-05-01 |
2020-06-23 |
Ионис Фармасьютикалз, Инк. |
Композиции и способы модулирования экспрессии рецептора гормона роста
|
WO2015171918A2
(en)
|
2014-05-07 |
2015-11-12 |
Louisiana State University And Agricultural And Mechanical College |
Compositions and uses for treatment thereof
|
WO2015172153A1
(en)
|
2014-05-09 |
2015-11-12 |
Yale University |
Topical formulation of hyperbranched polyglycerol-coated particles thereof
|
US11918695B2
(en)
|
2014-05-09 |
2024-03-05 |
Yale University |
Topical formulation of hyperbranched polymer-coated particles
|
US10335500B2
(en)
|
2014-05-12 |
2019-07-02 |
The Johns Hopkins University |
Highly stable biodegradable gene vector platforms for overcoming biological barriers
|
AU2015259362B2
(en)
|
2014-05-12 |
2018-02-15 |
The Johns Hopkins University |
Engineering synthetic brain penetrating gene vectors
|
TW201607559A
(zh)
|
2014-05-12 |
2016-03-01 |
阿尼拉製藥公司 |
治療serpinc1相關疾患之方法和組成物
|
CA2948373A1
(en)
|
2014-05-16 |
2015-11-19 |
Oregon State University |
Antisense antibacterial compounds and methods
|
CA2948568A1
(en)
|
2014-05-19 |
2015-11-26 |
David Greenberg |
Antisense antibacterial compounds and methods
|
US10570169B2
(en)
|
2014-05-22 |
2020-02-25 |
Ionis Pharmaceuticals, Inc. |
Conjugated antisense compounds and their use
|
KR102410687B1
(ko)
|
2014-05-22 |
2022-06-22 |
알닐람 파마슈티칼스 인코포레이티드 |
안지오텐시노겐 (agt) irna 조성물 및 이의 사용 방법
|
WO2015179741A1
(en)
|
2014-05-23 |
2015-11-26 |
Genzyme Corporation |
Inhibiting or downregulating glycogen synthase by creating premature stop codons using antisense oligonucleotides
|
CA2950589A1
(en)
|
2014-06-02 |
2015-12-10 |
Children's Medical Center Corporation |
Methods and compositions for immunomodulation
|
US10434064B2
(en)
|
2014-06-04 |
2019-10-08 |
Exicure, Inc. |
Multivalent delivery of immune modulators by liposomal spherical nucleic acids for prophylactic or therapeutic applications
|
US10799584B2
(en)
|
2014-06-09 |
2020-10-13 |
The United States Of America, As Represented By The Secretary, Department Of Health And Human Services National Institutes Of Health |
Combination therapies using agents that target tumor-associated stroma or tumor cells and alkylating agents
|
US11033620B2
(en)
|
2014-06-09 |
2021-06-15 |
Biomed Valley Discoveries, Inc. |
Combination therapies targeting tumor-associated stroma or tumor cells and microtubules
|
WO2015191583A2
(en)
|
2014-06-09 |
2015-12-17 |
Biomed Valley Discoveries, Inc. |
Combination therapies targeting tumor-associated stroma or tumor cells and topoisomerase
|
US10758526B2
(en)
|
2014-06-09 |
2020-09-01 |
The United States Of America, As Represented By The Secretary, Department Of Health And Human Services National Institutes Of Health |
Combination therapies using agents that target tumor-associated stroma or tumor cells and other pathways
|
US10434174B2
(en)
|
2014-06-09 |
2019-10-08 |
The United States Of America, As Represented By The Secretary, Department Of Health And Human Services |
Combination therapies using platinum agents and agents that target tumor-associated stroma or tumor cells
|
US11034757B2
(en)
|
2014-06-09 |
2021-06-15 |
Biomed Valley Discoveries, Inc. |
Combination therapies using agents that target tumor-associated stroma or tumor cells and tumor vasculature
|
WO2015191617A2
(en)
|
2014-06-09 |
2015-12-17 |
Biomed Valley Discoveries, Inc. |
Combination therapies using anti-metabolites and agents that target tumor-associated stroma or tumor cells
|
CA2951561C
(en)
|
2014-06-10 |
2023-04-18 |
Dxterity Diagnostics Incorporated |
Devices and methods for collecting and stabilizing biological samples
|
JP6851201B2
(ja)
|
2014-06-10 |
2021-03-31 |
エラスムス ユニバーシティ メディカルセンター ロッテルダムErasmus University Medical Center Rotterdam |
ポンペ病の治療に有用なアンチセンスオリゴヌクレオチド
|
TW201620526A
(zh)
|
2014-06-17 |
2016-06-16 |
愛羅海德研究公司 |
用於抑制α-1抗胰蛋白酶基因表現之組合物及方法
|
WO2015200223A1
(en)
|
2014-06-23 |
2015-12-30 |
Monsanto Technology Llc |
Compositions and methods for regulating gene expression via rna interference
|
US11807857B2
(en)
|
2014-06-25 |
2023-11-07 |
Monsanto Technology Llc |
Methods and compositions for delivering nucleic acids to plant cells and regulating gene expression
|
EP3760208B1
(de)
|
2014-06-25 |
2024-05-29 |
The General Hospital Corporation |
Targeting von humanem satellit ii (hsatii)
|
RU2017104284A
(ru)
|
2014-07-15 |
2018-08-15 |
Йиссум Рисеч Девелопмент Компани Оф Зе Хебрю Юниверсити Оф Джерусалем Лтд. |
Выделенные полипептиды cd44 и их применение
|
EP3169693B1
(de)
*
|
2014-07-16 |
2022-03-09 |
ModernaTX, Inc. |
Chimäre polynukleotide
|
US9951327B1
(en)
|
2014-07-17 |
2018-04-24 |
Integrated Dna Technologies, Inc. |
Efficient and rapid method for assembling and cloning double-stranded DNA fragments
|
CN106715458A
(zh)
|
2014-07-18 |
2017-05-24 |
华盛顿大学 |
癌症疫苗组合物及其使用方法
|
EP3172321B2
(de)
|
2014-07-21 |
2023-01-04 |
Illumina, Inc. |
Polynukleotidanreicherung mit crispr-cas-systemen
|
EP3171895A1
(de)
|
2014-07-23 |
2017-05-31 |
Modernatx, Inc. |
Modifizierte polynukleotide zur herstellung von intrabodys
|
EP3578668B1
(de)
|
2014-07-24 |
2020-12-30 |
Abbott Molecular Inc. |
Verfahren zum nachweis und zur analyse von mycobacterium tuberculosis
|
US11072681B2
(en)
|
2014-07-28 |
2021-07-27 |
The Regents Of The University Of California |
Compositions and methods of making polymerizing nucleic acids
|
RU2754955C2
(ru)
|
2014-07-29 |
2021-09-08 |
Монсанто Текнолоджи Ллс |
Композиции и способы борьбы с насекомыми-вредителями
|
CN107074923B
(zh)
|
2014-07-31 |
2021-08-03 |
Uab研究基金会 |
Apoe模拟肽及对清除血浆胆固醇的较高效力
|
EP3174976B1
(de)
|
2014-08-01 |
2020-10-28 |
GPB Scientific, Inc. |
Verfahren und systeme zur verarbeitung von partikeln
|
WO2016022526A1
(en)
*
|
2014-08-04 |
2016-02-11 |
The Trustees Of The University Of Pennsylvania |
Ruthenium-based photolinkers and methods of use
|
WO2016023036A1
(en)
|
2014-08-08 |
2016-02-11 |
The Regents Of The University Of California |
High density peptide polymers
|
EP3183007B1
(de)
|
2014-08-19 |
2020-06-17 |
Northwestern University |
Therapeutika mit protein/oligonukleotid-kernschalennanopartikeln
|
CA2958879A1
(en)
|
2014-08-22 |
2016-02-25 |
Auckland Uniservices Limited |
Channel modulators
|
WO2016030899A1
(en)
|
2014-08-28 |
2016-03-03 |
Yeda Research And Development Co. Ltd. |
Methods of treating amyotrophic lateral scleroses
|
EP3185910A4
(de)
|
2014-08-29 |
2018-01-10 |
Children's Medical Center Corporation |
Verfahren und zusammensetzungen zur krebsbehandlung
|
WO2016033424A1
(en)
|
2014-08-29 |
2016-03-03 |
Genzyme Corporation |
Methods for the prevention and treatment of major adverse cardiovascular events using compounds that modulate apolipoprotein b
|
HUE059857T2
(hu)
|
2014-08-29 |
2023-01-28 |
Alnylam Pharmaceuticals Inc |
Patizirán transztiretin által közvetített amiloidózis kezelésében történõ alkalmazásra
|
LT3189074T
(lt)
|
2014-09-05 |
2021-06-10 |
Rsem, Limited Partnership |
Kompozicijos ir būdai skirti uždegimo gydymui ir prevencijai
|
EP3191591A1
(de)
|
2014-09-12 |
2017-07-19 |
Alnylam Pharmaceuticals, Inc. |
Gegen komplementkomponente c5 gerichtete polynukleotidwirkstoffe und verfahren zur verwendung davon
|
US10913973B2
(en)
|
2014-09-17 |
2021-02-09 |
Board Of Regents, The University Texas System |
Methods and devices related to toehold-based strand displacement with loop-mediated isothermal amplification
|
EP3198012B1
(de)
|
2014-09-26 |
2019-09-04 |
University of Massachusetts |
Rna-modulierende stoffe
|
JP2017534295A
(ja)
|
2014-09-29 |
2017-11-24 |
ザ ジャクソン ラボラトリー |
エレクトロポレーションによる遺伝子改変哺乳動物の高効率ハイスループット生成
|
SG11201702614SA
(en)
|
2014-10-01 |
2017-04-27 |
Eagle Biolog Inc |
Polysaccharide and nucleic acid formulations containing viscosity-lowering agents
|
US10583201B2
(en)
|
2014-10-10 |
2020-03-10 |
Massachusetts Eye And Ear Infirmary |
Efficient delivery of therapeutic molecules in vitro and in vivo
|
JOP20200115A1
(ar)
|
2014-10-10 |
2017-06-16 |
Alnylam Pharmaceuticals Inc |
تركيبات وطرق لتثبيط التعبير الجيني عن hao1 (حمض أوكسيداز هيدروكسيلي 1 (أوكسيداز جليكولات))
|
EP3206751A4
(de)
|
2014-10-14 |
2018-06-13 |
The J. David Gladstone Institutes |
Zusammensetzungen und verfahren zur reaktivierung von latentem immundefizienzvirus
|
WO2016061487A1
(en)
|
2014-10-17 |
2016-04-21 |
Alnylam Pharmaceuticals, Inc. |
Polynucleotide agents targeting aminolevulinic acid synthase-1 (alas1) and uses thereof
|
EP3212773B1
(de)
|
2014-10-29 |
2021-09-15 |
Massachusetts Eye and Ear Infirmary |
Effiziente abgabe von therapeutischen molekülen an zellen des innenohres
|
US11071790B2
(en)
|
2014-10-29 |
2021-07-27 |
Massachusetts Eye And Ear Infirmary |
Method for efficient delivery of therapeutic molecules in vitro and in vivo
|
EP3904519A1
(de)
|
2014-10-30 |
2021-11-03 |
Genzyme Corporation |
Polynukleotidwirkstoffe mit abzielung auf serpinc1 (at3) und verfahren zur verwendung davon
|
JOP20200092A1
(ar)
|
2014-11-10 |
2017-06-16 |
Alnylam Pharmaceuticals Inc |
تركيبات iRNA لفيروس الكبد B (HBV) وطرق لاستخدامها
|
EP3218513B1
(de)
|
2014-11-11 |
2018-10-31 |
Illumina, Inc. |
Polynukleotidamplifikation mit crispr-cas-systemen
|
AU2015346527A1
(en)
|
2014-11-11 |
2017-06-29 |
Genmark Diagnostics, Inc. |
Instrument and cartridge for performing assays in a closed sample preparation and reaction system
|
US9598722B2
(en)
|
2014-11-11 |
2017-03-21 |
Genmark Diagnostics, Inc. |
Cartridge for performing assays in a closed sample preparation and reaction system
|
US10005080B2
(en)
|
2014-11-11 |
2018-06-26 |
Genmark Diagnostics, Inc. |
Instrument and cartridge for performing assays in a closed sample preparation and reaction system employing electrowetting fluid manipulation
|
WO2016081444A1
(en)
|
2014-11-17 |
2016-05-26 |
Alnylam Pharmaceuticals, Inc. |
Apolipoprotein c3 (apoc3) irna compositions and methods of use thereof
|
WO2016081621A1
(en)
|
2014-11-18 |
2016-05-26 |
Yale University |
Formulations for targeted release of agents under low ph conditions and methods of use thereof
|
US10682422B2
(en)
|
2014-11-18 |
2020-06-16 |
Yale University |
Formulations for targeted release of agents under low pH conditions and methods of use thereof
|
EP3226889A4
(de)
|
2014-11-19 |
2018-11-21 |
The Trustees of Columbia University in the City of New York |
Osteocalcin zur behandlung von gebrechlichkeit im zusammenhang mit alterung
|
EP3220895B1
(de)
|
2014-11-21 |
2022-08-31 |
Northwestern University |
Sequenzspezifische zelluläre aufnahme von sphärischen nukleinsäurenanopartikelkonjugaten
|
WO2016086104A1
(en)
|
2014-11-25 |
2016-06-02 |
Ionis Pharmaceuticals, Inc. |
Modulation of ube3a-ats expression
|
WO2016094845A2
(en)
|
2014-12-12 |
2016-06-16 |
Woolf Tod M |
Compositions and methods for editing nucleic acids in cells utilizing oligonucleotides
|
US9909169B2
(en)
|
2014-12-17 |
2018-03-06 |
Roche Molecular Systems, Inc. |
Allele-specific amplification of nucleic acids using blocking oligonucleotides for wild type suppression
|
US9688707B2
(en)
|
2014-12-30 |
2017-06-27 |
Ionis Pharmaceuticals, Inc. |
Bicyclic morpholino compounds and oligomeric compounds prepared therefrom
|
US9944978B2
(en)
|
2014-12-30 |
2018-04-17 |
Telomere Diagnostics, Inc. |
Multiplex quantitative PCR
|
AU2015372560B2
(en)
|
2014-12-31 |
2021-12-02 |
Board Of Regents, The University Of Texas System |
Antisense antibacterial compounds and methods
|
WO2016112132A1
(en)
|
2015-01-06 |
2016-07-14 |
Ionis Pharmaceuticals, Inc. |
Compositions for modulating expression of c9orf72 antisense transcript
|
WO2016115490A1
(en)
|
2015-01-16 |
2016-07-21 |
Ionis Pharmaceuticals, Inc. |
Compounds and methods for modulation of dux4
|
BR112017015203A2
(pt)
|
2015-01-16 |
2018-03-13 |
Hope City |
anticorpos de penetração celular
|
US9434947B2
(en)
|
2015-01-20 |
2016-09-06 |
Oregon Health & Science University |
Modulation of KCNH2 isoform expression by oligonucleotides as a therapeutic approach for long QT syndrome
|
MX2017009521A
(es)
|
2015-01-22 |
2018-11-09 |
Monsanto Technology Llc |
Composiciones y métodos para controlar leptinotarsa.
|
WO2016118812A1
(en)
|
2015-01-23 |
2016-07-28 |
Vanderbilt University |
A robust interferometer and methods of using same
|
CA2974715C
(en)
|
2015-01-27 |
2020-05-05 |
The Johns Hopkins University |
Hypotonic hydrogel formulations for enhanced transport of active agents at mucosal surfaces
|
US10676726B2
(en)
|
2015-02-09 |
2020-06-09 |
Duke University |
Compositions and methods for epigenome editing
|
AU2016219328B2
(en)
|
2015-02-10 |
2022-04-21 |
Illumina, Inc. |
Methods and compositions for analyzing cellular components
|
CA2976445A1
(en)
|
2015-02-13 |
2016-08-18 |
Alnylam Pharmaceuticals, Inc. |
Patatin-like phospholipase domain containing 3 (pnpla3) irna compositions and methods of use thereof
|
EP3262173A2
(de)
|
2015-02-23 |
2018-01-03 |
Crispr Therapeutics AG |
Materialien und verfahren zur behandlung von humangenetischen erkrankungen einschliesslich hämoglobinopathien
|
US10450342B2
(en)
|
2015-02-23 |
2019-10-22 |
Ionis Pharmaceuticals, Inc. |
Method for solution phase detritylation of oligomeric compounds
|
LT3262059T
(lt)
|
2015-02-24 |
2022-02-25 |
City Of Hope |
Chemiškai koduotos erdviniu požiūriu kryptingos bibliotekų atrankos platformos
|
ES2848377T3
(es)
|
2015-02-26 |
2021-08-09 |
Ionis Pharmaceuticals Inc |
Moduladores específicos de alelo de RODOPSINA P23H
|
US11129844B2
(en)
|
2015-03-03 |
2021-09-28 |
Ionis Pharmaceuticals, Inc. |
Compositions and methods for modulating MECP2 expression
|
EP3268475B1
(de)
|
2015-03-11 |
2020-10-21 |
Yissum Research and Development Company of the Hebrew University of Jerusalem Ltd. |
Köderoligonukleotide zur behandlung von krankheiten
|
MA41795A
(fr)
|
2015-03-18 |
2018-01-23 |
Sarepta Therapeutics Inc |
Exclusion d'un exon induite par des composés antisens dans la myostatine
|
US9708647B2
(en)
|
2015-03-23 |
2017-07-18 |
Insilixa, Inc. |
Multiplexed analysis of nucleic acid hybridization thermodynamics using integrated arrays
|
EP3274473B1
(de)
|
2015-03-24 |
2020-10-28 |
Pacific Biosciences of California, Inc. |
Verfahren und zusammensetzungen zum laden einer einzelmolekülzusammensetzung
|
EP4218771A1
(de)
|
2015-03-27 |
2023-08-02 |
Yeda Research and Development Co. Ltd |
Verfahren zur behandlung von motoneuronenerkrankungen
|
WO2016160721A1
(en)
|
2015-03-27 |
2016-10-06 |
President And Fellows Of Harvard College |
Modified t cells and methods of making and using the same
|
CA2980010C
(en)
|
2015-03-27 |
2023-10-03 |
The Scripps Research Institute |
Lipid probes and uses thereof
|
CA2981474A1
(en)
|
2015-03-31 |
2016-10-06 |
Oncosec Medical Incorporated |
Systems and methods for improved tissue-sensing based electroporation
|
EP3283502A4
(de)
|
2015-04-07 |
2019-04-03 |
The General Hospital Corporation |
Verfahren zur reaktivierung von genen auf dem inaktiven x-chromosom
|
MX2017012610A
(es)
|
2015-04-08 |
2018-03-16 |
Alnylam Pharmaceuticals Inc |
Composiciones y metodos para inhibir la expresion del gen lect2.
|
US20180126014A1
(en)
|
2015-04-15 |
2018-05-10 |
Yale University |
Compositions for enhancing delivery of agents across the blood brain barrier and methods of use thereof
|
CN104845967B
(zh)
|
2015-04-15 |
2020-12-11 |
苏州新海生物科技股份有限公司 |
寡聚核苷酸片段及使用其的选择性扩增目标核酸序列变异体的方法及应用
|
CN113265404A
(zh)
|
2015-04-16 |
2021-08-17 |
Ionis制药公司 |
用于调节c9orf72表达的组合物
|
US10407678B2
(en)
|
2015-04-16 |
2019-09-10 |
Ionis Pharmaceuticals, Inc. |
Compositions for modulating expression of C9ORF72 antisense transcript
|
EP3289104B1
(de)
|
2015-04-29 |
2020-11-04 |
New York University |
Verfahren zur behandlung von hochwertigen gliomen
|
BR112017023754B1
(pt)
|
2015-05-04 |
2022-08-09 |
Beeologics, Inc. |
Composições inseticidas, e uso de um ácido nucleico
|
US20180161300A1
(en)
|
2015-05-11 |
2018-06-14 |
Yeda Research And Development Co., Ltd. |
Citrin inhibitors for the treatment of cancer
|
KR20240035901A
(ko)
|
2015-05-19 |
2024-03-18 |
사렙타 쎄러퓨틱스 인코퍼레이티드 |
펩티드 올리고뉴클레오티드 콘주게이트
|
US10787664B2
(en)
|
2015-05-26 |
2020-09-29 |
City Of Hope |
Compounds of chemically modified oligonucleotides and methods of use thereof
|
MX2017015582A
(es)
|
2015-06-01 |
2018-09-06 |
Univ Temple |
Metodos y composiciones para tratamiento guiado por arn de infeccion por vih.
|
US10196701B2
(en)
|
2015-06-01 |
2019-02-05 |
The Penn State Research Foundation |
Hepatitis B virus capsid assembly
|
EP3302497A4
(de)
|
2015-06-01 |
2019-01-16 |
Sarepta Therapeutics, Inc. |
Antisense-induszierte exonexklusion in typ-vii-kollagen
|
US10883103B2
(en)
|
2015-06-02 |
2021-01-05 |
Monsanto Technology Llc |
Compositions and methods for delivery of a polynucleotide into a plant
|
AU2016270913A1
(en)
|
2015-06-03 |
2018-01-04 |
Monsanto Technology Llc |
Methods and compositions for introducing nucleic acids into plants
|
US10392607B2
(en)
|
2015-06-03 |
2019-08-27 |
The Regents Of The University Of California |
Cas9 variants and methods of use thereof
|
EP3302489A4
(de)
|
2015-06-04 |
2019-02-06 |
Sarepta Therapeutics, Inc. |
Verfahren und verbindungen zur behandlung von krankheiten und leiden im zusammenhang mit lymphozyten
|
US10695762B2
(en)
|
2015-06-05 |
2020-06-30 |
Miroculus Inc. |
Evaporation management in digital microfluidic devices
|
WO2016197103A1
(en)
|
2015-06-05 |
2016-12-08 |
Miroculus Inc. |
Air-matrix digital microfluidics apparatuses and methods for limiting evaporation and surface fouling
|
EP3527672B1
(de)
|
2015-06-09 |
2022-10-05 |
Centrillion Technology Holdings Corporation |
Oligonukleotide arrays zur sequenzierung von nukleinsäuren
|
WO2016201301A1
(en)
|
2015-06-12 |
2016-12-15 |
Alnylam Pharmaceuticals, Inc. |
Complement component c5 irna compositions and methods of use thereof
|
WO2016205323A1
(en)
|
2015-06-18 |
2016-12-22 |
Alnylam Pharmaceuticals, Inc. |
Polynucleotde agents targeting hydroxyacid oxidase (glycolate oxidase, hao1) and methods of use thereof
|
WO2016209862A1
(en)
|
2015-06-23 |
2016-12-29 |
Alnylam Pharmaceuticals, Inc. |
Glucokinase (gck) irna compositions and methods of use thereof
|
WO2016210241A1
(en)
|
2015-06-26 |
2016-12-29 |
Beth Israel Deaconess Medical Center, Inc. |
Cancer therapy targeting tetraspanin 33 (tspan33) in myeloid derived suppressor cells
|
AU2016285724A1
(en)
|
2015-06-29 |
2017-11-16 |
Ionis Pharmaceuticals, Inc. |
Modified CRISPR RNA and modified single CRISPR RNA and uses thereof
|
AU2016287499B2
(en)
|
2015-06-29 |
2022-08-04 |
Caris Science, Inc. |
Therapeutic oligonucleotides
|
EP3313186A4
(de)
|
2015-06-29 |
2019-04-03 |
Biomed Valley Discoveries, Inc. |
Lpt-723-und immunkontrollpunkthemmer-kombinationen und behandlungsverfahren
|
SG10202006563PA
(en)
|
2015-07-10 |
2020-08-28 |
Ionis Pharmaceuticals Inc |
Modulators of diacyglycerol acyltransferase 2 (dgat2)
|
WO2017011286A1
(en)
|
2015-07-10 |
2017-01-19 |
Alnylam Pharmaceuticals, Inc. |
Insulin-like growth factor binding protein, acid labile subunit (igfals) and insulin-like growth factor 1 (igf-1) irna compositions and methods of use thereof
|
WO2017011565A1
(en)
|
2015-07-14 |
2017-01-19 |
Abbott Molecular Inc. |
Compositions and methods for identifying drug resistant tuberculosis
|
US10941176B2
(en)
|
2015-07-28 |
2021-03-09 |
Caris Science, Inc. |
Therapeutic oligonucleotides
|
US11273167B2
(en)
|
2015-08-03 |
2022-03-15 |
The Regents Of The University Of California |
Compositions and methods for modulating ABHD2 activity
|
ES2965461T3
(es)
|
2015-08-03 |
2024-04-15 |
Biokine Therapeutics Ltd |
Inhibidor de CXCR4 para el tratamiento del cáncer
|
WO2017021961A1
(en)
|
2015-08-04 |
2017-02-09 |
Yeda Research And Development Co. Ltd. |
Methods of screening for riboswitches and attenuators
|
US11661463B2
(en)
|
2015-08-06 |
2023-05-30 |
City Of Hope |
Cell penetrating protein-antibody conjugates and methods of use
|
KR20180038465A
(ko)
|
2015-08-07 |
2018-04-16 |
애로우헤드 파마슈티컬스 인코포레이티드 |
B형 간염 바이러스 감염에 대한 rnai 치료법
|
CN106434873B
(zh)
|
2015-08-13 |
2021-08-27 |
生捷科技控股公司 |
使核酸分子同步化的方法
|
BR112018003784A2
(pt)
|
2015-08-24 |
2018-09-25 |
Halo-Bio Rnai Therapeutics, Inc. |
nanopartículas de polinucleotídeo para a modulação da expressão gênica e sua utilização
|
EA201890619A1
(ru)
|
2015-09-02 |
2018-09-28 |
Элнилэм Фармасьютикалз, Инк. |
КОМПОЗИЦИИ iRNA ЛИГАНДА 1 БЕЛКА ЗАПРОГРАММИРОВАННОЙ ГИБЕЛИ КЛЕТОК 1 (PD-L1) И СПОСОБЫ ИХ ПРИМЕНЕНИЯ
|
US9499861B1
(en)
|
2015-09-10 |
2016-11-22 |
Insilixa, Inc. |
Methods and systems for multiplex quantitative nucleic acid amplification
|
EP3347714B1
(de)
|
2015-09-10 |
2021-03-10 |
InSilixa Inc. |
Verfahren für quantitative multiplex-nukleinsäureamplifikation
|
US11434486B2
(en)
|
2015-09-17 |
2022-09-06 |
Modernatx, Inc. |
Polynucleotides containing a morpholino linker
|
BR112018004620A2
(pt)
|
2015-09-24 |
2018-09-25 |
Ionis Pharmaceuticals, Inc. |
moduladores da expressão de kras
|
CA2999177A1
(en)
|
2015-09-24 |
2017-03-30 |
The Regents Of The University Of California |
Synthetic sphingolipid-like molecules, drugs, methods of their synthesis and methods of treatment
|
EP3353297A1
(de)
|
2015-09-24 |
2018-08-01 |
Crispr Therapeutics AG |
Neuartige familie von rna-programmierbaren endonukleasen und deren verwendung in der genomeditierung und anderen anwendungen
|
WO2017053781A1
(en)
|
2015-09-25 |
2017-03-30 |
Ionis Pharmaceuticals, Inc. |
Compositions and methods for modulating ataxin 3 expression
|
US20190054113A1
(en)
|
2015-09-30 |
2019-02-21 |
Sarepta Therapeutics, Inc. |
Methods for treating muscular dystrophy
|
BR122020023854B1
(pt)
|
2015-10-08 |
2022-11-29 |
Ionis Pharmaceuticals, Inc |
Composto compreendendo oligonucleotídeo modificado e seu uso, uso do oligonucleotídeo modificado, composição e seu uso
|
EP3359668A4
(de)
|
2015-10-09 |
2019-06-05 |
Sarepta Therapeutics, Inc. |
Zusammensetzungen und verfahren zur behandlung von duchenne-muskeldystrophie und damit assoziierten erkrankungen
|
EP4089175A1
(de)
|
2015-10-13 |
2022-11-16 |
Duke University |
Genom-engineering mit typ-i-crispr-systemen in eukaryotischen zellen
|
US10829787B2
(en)
|
2015-10-14 |
2020-11-10 |
Life Technologies Corporation |
Ribonucleoprotein transfection agents
|
SK500652015A3
(sk)
|
2015-10-15 |
2017-05-03 |
Ústav Polymérov Sav |
Spôsob úpravy funkčného stavu ľubovoľnej mRNA umožňujúci jej selektívne a špecifické rozpoznanie
|
CN108367021A
(zh)
|
2015-10-15 |
2018-08-03 |
希望之城 |
包含硫代磷酸化寡脱氧核苷酸的化合物和组合物及其使用方法
|
EP3368089A4
(de)
|
2015-10-26 |
2019-05-29 |
Translate Bio Ma, Inc. |
Nanopartikelformulierungen zur freisetzung von nukleinsäurekomplexen
|
EP3368063B1
(de)
|
2015-10-28 |
2023-09-06 |
Vertex Pharmaceuticals Inc. |
Materialien und verfahren zur behandlung von duchenne-muskeldystrophie
|
CA3001362C
(en)
|
2015-10-30 |
2020-10-13 |
Genentech, Inc. |
Anti-htra1 antibodies and methods of use thereof
|
EP3370734B1
(de)
|
2015-11-05 |
2023-01-04 |
Children's Hospital Los Angeles |
Antisense-oligo zur verwendung bei der behandlung von akuter myeloischer leukämie
|
WO2017079739A1
(en)
|
2015-11-06 |
2017-05-11 |
Ionis Pharmaceuticals, Inc. |
MODULATING APOLIPOPROTEIN (a) EXPRESSION
|
EP4119569A1
(de)
|
2015-11-06 |
2023-01-18 |
Ionis Pharmaceuticals, Inc. |
Konjugierte antisense-verbindungen zur verwendung in der therapie
|
US11866727B2
(en)
|
2015-11-06 |
2024-01-09 |
Crispr Therapeutics Ag |
Materials and methods for treatment of glycogen storage disease type 1A
|
EP3373939A4
(de)
|
2015-11-10 |
2019-06-26 |
B.G. Negev Technologies and Applications Ltd., at Ben-Gurion University |
Mittel und verfahren zur verringerung der tumorigenität von krebsstammzellen
|
WO2017087708A1
(en)
|
2015-11-19 |
2017-05-26 |
The Brigham And Women's Hospital, Inc. |
Lymphocyte antigen cd5-like (cd5l)-interleukin 12b (p40) heterodimers in immunity
|
WO2017091630A1
(en)
|
2015-11-23 |
2017-06-01 |
The Regents Of The University Of California |
Tracking and manipulating cellular rna via nuclear delivery of crispr/cas9
|
JP6983779B2
(ja)
|
2015-11-30 |
2021-12-17 |
ザ リージェンツ オブ ザ ユニバーシティ オブ カリフォルニアThe Regents Of The University Of California |
非常に特異的な腫瘍細胞表面抗原を標的とするヒト抗体を用いた腫瘍特異的ペイロード送達及び免疫活性化
|
US11851653B2
(en)
|
2015-12-01 |
2023-12-26 |
Crispr Therapeutics Ag |
Materials and methods for treatment of alpha-1 antitrypsin deficiency
|
EP3389670A4
(de)
|
2015-12-04 |
2020-01-08 |
Ionis Pharmaceuticals, Inc. |
Verfahren zur behandlung von brustkrebs
|
AU2015416656B2
(en)
|
2015-12-07 |
2023-02-23 |
Erasmus University Medical Center Rotterdam |
Enzymatic replacement therapy and antisense therapy for Pompe disease
|
EA201891419A1
(ru)
|
2015-12-15 |
2019-01-31 |
Сарепта Терапьютикс, Инк. |
Пептид-олигонуклеотидные конъюгаты
|
AU2016369612B2
(en)
|
2015-12-17 |
2023-06-01 |
Modernatx, Inc. |
Polynucleotides encoding methylmalonyl-CoA mutase
|
WO2017106767A1
(en)
|
2015-12-18 |
2017-06-22 |
The Scripps Research Institute |
Production of unnatural nucleotides using a crispr/cas9 system
|
JP7393121B2
(ja)
|
2015-12-23 |
2023-12-06 |
オレゴン ステイト ユニバーシティー |
アンチセンス抗菌化合物および方法
|
CN109312339B
(zh)
|
2015-12-23 |
2022-01-28 |
克里斯珀医疗股份公司 |
用于治疗肌萎缩侧索硬化症和/或额颞叶变性的材料和方法
|
CA3010084A1
(en)
|
2015-12-23 |
2017-06-29 |
Oregon State University |
Antisense antibacterial compounds and methods
|
AU2017205462A1
(en)
|
2016-01-05 |
2018-06-07 |
Ionis Pharmaceuticals, Inc. |
Methods for reducing LRRK2 expression
|
CA3009691C
(en)
|
2016-01-06 |
2021-12-07 |
The University Of British Columbia |
Bifurcating mixers and methods of their use and manufacture
|
WO2017124086A1
(en)
|
2016-01-15 |
2017-07-20 |
The Jackson Laboratory |
Genetically modified non-human mammals by multi-cycle electroporation of cas9 protein
|
US10627396B2
(en)
|
2016-01-29 |
2020-04-21 |
Vanderbilt University |
Free-solution response function interferometry
|
EP3411078A1
(de)
|
2016-02-02 |
2018-12-12 |
Crispr Therapeutics AG |
Materialien und verfahren zur behandlung von schwerer kombinierter immundefizienz (scid) oder omenn-syndrom
|
EP3411396A1
(de)
|
2016-02-04 |
2018-12-12 |
Curis, Inc. |
Smoothened-mutant und verfahren zur verwendung davon
|
JP7176737B2
(ja)
|
2016-02-15 |
2022-11-22 |
テンプル ユニバーシティー オブ ザ コモンウェルス システム オブ ハイヤー エデュケーション |
レトロウイルス核酸配列の切除
|
JP2019508037A
(ja)
|
2016-02-16 |
2019-03-28 |
イェール ユニバーシティーYale Universit |
標的化遺伝子編集を増強するための組成物およびその使用方法
|
WO2017143061A1
(en)
|
2016-02-16 |
2017-08-24 |
Yale University |
Compositions and methods for treatment of cystic fibrosis
|
EP3416689B1
(de)
|
2016-02-18 |
2023-01-18 |
CRISPR Therapeutics AG |
Materialien und verfahren zur behandlung von schwerer kombinierter immundefizienz (scid) oder omenn syndrome
|
WO2017143150A1
(en)
|
2016-02-19 |
2017-08-24 |
City Of Hope |
Bi-specific aptamer
|
CA3054284A1
(en)
|
2016-02-25 |
2017-08-31 |
The Brigham And Women's Hospital, Inc. |
Treatment methods for fibrosis targeting smoc2
|
WO2017147483A1
(en)
|
2016-02-26 |
2017-08-31 |
The Board Of Trustees Of The Leland Stanford Junior University |
Multiplexed single molecule rna visualization with a two-probe proximity ligation system
|
US10767178B2
(en)
|
2016-02-26 |
2020-09-08 |
Yale University |
Compositions and methods of using piRNAS in cancer diagnostics and therapeutics
|
US20210189062A1
(en)
|
2016-03-01 |
2021-06-24 |
Alexion Pharmaceuticals, Inc. |
Biodegradable activated polymers for therapeutic delivery
|
WO2017155858A1
(en)
|
2016-03-07 |
2017-09-14 |
Insilixa, Inc. |
Nucleic acid sequence identification using solid-phase cyclic single base extension
|
EP3426677B1
(de)
|
2016-03-08 |
2023-12-06 |
Kemyth Biotech Co., Ltd. |
Verwendung von pneumolysinpeptiden als antagonisten gegen den toll-like-rezeptor 4 und verfahren zur behandlung von krankheiten im zusammenhang mit toll-like-rezeptor 4
|
AU2017229778A1
(en)
|
2016-03-09 |
2018-08-16 |
Ionis Pharmaceuticals, Inc. |
Methods and compositions for inhibiting PMP22 expression
|
WO2017161168A1
(en)
|
2016-03-16 |
2017-09-21 |
Ionis Pharmaceuticals, Inc. |
Modulation of dyrk1b expression
|
EP3429632B1
(de)
|
2016-03-16 |
2023-01-04 |
CRISPR Therapeutics AG |
Materialien und verfahren zur behandlung von erblicher haemochromatose
|
EP3429690A4
(de)
|
2016-03-16 |
2019-10-23 |
Ionis Pharmaceuticals, Inc. |
Verfahren zur modulation von keap1
|
WO2017161357A1
(en)
|
2016-03-18 |
2017-09-21 |
Caris Science, Inc. |
Oligonucleotide probes and uses thereof
|
WO2017173247A1
(en)
|
2016-03-31 |
2017-10-05 |
City Of Hope |
Aptamer compositions and the use thereof
|
US20190117799A1
(en)
|
2016-04-01 |
2019-04-25 |
The Brigham And Women's Hospital, Inc. |
Stimuli-responsive nanoparticles for biomedical applications
|
CA3017532A1
(en)
|
2016-04-13 |
2017-10-19 |
Ionis Pharmaceuticals, Inc. |
Methods for reducing c9orf72 expression
|
WO2017181163A2
(en)
|
2016-04-16 |
2017-10-19 |
Oncocyte Corporation |
Methods and compositions for detection and diagnosis of breast cancer
|
EP3445405A4
(de)
|
2016-04-18 |
2019-12-18 |
Sarepta Therapeutics, Inc. |
Antisense-oligomere und verfahren zur verwendung davon zur behandlung von erkrankungen in zusammenhang mit dem saure-alpha-glucosidase-gen
|
FI3445388T3
(fi)
|
2016-04-18 |
2024-05-15 |
Vertex Pharma |
Materiaaleja ja menetelmiä hemoglobinopatioiden hoitamiseksi
|
MA45295A
(fr)
|
2016-04-19 |
2019-02-27 |
Alnylam Pharmaceuticals Inc |
Composition d'arni de protéine de liaison de lipoprotéines haute densité (hdlbp/vigiline) et procédés pour les utiliser
|
BR112018072279A2
(pt)
|
2016-04-29 |
2019-02-12 |
Sarepta Therapeutics, Inc. |
análogos de oligonucleotídeo tendo como alvo lmna humana
|
US10845367B2
(en)
|
2016-05-04 |
2020-11-24 |
Abilita Bio, Inc. |
Modified multispanning membrane polypeptides and methods of use thereof to screen therapeutic agents
|
WO2017191503A1
(en)
|
2016-05-05 |
2017-11-09 |
Crispr Therapeutics Ag |
Materials and methods for treatment of hemoglobinopathies
|
WO2017193053A1
(en)
|
2016-05-06 |
2017-11-09 |
Woolf Tod M |
Improved methods for genome editing with and without programmable nucleases
|
WO2017197128A1
(en)
|
2016-05-11 |
2017-11-16 |
Yale University |
Poly(amine-co-ester) nanoparticles and methods of use thereof
|
DK3455372T3
(da)
|
2016-05-11 |
2020-01-06 |
Illumina Inc |
Polynukleotidberigelse og -amplifikation ved anvendelse af argonautsystemer
|
WO2017201315A1
(en)
|
2016-05-18 |
2017-11-23 |
Roche Sequencing Solutions, Inc. |
Quantitative real time pcr amplification using an electrowetting-based device
|
IL263044B1
(en)
|
2016-05-24 |
2024-02-01 |
Sarepta Therapeutics Inc |
Processes for the preparation of phosphorodiamidate morpholino oligomers
|
CN109563114B
(zh)
|
2016-05-24 |
2022-08-12 |
萨勒普塔医疗公司 |
用于制备寡聚物的方法
|
US11472824B2
(en)
|
2016-05-24 |
2022-10-18 |
Sarepta Therapeutics, Inc. |
Processes for preparing phosphorodiamidate morpholino oligomers
|
DK3464306T3
(da)
|
2016-05-24 |
2024-05-21 |
Sarepta Therapeutics Inc |
Fremgangsmåder til fremstilling af phosphorodiamidat-morpholino-oligomerer
|
AU2017278699A1
(en)
|
2016-05-24 |
2018-11-15 |
Sarepta Therapeutics, Inc. |
Pharmaceutical composition comprising Eteplirsen
|
MA45362A
(fr)
|
2016-05-24 |
2019-04-10 |
Sarepta Therapeutics Inc |
Procédés de préparation d'oligomères morpholino de phosphorodiamidate
|
CA3025486A1
(en)
|
2016-05-25 |
2017-11-30 |
Caris Science, Inc. |
Oligonucleotide probes and uses thereof
|
KR102592388B1
(ko)
|
2016-06-09 |
2023-10-20 |
더 리전트 오브 더 유니버시티 오브 캘리포니아 |
종이-기반 면역검정법에서 사용하기 위한 바이오마커 농축 및 신호 증폭, 그리고 dna의 추출, 농축 및 증폭을 위한 단일 플랫폼
|
EP3469083A1
(de)
|
2016-06-10 |
2019-04-17 |
Alnylam Pharmaceuticals, Inc. |
Gegen komplementkomponente c5 gerichtete irna-zusammensetzungen und verfahren zur verwendung davon zur behandlung von paroxysmaler nächtlicher hämoglobinurie (pnh)
|
US11779657B2
(en)
|
2016-06-10 |
2023-10-10 |
City Of Hope |
Compositions and methods for mitochondrial genome editing
|
US10544457B2
(en)
|
2016-06-14 |
2020-01-28 |
Pacific Biosciences Of California, Inc. |
Methods and compositions for enriching compositions for polymerase enzyme complexes
|
EP3471740A4
(de)
|
2016-06-15 |
2020-03-04 |
University of Utah Research Foundation |
Zusammensetzungen und verfahren zur verwendung von albuminbasierten nanomedikamenten
|
US10337051B2
(en)
|
2016-06-16 |
2019-07-02 |
The Regents Of The University Of California |
Methods and compositions for detecting a target RNA
|
EP3471781A4
(de)
|
2016-06-17 |
2020-05-06 |
Ionis Pharmaceuticals, Inc. |
Modulierung der gys1-expression
|
EP4163293A1
(de)
|
2016-06-24 |
2023-04-12 |
The Scripps Research Institute |
Neuartiger nukleosid-triphosphat-transporter und verwendungen davon
|
CA3029119A1
(en)
|
2016-06-29 |
2018-01-04 |
Crispr Therapeutics Ag |
Materials and methods for treatment of friedreich ataxia and other related disorders
|
WO2018002762A1
(en)
|
2016-06-29 |
2018-01-04 |
Crispr Therapeutics Ag |
Materials and methods for treatment of amyotrophic lateral sclerosis (als) and other related disorders
|
EP3478829A1
(de)
|
2016-06-29 |
2019-05-08 |
Crispr Therapeutics AG |
Materialien und verfahren zur behandlung von myotoner dystrophie typ 1 (dm1) und anderen erkrankungen
|
CA3024153A1
(en)
|
2016-06-30 |
2017-11-30 |
Sarepta Therapeutics, Inc. |
Processes for preparing phosphorodiamidate morpholino oligomers
|
CA3025575A1
(en)
|
2016-06-30 |
2018-01-04 |
Sarepta Therapeutics, Inc. |
Exon skipping oligomers for muscular dystrophy
|
AU2017292169B2
(en)
|
2016-07-06 |
2021-12-23 |
Vertex Pharmaceuticals Incorporated |
Materials and methods for treatment of pain related disorders
|
EP3481857A1
(de)
|
2016-07-06 |
2019-05-15 |
Crispr Therapeutics AG |
Materialien und verfahren zur behandlung von schmerbedingten erkrankungen
|
WO2018007871A1
(en)
|
2016-07-08 |
2018-01-11 |
Crispr Therapeutics Ag |
Materials and methods for treatment of transthyretin amyloidosis
|
EP3481430A4
(de)
|
2016-07-11 |
2020-04-01 |
Translate Bio Ma, Inc. |
Nukleinsäurekonjugate und verwendungen davon
|
WO2018013558A1
(en)
|
2016-07-12 |
2018-01-18 |
Life Technologies Corporation |
Compositions and methods for detecting nucleic acid regions
|
SG11201900238UA
(en)
|
2016-07-15 |
2019-02-27 |
Ionis Pharmaceuticals Inc |
Compounds and methods for modulation of smn2
|
JP2019520844A
(ja)
|
2016-07-21 |
2019-07-25 |
マックスサイト インコーポレーティッド |
ゲノムdnaを改変するための方法および組成物
|
US10711300B2
(en)
|
2016-07-22 |
2020-07-14 |
Pacific Biosciences Of California, Inc. |
Methods and compositions for delivery of molecules and complexes to reaction sites
|
WO2018020323A2
(en)
|
2016-07-25 |
2018-02-01 |
Crispr Therapeutics Ag |
Materials and methods for treatment of fatty acid disorders
|
US20180028688A1
(en)
|
2016-07-27 |
2018-02-01 |
The Board Of Trustees Of The Leland Stanford Junior University |
Immolative cell-penetrating complexes for nucleic acid delivery
|
JOP20170161A1
(ar)
|
2016-08-04 |
2019-01-30 |
Arrowhead Pharmaceuticals Inc |
عوامل RNAi للعدوى بفيروس التهاب الكبد ب
|
NL2017295B1
(en)
|
2016-08-05 |
2018-02-14 |
Univ Erasmus Med Ct Rotterdam |
Antisense oligomeric compound for Pompe disease
|
NL2017294B1
(en)
|
2016-08-05 |
2018-02-14 |
Univ Erasmus Med Ct Rotterdam |
Natural cryptic exon removal by pairs of antisense oligonucleotides.
|
WO2018039281A1
(en)
|
2016-08-22 |
2018-03-01 |
Miroculus Inc. |
Feedback system for parallel droplet control in a digital microfluidic device
|
US11364304B2
(en)
|
2016-08-25 |
2022-06-21 |
Northwestern University |
Crosslinked micellar spherical nucleic acids
|
PT3506909T
(pt)
|
2016-09-02 |
2022-08-16 |
Dicerna Pharmaceuticals Inc |
Análogos de 4¿-fosfato e oligonucleótidos compreendendo os mesmos
|
JP7063885B2
(ja)
|
2016-09-13 |
2022-05-09 |
ザ ジャクソン ラボラトリー |
標的にされた増大するdna脱メチル化
|
EP3512563A1
(de)
|
2016-09-16 |
2019-07-24 |
The Johns Hopkins University |
Protein-nanocages mit verbesserter schleimpenetration zur gezielten gewebe- und intrazellulären verabreichung
|
EP3516401A1
(de)
|
2016-09-19 |
2019-07-31 |
Genmark Diagnostics Inc. |
Instrument zur verarbeitung einer kassette zur durchführung von tests in einem geschlossenen probenvorbereitungs- und -reaktionssystem
|
JP2019534862A
(ja)
|
2016-09-20 |
2019-12-05 |
ザ リージェンツ オブ ザ ユニヴァーシティ オブ コロラド,ア ボディ コーポレイト |
ホスホルアミダイト化学を使用する骨格修飾モルホリノオリゴヌクレオチド及びキメラの合成
|
JOP20190065A1
(ar)
|
2016-09-29 |
2019-03-28 |
Ionis Pharmaceuticals Inc |
مركبات وطرق لتقليل التعبير عن tau
|
AU2017335890B2
(en)
|
2016-09-30 |
2024-05-09 |
The Regents Of The University Of California |
RNA-guided nucleic acid modifying enzymes and methods of use thereof
|
KR20190065341A
(ko)
|
2016-10-06 |
2019-06-11 |
아이오니스 파마수티컬즈, 인코포레이티드 |
올리고머 화합물들의 접합 방법
|
EP3532638A4
(de)
|
2016-10-31 |
2020-07-29 |
University of Massachusetts |
Targeting von microrna-101-3p in der krebstherapie
|
JOP20190104A1
(ar)
|
2016-11-10 |
2019-05-07 |
Ionis Pharmaceuticals Inc |
مركبات وطرق لتقليل التعبير عن atxn3
|
CA3043277A1
(en)
|
2016-11-11 |
2018-05-17 |
The Regents Of The University Of California |
Anti-cd46 antibodies and methods of use
|
US11008325B2
(en)
|
2016-11-14 |
2021-05-18 |
Virginia Commonwealth University |
Inhibitors of cancer invasion, attachment, and/or metastasis
|
TW202313978A
(zh)
|
2016-11-23 |
2023-04-01 |
美商阿尼拉製藥公司 |
絲胺酸蛋白酶抑制因子A1 iRNA組成物及其使用方法
|
EP3330276A1
(de)
|
2016-11-30 |
2018-06-06 |
Universität Bern |
Neuartige bicyclische nukleoside und daraus hergestellte oligomere
|
US11033570B2
(en)
|
2016-12-02 |
2021-06-15 |
Cold Spring Harbor Laboratory |
Modulation of Lnc05 expression
|
JP7206214B2
(ja)
|
2016-12-13 |
2023-01-17 |
シアトル チルドレンズ ホスピタル (ディービーエイ シアトル チルドレンズ リサーチ インスティテュート) |
インビトロ及びインビボで操作された細胞において発現された化学誘導シグナル伝達複合体の外因性薬物活性化の方法
|
AU2017376950B2
(en)
|
2016-12-16 |
2024-02-22 |
Alnylam Pharmaceuticals, Inc. |
Methods for treating or preventing TTR-associated diseases using transthyretin (TTR) iRNA compositions
|
WO2018112470A1
(en)
|
2016-12-16 |
2018-06-21 |
The Brigham And Women's Hospital, Inc. |
Co-delivery of nucleic acids for simultaneous suppression and expression of target genes
|
KR102639633B1
(ko)
|
2016-12-19 |
2024-02-26 |
사렙타 쎄러퓨틱스 인코퍼레이티드 |
근육 이상증에 대한 엑손 스킵핑 올리고머 결합체
|
NZ755416A
(en)
|
2016-12-19 |
2023-05-26 |
Sarepta Therapeutics Inc |
Exon skipping oligomer conjugates for muscular dystrophy
|
IL267246B2
(en)
|
2016-12-19 |
2023-03-01 |
Sarepta Therapeutics Inc |
Exon-skipping oligomer conjugates for muscular dystrophy
|
WO2018126082A1
(en)
|
2016-12-28 |
2018-07-05 |
Miroculis Inc. |
Digital microfluidic devices and methods
|
US10450565B2
(en)
|
2017-01-10 |
2019-10-22 |
Arrowhead Pharmaceuticals, Inc. |
Alpha-1 antitrypsin (AAT) RNAi agents, compositions including AAT RNAi agents, and methods of use
|
EP3570829A4
(de)
|
2017-01-18 |
2021-03-10 |
The Scripps Research Institute |
Fotoreaktive liganden und verwendungen davon
|
WO2018136702A1
(en)
|
2017-01-23 |
2018-07-26 |
Regeneron Pharmaceuticals, Inc. |
Hydroxysteroid 17-beta dehydrogenase 13 (hsd17b13) variants and uses thereof
|
EP3574109B1
(de)
|
2017-01-24 |
2023-07-26 |
Vastogen, Inc. |
Verfahren zur konstruktion von kopien von nukleinsäuremolekülen
|
WO2018154439A1
(en)
|
2017-02-22 |
2018-08-30 |
Crispr Therapeutics Ag |
Materials and methods for treatment of spinocerebellar ataxia type 1 (sca1) and other spinocerebellar ataxia type 1 protein (atxn1) gene related conditions or disorders
|
CN110662838B
(zh)
|
2017-02-22 |
2024-05-28 |
克里斯珀医疗股份公司 |
用于基因编辑的组合物和方法
|
US20200040061A1
(en)
|
2017-02-22 |
2020-02-06 |
Crispr Therapeutics Ag |
Materials and methods for treatment of early onset parkinson's disease (park1) and other synuclein, alpha (snca) gene related conditions or disorders
|
EP3585899A1
(de)
|
2017-02-22 |
2020-01-01 |
CRISPR Therapeutics AG |
Materialien und verfahren zur behandlung von primärer hyperoxalurie typ 1 (ph1) und anderen mit dem alanin-glyoxylataminotransferase (agxt)-gen assoziierten erkrankungen oder störungen
|
EP3585900B1
(de)
|
2017-02-22 |
2022-12-21 |
CRISPR Therapeutics AG |
Materialien und methoden zur behandlung von spinocerebellar ataxia typ 2 (sca2) und anderen spinocerebellar ataxia typ 2 protein (atxn2) gen verwandten erkrankungen oder störungen
|
US11591647B2
(en)
|
2017-03-06 |
2023-02-28 |
Singular Genomics Systems, Inc. |
Nucleic acid sequencing-by-synthesis (SBS) methods that combine SBS cycle steps
|
WO2018165564A1
(en)
|
2017-03-09 |
2018-09-13 |
Ionis Pharmaceuticals, Inc. |
Morpholino modified oligomeric compounds
|
WO2018169960A1
(en)
|
2017-03-17 |
2018-09-20 |
The Johns Hopkins University |
Nanoparticle formulations for enhanced drug delivery to the bladder
|
JOP20190215A1
(ar)
|
2017-03-24 |
2019-09-19 |
Ionis Pharmaceuticals Inc |
مُعدّلات التعبير الوراثي عن pcsk9
|
WO2018183969A1
(en)
|
2017-03-30 |
2018-10-04 |
California Institute Of Technology |
Barcoded rapid assay platform for efficient analysis of candidate molecules and methods of making and using the platform
|
WO2018187493A1
(en)
|
2017-04-04 |
2018-10-11 |
Yale University |
Compositions and methods for in utero delivery
|
US11623219B2
(en)
|
2017-04-04 |
2023-04-11 |
Miroculus Inc. |
Digital microfluidics apparatuses and methods for manipulating and processing encapsulated droplets
|
MA50278A
(fr)
|
2017-04-18 |
2020-02-26 |
Alnylam Pharmaceuticals Inc |
Méthodes pour le traitement de sujets atteints d'une infection par le virus de l'hépatite b (vhb)
|
CA3059321A1
(en)
|
2017-04-20 |
2018-10-25 |
Synthena Ag |
Modified oligomeric compounds comprising tricyclo-dna nucleosides and uses thereof
|
EP3612215A4
(de)
|
2017-04-20 |
2021-05-26 |
aTyr Pharma, Inc. |
Zusammensetzungen und verfahren zur behandlung von lungenentzündungen
|
WO2018193428A1
(en)
|
2017-04-20 |
2018-10-25 |
Synthena Ag |
Modified oligomeric compounds comprising tricyclo-dna nucleosides and uses thereof
|
WO2018195486A1
(en)
|
2017-04-21 |
2018-10-25 |
The Broad Institute, Inc. |
Targeted delivery to beta cells
|
JP2020517735A
(ja)
|
2017-04-21 |
2020-06-18 |
ピー・エイチ・アイ・セラピューティクス・インコーポレイテッド |
ざ瘡を治療するためのプロピオニバクテリウムアクネス(Propionibacterium acnes)バクテリオファージを含む組成物
|
US11466069B2
(en)
|
2017-04-28 |
2022-10-11 |
Auckland Uniservices Limited |
Methods of treatment and novel constructs
|
US11299776B2
(en)
|
2017-05-10 |
2022-04-12 |
Board Of Regents, The University Of Texas System |
Methods and devices related to amplifying nucleic acid at a variety of temperatures
|
WO2018208998A1
(en)
|
2017-05-10 |
2018-11-15 |
The Regents Of The University Of California |
Directed editing of cellular rna via nuclear delivery of crispr/cas9
|
IL270415B1
(en)
|
2017-05-12 |
2024-04-01 |
Crispr Therapeutics Ag |
Materials and methods for cell engineering and their uses in immuno-oncology
|
WO2018212271A1
(ja)
|
2017-05-18 |
2018-11-22 |
国立大学法人京都大学 |
脊髄小脳変性症36型の予防又は治療用組成物
|
US11554178B2
(en)
|
2017-06-30 |
2023-01-17 |
City Of Hope |
Compositions and methods of modulating macrophage activity
|
AU2018300069A1
(en)
|
2017-07-11 |
2020-02-27 |
Synthorx, Inc. |
Incorporation of unnatural nucleotides and methods thereof
|
EP3651799A1
(de)
|
2017-07-13 |
2020-05-20 |
Massachusetts Institute of Technology |
Targeting des hdac2-sp3-komplexes zur verbesserung der synaptischen funktion
|
US11690920B2
(en)
|
2017-07-13 |
2023-07-04 |
Northwestern University |
General and direct method for preparing oligonucleotide-functionalized metal-organic framework nanoparticles
|
CN111093710A
(zh)
|
2017-07-13 |
2020-05-01 |
希望之城 |
硫代磷酸酯缀合的肽及其使用方法
|
JP7277432B2
(ja)
|
2017-07-13 |
2023-05-19 |
アルナイラム ファーマシューティカルズ, インコーポレイテッド |
乳酸脱水素酵素A(LDHA)iRNA組成物及びその使用方法
|
GB201711809D0
(en)
|
2017-07-21 |
2017-09-06 |
Governors Of The Univ Of Alberta |
Antisense oligonucleotide
|
US11413617B2
(en)
|
2017-07-24 |
2022-08-16 |
Miroculus Inc. |
Digital microfluidics systems and methods with integrated plasma collection device
|
AU2018309739B2
(en)
|
2017-07-31 |
2022-01-27 |
The Trustees Of Columbia University In The City Of New York |
Compounds, Compositions, and Methods for Treating T-cell Acute Lymphoblastic Leukemia
|
WO2019028425A1
(en)
|
2017-08-03 |
2019-02-07 |
Synthorx, Inc. |
CONJUGATES OF CYTOKINE FOR THE TREATMENT OF AUTOIMMUNE DISEASES
|
NL2019390B1
(en)
|
2017-08-04 |
2019-02-21 |
Univ Leiden |
Screening Method
|
EP3665202A1
(de)
|
2017-08-09 |
2020-06-17 |
Massachusetts Institute Of Technology |
Albumin-bindende peptidkonjugate und verfahren dafür
|
EP3664814A4
(de)
|
2017-08-11 |
2021-05-05 |
City of Hope |
Rna-aptamere gegen transferrin-rezeptor (tfr)
|
AU2018318231A1
(en)
|
2017-08-18 |
2020-02-13 |
Ionis Pharmaceuticals, Inc. |
Modulation of the notch signaling pathway for treatment of respiratory disorders
|
EP3675826B1
(de)
|
2017-08-31 |
2023-05-31 |
Life Technologies Corporation |
Kationische lipidzusammensetzungen zur gewebespezifischen verabreichung
|
EP3676009A4
(de)
|
2017-09-01 |
2021-06-16 |
Miroculus Inc. |
Digitale mikrofluidikvorrichtungen und verfahren zu ihrer verwendung
|
US20200299729A1
(en)
|
2017-09-08 |
2020-09-24 |
Life Technologies Corporation |
Methods for improved homologous recombination and compositions thereof
|
EP3679143A1
(de)
|
2017-09-08 |
2020-07-15 |
Life Technologies Corporation |
Verfahren zur verbesserten homologen rekombination und zusammensetzungen davon
|
US10517889B2
(en)
|
2017-09-08 |
2019-12-31 |
Ionis Pharmaceuticals, Inc. |
Modulators of SMAD7 expression
|
EP3684931A1
(de)
|
2017-09-19 |
2020-07-29 |
Alnylam Pharmaceuticals, Inc. |
Zusammensetzungen und verfahren zur behandlung von transthyretin(ttr)-vermittelter amyloidose
|
EA201991450A1
(ru)
|
2017-09-22 |
2019-12-30 |
Сарепта Терапьютикс, Инк. |
Конъюгаты олигомеров для пропуска экзона при мышечной дистрофии
|
WO2019067981A1
(en)
|
2017-09-28 |
2019-04-04 |
Sarepta Therapeutics, Inc. |
POLYTHERAPIES FOR TREATING MUSCLE DYSTROPHY
|
WO2019067975A1
(en)
|
2017-09-28 |
2019-04-04 |
Sarepta Therapeutics, Inc. |
POLYTHERAPIES FOR TREATING MUSCLE DYSTROPHY
|
EP3687519A1
(de)
|
2017-09-28 |
2020-08-05 |
Sarepta Therapeutics, Inc. |
Kombinationstherapien zur behandlung von muskeldystrophie
|
KR20200067190A
(ko)
|
2017-10-17 |
2020-06-11 |
크리스퍼 테라퓨틱스 아게 |
A형 혈우병을 위한 유전자 편집용 조성물 및 방법
|
US11555189B2
(en)
|
2017-10-18 |
2023-01-17 |
Sarepta Therapeutics, Inc. |
Antisense oligomer compounds
|
US11099202B2
(en)
|
2017-10-20 |
2021-08-24 |
Tecan Genomics, Inc. |
Reagent delivery system
|
US20210180091A1
(en)
|
2017-10-26 |
2021-06-17 |
Vertex Pharmaceuticals Incorporated |
Materials and methods for treatment of hemoglobinopathies
|
US20210180053A1
(en)
|
2017-11-01 |
2021-06-17 |
Novartis Ag |
Synthetic rnas and methods of use
|
EP3704252A1
(de)
|
2017-11-01 |
2020-09-09 |
Alnylam Pharmaceuticals, Inc. |
Gegen komplementkomponente c3 gerichtete irna-zusammensetzungen und verfahren zur verwendung davon
|
TWI809004B
(zh)
|
2017-11-09 |
2023-07-21 |
美商Ionis製藥公司 |
用於降低snca表現之化合物及方法
|
WO2019092507A2
(en)
|
2017-11-09 |
2019-05-16 |
Crispr Therapeutics Ag |
Crispr/cas systems for treatment of dmd
|
WO2019092269A1
(en)
|
2017-11-13 |
2019-05-16 |
F. Hoffmann-La Roche Ag |
Devices for sample analysis using epitachophoresis
|
EP3710587A1
(de)
|
2017-11-16 |
2020-09-23 |
Alnylam Pharmaceuticals, Inc. |
Apolipoprotein-c3 kisspeptin 1 (kiss1)-irna-zusammensetzungen und verfahren zur verwendung davon
|
WO2019100039A1
(en)
|
2017-11-20 |
2019-05-23 |
Alnylam Pharmaceuticals, Inc. |
Serum amyloid p component (apcs) irna compositions and methods of use thereof
|
WO2019100053A1
(en)
|
2017-11-20 |
2019-05-23 |
University Of Georgia Research Foundation, Inc. |
Compositions and methods for modulating hif-2α to improve muscle generation and repair
|
EP3714055A1
(de)
|
2017-11-21 |
2020-09-30 |
CRISPR Therapeutics AG |
Materialien und verfahren zur behandlung von autosomal-dominanter retinitis pigmentosa
|
US11728007B2
(en)
|
2017-11-30 |
2023-08-15 |
Grail, Llc |
Methods and systems for analyzing nucleic acid sequences using mappability analysis and de novo sequence assembly
|
KR20200106159A
(ko)
|
2017-12-05 |
2020-09-11 |
버텍스 파마슈티칼스 인코포레이티드 |
크리스퍼-cas9 변형된 cd34+ 인간 조혈 줄기 및 전구 세포 및 그의 용도
|
EP3724206B1
(de)
|
2017-12-14 |
2023-06-28 |
Ionis Pharmaceuticals, Inc. |
Konjugierte antisense-verbindungen und deren verwendung
|
CA3084825A1
(en)
|
2017-12-14 |
2019-06-20 |
Crispr Therapeutics Ag |
Novel rna-programmable endonuclease systems and their use in genome editing and other applications
|
CA3086343A1
(en)
|
2017-12-18 |
2019-06-27 |
Alnylam Pharmaceuticals, Inc. |
High mobility group box-1 (hmgb1) irna compositions and methods of use thereof
|
WO2019126037A1
(en)
|
2017-12-19 |
2019-06-27 |
City Of Hope |
Modified tracrrnas grnas, and uses thereof
|
CN111836892A
(zh)
|
2017-12-21 |
2020-10-27 |
克里斯珀医疗股份公司 |
用于治疗2a型乌谢尔综合征的材料和方法
|
WO2019126641A2
(en)
|
2017-12-21 |
2019-06-27 |
Ionis Pharmaceuticals, Inc. |
Modulation of frataxin expression
|
WO2019123430A1
(en)
|
2017-12-21 |
2019-06-27 |
Casebia Therapeutics Llp |
Materials and methods for treatment of usher syndrome type 2a and/or non-syndromic autosomal recessive retinitis pigmentosa (arrp)
|
US11242568B2
(en)
|
2017-12-29 |
2022-02-08 |
City Of Hope |
DNA methylation diagnostic test for breast cancer
|
WO2019140330A1
(en)
|
2018-01-12 |
2019-07-18 |
Casebia Therapeutics Limited Liability Partnership |
Compositions and methods for gene editing by targeting transferrin
|
PE20211242A1
(es)
|
2018-01-15 |
2021-07-09 |
Ionis Pharmaceuticals Inc |
Moduladores de la expresion dnm2
|
JP2021510714A
(ja)
|
2018-01-19 |
2021-04-30 |
シンセナ アーゲー |
トリシクロ−dnaヌクレオシド前駆体およびそれを調製するためのプロセス
|
WO2019147743A1
(en)
|
2018-01-26 |
2019-08-01 |
Massachusetts Institute Of Technology |
Structure-guided chemical modification of guide rna and its applications
|
US11268077B2
(en)
|
2018-02-05 |
2022-03-08 |
Vertex Pharmaceuticals Incorporated |
Materials and methods for treatment of hemoglobinopathies
|
US11566236B2
(en)
|
2018-02-05 |
2023-01-31 |
Vertex Pharmaceuticals Incorporated |
Materials and methods for treatment of hemoglobinopathies
|
WO2019155465A1
(en)
|
2018-02-08 |
2019-08-15 |
Yeda Research And Development Co. Ltd. |
Methods of identifying and using agents for treating diseases associated with intestinal barrier dysfunction
|
US11332733B2
(en)
|
2018-02-12 |
2022-05-17 |
lonis Pharmaceuticals, Inc. |
Modified compounds and uses thereof
|
US20210130824A1
(en)
|
2018-02-16 |
2021-05-06 |
Crispr Therapeutics Ag |
Compositions and methods for gene editing by targeting fibrinogen-alpha
|
MX2020008772A
(es)
|
2018-02-26 |
2020-10-01 |
Synthorx Inc |
Conjugados de il-15, y sus usos.
|
US11732260B2
(en)
|
2018-03-02 |
2023-08-22 |
Ionis Pharmaceuticals, Inc. |
Compounds and methods for the modulation of amyloid-β precursor protein
|
BR112020016001A2
(pt)
|
2018-03-02 |
2020-12-15 |
Ionis Pharmaceuticals, Inc. |
Moduladores de expressão irf4
|
CN112105625A
(zh)
|
2018-03-07 |
2020-12-18 |
赛诺菲 |
核苷酸前体、核苷酸类似物以及含其的寡聚化合物
|
CA3092345A1
(en)
|
2018-03-13 |
2019-09-19 |
The Regents Of The University Of California |
Inhibitors of integrin alpha 2 beta 1 and methods of use
|
WO2019183150A1
(en)
|
2018-03-19 |
2019-09-26 |
Casebia Therapeutics Limited Liability Partnership |
Novel rna-programmable endonuclease systems and uses thereof
|
EP3768694A4
(de)
|
2018-03-22 |
2021-12-29 |
Ionis Pharmaceuticals, Inc. |
Verfahren zur modulierung der fmr1-expression
|
US20210147847A1
(en)
|
2018-03-30 |
2021-05-20 |
Rheinische Friedrich-Wilhelms-Universitat Bonn |
Aptamers for targeted activaton of t cell-mediated immunity
|
AU2019247490A1
(en)
|
2018-04-06 |
2020-10-22 |
Children's Medical Center Corporation |
Compositions and methods for somatic cell reprogramming and modulating imprinting
|
JP7275164B2
(ja)
|
2018-04-11 |
2023-05-17 |
アイオーニス ファーマシューティカルズ, インコーポレーテッド |
Ezh2発現の調節因子
|
WO2019204668A1
(en)
|
2018-04-18 |
2019-10-24 |
Casebia Therapeutics Limited Liability Partnership |
Compositions and methods for knockdown of apo(a) by gene editing for treatment of cardiovascular disease
|
US20210189460A1
(en)
|
2018-04-25 |
2021-06-24 |
Qiagen Sciences Llc |
Sequential paired-end sequencing
|
AU2019260687B2
(en)
|
2018-04-27 |
2022-09-22 |
Seattle Children's Hospital (dba Seattle Children's Research Institute) |
Rapamycin resistant cells
|
JP7438135B2
(ja)
|
2018-05-09 |
2024-02-26 |
アイオーニス ファーマシューティカルズ, インコーポレーテッド |
Fxiの発現を低下させるための化合物及び方法
|
UY38225A
(es)
|
2018-05-09 |
2019-11-29 |
Ionis Pharmaceuticals Inc |
Compuestos y métodos para reducir de la expresión de atxn3
|
TW202016304A
(zh)
|
2018-05-14 |
2020-05-01 |
美商阿尼拉製藥公司 |
血管收縮素原(AGT)iRNA組成物及其使用方法
|
CA3096855A1
(en)
|
2018-05-23 |
2019-11-28 |
Miroculus Inc. |
Control of evaporation in digital microfluidics
|
US10758629B2
(en)
|
2018-05-29 |
2020-09-01 |
Sarepta Therapeutics, Inc. |
Exon skipping oligomer conjugates for muscular dystrophy
|
CA3102109A1
(en)
|
2018-05-30 |
2019-12-05 |
Dtx Pharma, Inc. |
Lipid-modified nucleic acid compounds and methods
|
US10987428B2
(en)
|
2018-06-01 |
2021-04-27 |
City Of Hope |
Phosphorothioate-conjugated miRNAs and methods of using the same
|
EP3806868A4
(de)
|
2018-06-13 |
2022-06-22 |
Sarepta Therapeutics, Inc. |
Exon-skipping-oligomere für muskeldystrophie
|
CA3103429A1
(en)
|
2018-06-14 |
2019-12-19 |
Don W. Cleveland |
Compounds and methods for increasing stmn2 expression
|
WO2020006267A1
(en)
|
2018-06-27 |
2020-01-02 |
Ionis Pharmaceuticals, Inc. |
Compounds and methods for reducing lrrk2 expression
|
US11827877B2
(en)
|
2018-06-28 |
2023-11-28 |
Crispr Therapeutics Ag |
Compositions and methods for genomic editing by insertion of donor polynucleotides
|
AU2019310097A1
(en)
|
2018-07-25 |
2021-02-04 |
Ionis Pharmaceuticals, Inc. |
Compounds and methods for reducing ATXN2 expression
|
TW202020153A
(zh)
|
2018-07-27 |
2020-06-01 |
美商薩羅塔治療公司 |
用於肌肉萎縮症之外顯子跳躍寡聚物
|
US10857174B2
(en)
|
2018-07-27 |
2020-12-08 |
United States Government As Represented By The Department Of Veterans Affairs |
Morpholino oligonucleotides useful in cancer treatment
|
WO2020028617A1
(en)
|
2018-08-01 |
2020-02-06 |
University Of Georgia Research Foundation, Inc. |
Compositions and methods for improving embryo development
|
EP3830301B1
(de)
|
2018-08-01 |
2024-05-22 |
Mammoth Biosciences, Inc. |
Programmierbare nuklease-zusammensetzungen und verwendungsverfahren dafür
|
US20210189431A1
(en)
|
2018-08-10 |
2021-06-24 |
Yale University |
Compositions and methods for embryonic gene editing in vitro
|
WO2020036862A1
(en)
|
2018-08-13 |
2020-02-20 |
Alnylam Pharmaceuticals, Inc. |
HEPATITIS B VIRUS (HBV) dsRNA AGENT COMPOSITIONS AND METHODS OF USE THEREOF
|
US11987792B2
(en)
|
2018-08-16 |
2024-05-21 |
Alnylam Pharmaceuticals, Inc. |
Compositions and methods for inhibiting expression of the LECT2 gene
|
JP7476199B2
(ja)
|
2018-08-20 |
2024-04-30 |
ロジコン, インコーポレイテッド |
Scn1a脳症の治療のためのscn2aを標的とするアンチセンスオリゴヌクレオチド
|
CA3110661A1
(en)
|
2018-08-29 |
2020-03-05 |
University Of Massachusetts |
Inhibition of protein kinases to treat friedreich ataxia
|
MX2021002266A
(es)
|
2018-08-31 |
2021-05-27 |
Univ Yale |
Composiciones y metodos para aumentar la edicion de genes basados en nucleasa y triplex.
|
WO2020047344A1
(en)
|
2018-08-31 |
2020-03-05 |
Yale University |
Compositions and methods for enhancing donor oligonucleotide-based gene editing
|
WO2020051507A1
(en)
|
2018-09-06 |
2020-03-12 |
The Broad Institute, Inc. |
Nucleic acid assemblies for use in targeted delivery
|
US20200080107A1
(en)
|
2018-09-07 |
2020-03-12 |
Crispr Therapeutics Ag |
Universal donor cells
|
EP3620520A1
(de)
|
2018-09-10 |
2020-03-11 |
Universidad del Pais Vasco |
Neuartiges target zur behandlung einer stoffwechselerkrankung in einem individuum
|
EP3850110A4
(de)
|
2018-09-11 |
2022-06-08 |
Singular Genomics Systems, Inc. |
Modifizierte archaeale polymerasen der familie b
|
JP2022500442A
(ja)
|
2018-09-14 |
2022-01-04 |
ノースウェスタン ユニバーシティ |
Dnaとのタンパク質重合のプログラミング
|
EP3853364A1
(de)
|
2018-09-18 |
2021-07-28 |
Alnylam Pharmaceuticals, Inc. |
Ketohexokinase (khk)-irna-zusammensetzungen und verfahren zur verwendung davon
|
TW202023573A
(zh)
|
2018-09-19 |
2020-07-01 |
美商Ionis製藥公司 |
Pnpla3表現之調節劑
|
WO2020061381A1
(en)
|
2018-09-19 |
2020-03-26 |
La Jolla Institute For Immunology |
Ptprs and proteoglycans in rheumatoid arthritis
|
WO2020074742A1
(en)
|
2018-10-12 |
2020-04-16 |
F. Hoffmann-La Roche Ag |
Detection methods for epitachophoresis workflow automation
|
EP3867377A1
(de)
|
2018-10-17 |
2021-08-25 |
CRISPR Therapeutics AG |
Zusammensetzungen und verfahren zur abgabe von transgenen
|
WO2020086834A1
(en)
|
2018-10-25 |
2020-04-30 |
Singular Genomics Systems, Inc. |
Nucleotide analogues
|
US10913951B2
(en)
|
2018-10-31 |
2021-02-09 |
University of Pittsburgh—of the Commonwealth System of Higher Education |
Silencing of HNF4A-P2 isoforms with siRNA to improve hepatocyte function in liver failure
|
TW202028222A
(zh)
|
2018-11-14 |
2020-08-01 |
美商Ionis製藥公司 |
Foxp3表現之調節劑
|
PE20211869A1
(es)
|
2018-11-15 |
2021-09-21 |
Ionis Pharmaceuticals Inc |
Moduladores de la expresion de irf5
|
NL2022043B1
(en)
|
2018-11-21 |
2020-06-03 |
Akershus Univ Hf |
Tagmentation-Associated Multiplex PCR Enrichment Sequencing
|
CA3117694A1
(en)
|
2018-11-21 |
2020-05-28 |
Ionis Pharmaceuticals, Inc. |
Compounds and methods for reducing prion expression
|
IL263184A
(en)
|
2018-11-21 |
2020-05-31 |
Yarden Yosef |
Method of treating cancer and compositions for same
|
WO2020112195A1
(en)
|
2018-11-30 |
2020-06-04 |
Yale University |
Compositions, technologies and methods of using plerixafor to enhance gene editing
|
US20210332495A1
(en)
|
2018-12-06 |
2021-10-28 |
Northwestern University |
Protein Crystal Engineering Through DNA Hybridization Interactions
|
EP3894558A1
(de)
|
2018-12-13 |
2021-10-20 |
Sarepta Therapeutics, Inc. |
Exon-skipping-oligomerkonjugate für muskeldystrophie
|
KR20210103931A
(ko)
|
2018-12-14 |
2021-08-24 |
일루미나 케임브리지 리미티드 |
서열분석 동안 비표지된 뉴클레오타이드에 의한 페이싱 감소
|
CN112654714A
(zh)
|
2018-12-17 |
2021-04-13 |
伊卢米纳剑桥有限公司 |
用于测序的引物寡核苷酸
|
AU2019411266A1
(en)
|
2018-12-17 |
2021-01-07 |
Illumina Cambridge Limited |
Compositions for use in polyunucleotide sequencing
|
SI3897672T1
(sl)
|
2018-12-20 |
2024-02-29 |
Humabs Biomed Sa |
Kombinirana terapija HBV
|
CN113631709A
(zh)
|
2018-12-20 |
2021-11-09 |
普拉克西斯精密药物股份有限公司 |
用于治疗kcnt1相关病症的组合物和方法
|
EP3674702A1
(de)
|
2018-12-27 |
2020-07-01 |
Imec VZW |
Verfahren zur sequenzierung eines polynukleotids mittels eines biofet
|
WO2020142754A2
(en)
|
2019-01-04 |
2020-07-09 |
Mammoth Biosciences, Inc. |
Programmable nuclease improvements and compositions and methods for nucleic acid amplification and detection
|
EP3908286A4
(de)
|
2019-01-08 |
2022-10-12 |
Singular Genomics Systems, Inc. |
Nukleotidspaltbare linker und verwendungen davon
|
AU2020209186A1
(en)
|
2019-01-16 |
2021-09-09 |
Genzyme Corporation |
Serpinc1 iRNA compositions and methods of use thereof
|
US20220098578A1
(en)
|
2019-01-31 |
2022-03-31 |
Bar Ilan University |
Neoantigens created by aberrant-induced splicing and uses thereof in enhancing immunotherapy
|
US11214803B2
(en)
|
2019-01-31 |
2022-01-04 |
Ionis Pharmaceuticals, Inc. |
Modulators of YAP1 expression
|
EP3917574A4
(de)
|
2019-02-01 |
2022-11-02 |
The Board of Trustees of the Leland Stanford Junior University |
Immolative zellpenetrierende komplexe zur nukleinsäureabgabe an die lunge
|
MX2021009259A
(es)
|
2019-02-06 |
2021-08-24 |
Synthorx Inc |
Conjugados de il-2 y metodos de uso del mismo.
|
EP3921418A4
(de)
|
2019-02-06 |
2023-02-08 |
Singular Genomics Systems, Inc. |
Zusammensetzungen und verfahren zur nukleinsäuresequenzierung
|
WO2020168362A1
(en)
|
2019-02-15 |
2020-08-20 |
Crispr Therapeutics Ag |
Gene editing for hemophilia a with improved factor viii expression
|
WO2020171889A1
(en)
|
2019-02-19 |
2020-08-27 |
University Of Rochester |
Blocking lipid accumulation or inflammation in thyroid eye disease
|
WO2020170240A1
(en)
|
2019-02-21 |
2020-08-27 |
Yissum Research Development Company Of The Hebrew University Of Jerusalem Ltd. |
Method for reduction drug-induced nephrotoxicity
|
US11504425B2
(en)
|
2019-02-26 |
2022-11-22 |
Wayne State University |
Amphiphilic oligodeoxynucleotide conjugates as adjuvant enhancers
|
CN113544271A
(zh)
|
2019-02-27 |
2021-10-22 |
Ionis制药公司 |
Malat1表达的调节剂
|
EP3935184A1
(de)
|
2019-03-04 |
2022-01-12 |
King Abdullah University Of Science And Technology |
Zusammensetzungen und verfahren zur gezielten nukleinsäureanreicherung durch schleifen-adapterschutz und exonuklease-verdau
|
AU2020231380A1
(en)
|
2019-03-07 |
2021-09-23 |
The Regents Of The University Of California |
CRISPR-Cas effector polypeptides and methods of use thereof
|
CN113825834A
(zh)
|
2019-03-11 |
2021-12-21 |
索伦托药业有限公司 |
使用rna引导的核酸内切酶进行dna构建体整合的改进工艺
|
US20220145274A1
(en)
|
2019-03-12 |
2022-05-12 |
Crispr Therapeutics Ag |
Novel high fidelity rna-programmable endonuclease systems and uses thereof
|
EP3937780A4
(de)
|
2019-03-14 |
2022-12-07 |
InSilixa, Inc. |
Verfahren und systeme zur zeitgesteuerten fluoreszenzbasierten detektion
|
EP3941483A4
(de)
|
2019-03-21 |
2023-10-18 |
Arnay Sciences, Llc |
Antisense-oligonukleotide zur allelspezifität
|
MX2021011498A
(es)
|
2019-03-28 |
2022-01-04 |
Sarepta Therapeutics Inc |
Metodos para tratar la distrofia muscular con casimersin.
|
JP2022527108A
(ja)
|
2019-03-29 |
2022-05-30 |
ディセルナ ファーマシューティカルズ インコーポレイテッド |
Kras関連疾患または障害の治療のための組成物及び方法
|
JP2022527105A
(ja)
|
2019-03-29 |
2022-05-30 |
アイオーニス ファーマシューティカルズ, インコーポレーテッド |
Ube3a-atsを調節するための化合物及び方法
|
WO2020203880A1
(ja)
|
2019-03-29 |
2020-10-08 |
田辺三菱製薬株式会社 |
Dux4の発現を調節するための化合物、方法及び医薬組成物
|
EP3953041A4
(de)
|
2019-04-08 |
2023-01-25 |
Miroculus Inc. |
Digitale mikrofluidikvorrichtungen mit mehreren patronen und verfahren zur verwendung
|
US20220193246A1
(en)
|
2019-04-18 |
2022-06-23 |
Sarepta Therapeutics, Inc. |
Compositions for treating muscular dystrophy
|
US11814464B2
(en)
|
2019-04-29 |
2023-11-14 |
Yale University |
Poly(amine-co-ester) polymers and polyplexes with modified end groups and methods of use thereof
|
KR20220004675A
(ko)
|
2019-05-03 |
2022-01-11 |
다이서나 파마수이티컬, 인크. |
단축 센스 가닥을 갖는 이중 가닥 핵산 억제제 분자
|
US20210047649A1
(en)
|
2019-05-08 |
2021-02-18 |
Vertex Pharmaceuticals Incorporated |
Crispr/cas all-in-two vector systems for treatment of dmd
|
WO2020232024A1
(en)
|
2019-05-13 |
2020-11-19 |
Vir Biotechnology, Inc. |
Compositions and methods for treating hepatitis b virus (hbv) infection
|
JP7441243B2
(ja)
|
2019-05-14 |
2024-02-29 |
エフ. ホフマン-ラ ロシュ アーゲー |
試料分析のための装置および方法
|
WO2020230047A1
(en)
|
2019-05-15 |
2020-11-19 |
Affinito Alessadra |
Aptamers against glioblastoma
|
US20220243203A1
(en)
|
2019-05-28 |
2022-08-04 |
Ionis Pharmaceuticals, Inc. |
Compounds and methods for reducing fus expression
|
WO2020245198A1
(en)
|
2019-06-04 |
2020-12-10 |
Apterna Limited |
APTAMERS AGAINST TRANSFERRIN RECEPTOR (TfR)
|
JP2022538784A
(ja)
|
2019-06-14 |
2022-09-06 |
ザ スクリプス リサーチ インスティテュート |
半合成生物における複製、転写および翻訳のための試薬ならびに方法
|
WO2020254872A2
(en)
|
2019-06-17 |
2020-12-24 |
Crispr Therapeutics Ag |
Methods and compositions for improved homology directed repair
|
EP3987029A1
(de)
|
2019-06-19 |
2022-04-27 |
Sarepta Therapeutics, Inc. |
Verfahren zur behandlung von muskeldystrophie
|
WO2020257779A1
(en)
|
2019-06-21 |
2020-12-24 |
Yale University |
Hydroxymethyl-modified gamma-pna compositions and methods of use thereof
|
WO2020257776A1
(en)
|
2019-06-21 |
2020-12-24 |
Yale University |
Peptide nucleic acid compositions with modified hoogsteen binding segments and methods of use thereof
|
WO2021011803A1
(en)
|
2019-07-16 |
2021-01-21 |
Omniome, Inc. |
Synthetic nucleic acids having non-natural structures
|
BR112022001315A2
(pt)
|
2019-07-25 |
2022-04-12 |
Aspen Neuroscience Inc |
Métodos para identificação de neurônios dopaminérgicos e células progenitoras
|
US11524298B2
(en)
|
2019-07-25 |
2022-12-13 |
Miroculus Inc. |
Digital microfluidics devices and methods of use thereof
|
US11786546B2
(en)
|
2019-07-26 |
2023-10-17 |
Ionis Pharmaceuticals, Inc. |
Compounds and methods for modulating GFAP
|
WO2021022161A1
(en)
|
2019-07-31 |
2021-02-04 |
Yale University |
Compositions and methods for treating sickle cell disease
|
WO2021022109A1
(en)
|
2019-08-01 |
2021-02-04 |
Alnylam Pharmaceuticals, Inc. |
SERPIN FAMILY F MEMBER 2 (SERPINF2) iRNA COMPOSITIONS AND METHODS OF USE THEREOF
|
EP4007811A2
(de)
|
2019-08-01 |
2022-06-08 |
Alnylam Pharmaceuticals, Inc. |
Carboxypeptidase-b2(cpb2)-irna-zusammensetzungen und verfahren zur verwendung davon
|
WO2021025899A1
(en)
|
2019-08-02 |
2021-02-11 |
Sarepta Therapeutics, Inc. |
Phosphorodiamidate morpholino oligomer pharmaceutical compositions
|
WO2021030522A1
(en)
|
2019-08-13 |
2021-02-18 |
Alnylam Pharmaceuticals, Inc. |
SMALL RIBOSOMAL PROTEIN SUBUNIT 25 (RPS25) iRNA AGENT COMPOSITIONS AND METHODS OF USE THEREOF
|
BR112022002599A2
(pt)
|
2019-08-14 |
2022-07-19 |
Codiak Biosciences Inc |
Vesícula extracelular ligada a moléculas e usos da mesma
|
EP4013454A1
(de)
|
2019-08-15 |
2022-06-22 |
Synthorx, Inc. |
Immunonkologische kombinationstherapien mit il-2-konjugaten
|
EP4013767A4
(de)
|
2019-08-15 |
2023-10-25 |
Ionis Pharmaceuticals, Inc. |
Verbindungsmodifizierte oligomere verbindungen und ihre verwendungen
|
CA3148135A1
(en)
|
2019-08-23 |
2021-03-04 |
Carolina E. CAFFARO |
Il-15 conjugates and uses thereof
|
CN115151275A
(zh)
|
2019-08-30 |
2022-10-04 |
耶鲁大学 |
用于向细胞递送核酸的组合物和方法
|
BR112022003860A2
(pt)
|
2019-09-03 |
2022-08-16 |
Alnylam Pharmaceuticals Inc |
Composições e métodos para inibir a expressão do gene lect2
|
JP2022547053A
(ja)
|
2019-09-05 |
2022-11-10 |
クリスパー セラピューティクス アクチェンゲゼルシャフト |
ユニバーサルドナー細胞
|
EP4025690A1
(de)
|
2019-09-05 |
2022-07-13 |
CRISPR Therapeutics AG |
Universelle donorzellen
|
US20220372063A1
(en)
|
2019-09-05 |
2022-11-24 |
Sanofi |
Oligonucleotides containing nucleotide analogs
|
AU2020347154A1
(en)
|
2019-09-10 |
2022-03-03 |
Synthorx, Inc. |
IL-2 conjugates and methods of use to treat autoimmune diseases
|
TW202124406A
(zh)
|
2019-09-10 |
2021-07-01 |
美商歐姆尼歐美公司 |
核苷酸之可逆修飾
|
EP4028053A1
(de)
|
2019-09-11 |
2022-07-20 |
Bausch Health Ireland Limited |
Verfahren zur behandlung von nicht-alkoholischer fettleberkrankheit (nafld) mit il-17ra-antikörper
|
US11512295B2
(en)
|
2019-09-12 |
2022-11-29 |
Singular Genomics Systems, Inc. |
Modified thermoccocus polymerases
|
US20220389429A1
(en)
|
2019-10-04 |
2022-12-08 |
Alnylam Pharmaceuticals, Inc. |
Compositions and methods for silencing ugt1a1 gene expression
|
WO2021071909A1
(en)
|
2019-10-08 |
2021-04-15 |
Life Technologies Corporation |
Compositions and methods for homology-directed recombination
|
WO2021074772A1
(en)
|
2019-10-14 |
2021-04-22 |
Astrazeneca Ab |
Modulators of pnpla3 expression
|
WO2021076828A1
(en)
|
2019-10-18 |
2021-04-22 |
Alnylam Pharmaceuticals, Inc. |
Solute carrier family member irna compositions and methods of use thereof
|
CN115176004A
(zh)
|
2019-10-22 |
2022-10-11 |
阿尔尼拉姆医药品有限公司 |
补体成分C3 iRNA组合物及其使用方法
|
CN113939590A
(zh)
|
2019-10-25 |
2022-01-14 |
因美纳剑桥有限公司 |
用于在包含发夹环的多核苷酸模板的末端上产生非对称接头并从其测序的方法
|
WO2021087325A1
(en)
|
2019-11-01 |
2021-05-06 |
Alnylam Pharmaceuticals, Inc. |
Compositions and methods for silencing dnajb1-prkaca fusion gene expression
|
AR120341A1
(es)
|
2019-11-01 |
2022-02-09 |
Alnylam Pharmaceuticals Inc |
COMPOSICIONES DE AGENTES DE ARNi CONTRA LA HUNTINGTINA (HTT) Y SUS MÉTODOS DE USO
|
IL291786A
(en)
|
2019-11-04 |
2022-06-01 |
Synthorx Inc |
Interleukin 10 conjugates and their use
|
PE20230179A1
(es)
|
2019-11-13 |
2023-02-01 |
Alnylam Pharmaceuticals Inc |
Metodos y composiciones para el tratamiento de un trastorno asociado con angiotensinogeno (agt)
|
EP4061945A1
(de)
|
2019-11-22 |
2022-09-28 |
Alnylam Pharmaceuticals, Inc. |
Ataxin3 (atxn3)-rnai-wirkstoffzusammensetzungen und verfahren zu deren verwendung
|
CN115335521A
(zh)
|
2019-11-27 |
2022-11-11 |
克里斯珀医疗股份公司 |
合成rna分子的方法
|
KR20220110263A
(ko)
|
2019-12-04 |
2022-08-05 |
더 보드 오브 트러스티스 오브 더 리랜드 스탠포드 쥬니어 유니버시티 |
내인성 조절인자의 표적화에 의한 혈액-뇌 장벽 약물 수송의 향상
|
EP4073251A1
(de)
|
2019-12-13 |
2022-10-19 |
Alnylam Pharmaceuticals, Inc. |
Irna-wirkstoffzusammensetzungen des open reading frame 72 (c9orf72) des menschlichen chromosoms 9 und verfahren zu ihrer verwendung
|
WO2021126734A1
(en)
|
2019-12-16 |
2021-06-24 |
Alnylam Pharmaceuticals, Inc. |
Patatin-like phospholipase domain containing 3 (pnpla3) irna compositions and methods of use thereof
|
WO2021122944A1
(en)
|
2019-12-18 |
2021-06-24 |
Alia Therapeutics Srl |
Compositions and methods for treating retinitis pigmentosa
|
EP4077676A1
(de)
|
2019-12-18 |
2022-10-26 |
Novartis AG |
Zusammensetzungen und verfahren zur behandlung von hämoglobinopathien
|
EP4081653A4
(de)
|
2019-12-23 |
2023-07-26 |
Singular Genomics Systems, Inc. |
Verfahren für die long-read-sequenzierung
|
US20230111132A1
(en)
|
2019-12-23 |
2023-04-13 |
The Regents Of The University Of California |
Stabilization of mhc complexes
|
IL294459A
(en)
|
2019-12-31 |
2022-09-01 |
Singular Genomics Systems Inc |
Polynucleotide barcodes for long read sequencing
|
US11859172B2
(en)
|
2020-01-02 |
2024-01-02 |
The Trustees Of Columbia University In The City Of New York |
Programmable and portable CRISPR-Cas transcriptional activation in bacteria
|
EP4090665A1
(de)
|
2020-01-15 |
2022-11-23 |
Dicerna Pharmaceuticals, Inc. |
4'-o-methylenphosphonat-nukleinsäuren und analoge davon
|
US20230057461A1
(en)
|
2020-01-27 |
2023-02-23 |
The U.S.A., As Represented By The Secretary, Department Of Health And Human Services |
Rab13 and net1 antisense oligonucleotides to treat metastatic cancer
|
WO2021154941A1
(en)
|
2020-01-31 |
2021-08-05 |
Alnylam Pharmaceuticals, Inc. |
Complement component c5 irna compositions for use in the treatment of amyotrophic lateral sclerosis (als)
|
JP2023514190A
(ja)
|
2020-02-10 |
2023-04-05 |
アルナイラム ファーマシューティカルズ, インコーポレイテッド |
Vegf-a発現をサイレンシングするための組成物および方法
|
KR20220139366A
(ko)
|
2020-02-12 |
2022-10-14 |
에이에스오큐라 파마슈티칼스 쑤저우 캄파니, 리미티드 |
안티센스 올리고뉴클레오티드 및 펜드리드 증후군 치료를 위한 이의 용도
|
CN115397989A
(zh)
|
2020-02-18 |
2022-11-25 |
阿尔尼拉姆医药品有限公司 |
载脂蛋白C3(APOC3)iRNA组合物及其使用方法
|
US11034942B1
(en)
|
2020-02-27 |
2021-06-15 |
Singular Genomics Systems, Inc. |
Modified pyrococcus polymerases and uses thereof
|
KR20220148230A
(ko)
|
2020-02-28 |
2022-11-04 |
아이오니스 파마수티컬즈, 인코포레이티드 |
Smn2를 조절하기 위한 화합물 및 방법
|
EP4114947A1
(de)
|
2020-03-05 |
2023-01-11 |
Alnylam Pharmaceuticals, Inc. |
Komplementkomponenten-c3-irna-zusammensetzungen und verfahren zur verwendung davon zur behandlung oder prävention von mit komplementkomponenten-c3-assoziierten erkrankungen
|
CA3174473A1
(en)
|
2020-03-06 |
2021-09-10 |
Alnylam Pharmaceuticals, Inc. |
Compositions and methods for inhibiting expression of transthyretin (ttr)
|
CN115485383A
(zh)
|
2020-03-06 |
2022-12-16 |
阿尔尼拉姆医药品有限公司 |
己酮糖激酶(KHK)iRNA组合物及其使用方法
|
WO2021178893A2
(en)
|
2020-03-06 |
2021-09-10 |
Singular Genomics Systems, Inc. |
Linked paired strand sequencing
|
EP4121534A1
(de)
|
2020-03-18 |
2023-01-25 |
Alnylam Pharmaceuticals, Inc. |
Zusammensetzungen und verfahren zur behandlung von patienten mit einer heterozygoten alaninglyoxylat-aminotransferase-genvariante (agxt)
|
CN116209759A
(zh)
|
2020-03-26 |
2023-06-02 |
阿尔尼拉姆医药品有限公司 |
冠状病毒iRNA组合物及其使用方法
|
US20230190785A1
(en)
|
2020-03-30 |
2023-06-22 |
Alnylam Pharmaceuticals, Inc. |
Compositions and methods for silencing dnajc15 gene expression
|
CN117377763A
(zh)
|
2020-04-06 |
2024-01-09 |
阿尔尼拉姆医药品有限公司 |
用于沉默myoc表达的组合物和方法
|
CA3179678A1
(en)
|
2020-04-07 |
2021-10-14 |
Alnylam Pharmaceuticals, Inc. |
Compositions and methods for silencing scn9a expression
|
WO2021206922A1
(en)
|
2020-04-07 |
2021-10-14 |
Alnylam Pharmaceuticals, Inc. |
Transmembrane serine protease 2 (tmprss2) irna compositions and methods of use thereof
|
EP4133076A1
(de)
|
2020-04-07 |
2023-02-15 |
Alnylam Pharmaceuticals, Inc. |
Irna-zusammensetzungen aus angiotensin-konvertierendem enzym 2 (ace2) und verfahren zur verwendung davon
|
US11965162B2
(en)
|
2020-04-16 |
2024-04-23 |
The Johns Hopkins University |
MicroRNA and inhibitors thereof and methods of treatment
|
US11174281B1
(en)
|
2020-04-24 |
2021-11-16 |
Singular Genomics Systems, Inc. |
Modified nucleotides and uses thereof
|
JP2023523993A
(ja)
|
2020-04-27 |
2023-06-08 |
アルナイラム ファーマシューティカルズ, インコーポレイテッド |
アポリポタンパク質E(ApoE)iRNA剤組成物およびその使用方法
|
BR112022021136A2
(pt)
|
2020-04-30 |
2022-11-29 |
Alnylam Pharmaceuticals Inc |
Composições de irna de fator b de complemento (cfb) e métodos de uso das mesmas
|
CN115916176A
(zh)
|
2020-05-01 |
2023-04-04 |
加利福尼亚大学董事会 |
α2β1整联蛋白的抑制剂和其使用方法
|
TW202206596A
(zh)
|
2020-05-01 |
2022-02-16 |
美商Ionis製藥公司 |
調節atxn1之化合物及方法
|
EP4151237A1
(de)
|
2020-05-12 |
2023-03-22 |
Mitsubishi Tanabe Pharma Corporation |
Verbindung, verfahren und pharmazeutische zusammensetzung zur regulierung der expression von ataxin 3
|
WO2021231691A1
(en)
|
2020-05-15 |
2021-11-18 |
Korro Bio, Inc. |
Methods and compositions for the adar-mediated editing of retinoschisin 1 (rsi)
|
WO2021231680A1
(en)
|
2020-05-15 |
2021-11-18 |
Korro Bio, Inc. |
Methods and compositions for the adar-mediated editing of methyl-cpg binding protein 2 (mecp2)
|
EP4150088A1
(de)
|
2020-05-15 |
2023-03-22 |
Korro Bio, Inc. |
Verfahren und zusammensetzungen zur adar-vermittelten bearbeitung von argininosuccinat-synthetase (ass1)
|
US20210355463A1
(en)
|
2020-05-15 |
2021-11-18 |
Crispr Therapeutics Ag |
Messenger rna encoding cas9 for use in genome-editing systems
|
WO2021231692A1
(en)
|
2020-05-15 |
2021-11-18 |
Korro Bio, Inc. |
Methods and compositions for the adar-mediated editing of otoferlin (otof)
|
WO2021231685A1
(en)
|
2020-05-15 |
2021-11-18 |
Korro Bio, Inc. |
Methods and compositions for the adar-mediated editing of transmembrane channel-like protein 1 (tmc1)
|
WO2021231698A1
(en)
|
2020-05-15 |
2021-11-18 |
Korro Bio, Inc. |
Methods and compositions for the adar-mediated editing of argininosuccinate lyase (asl)
|
WO2021231827A2
(en)
|
2020-05-15 |
2021-11-18 |
Life Technologies Corporation |
Sirna sequences targeting coronavirus-2
|
WO2021231679A1
(en)
|
2020-05-15 |
2021-11-18 |
Korro Bio, Inc. |
Methods and compositions for the adar-mediated editing of gap junction protein beta 2 (gjb2)
|
EP4150086A1
(de)
|
2020-05-15 |
2023-03-22 |
Korro Bio, Inc. |
Verfahren und zusammensetzungen zur adar-vermittelten bearbeitung von leucinreicher repeat-kinase 2 (lrrk2)
|
WO2021237097A1
(en)
|
2020-05-21 |
2021-11-25 |
Alnylam Pharmaceuticals, Inc. |
Compositions and methods for inhibiting marc1 gene expression
|
CN115885042A
(zh)
|
2020-05-22 |
2023-03-31 |
波涛生命科学有限公司 |
双链寡核苷酸组合物及其相关方法
|
AR122534A1
(es)
|
2020-06-03 |
2022-09-21 |
Triplet Therapeutics Inc |
Métodos para el tratamiento de los trastornos de expansión por repetición de nucleótidos asociados con la actividad de msh3
|
WO2021248052A1
(en)
|
2020-06-05 |
2021-12-09 |
The Broad Institute, Inc. |
Compositions and methods for treating neoplasia
|
EP4162050A1
(de)
|
2020-06-09 |
2023-04-12 |
Alnylam Pharmaceuticals, Inc. |
Rnai-zusammensetzungen und verfahren zur verwendung davon zur verabreichung durch inhalation
|
IL299063A
(en)
|
2020-06-18 |
2023-02-01 |
Alnylam Pharmaceuticals Inc |
Xanthine dehydrogenase (xdh) RNA compositions and methods of using them
|
WO2021257262A1
(en)
|
2020-06-19 |
2021-12-23 |
Yale University |
Poly(amine-co-ester) polymers with modified end groups and enhanced pulmonary delivery
|
MX2022015765A
(es)
|
2020-06-24 |
2023-03-27 |
Vir Biotechnology Inc |
Anticuerpos modificados neutralizadores del virus de la hepatitis b y sus usos.
|
KR20230027235A
(ko)
|
2020-06-25 |
2023-02-27 |
신톡스, 인크. |
Il-2 콘쥬게이트 및 항-egfr 항체를 사용한 면역 종양학 병용 요법
|
IL298530A
(en)
|
2020-06-29 |
2023-01-01 |
Ionis Pharmaceuticals Inc |
Compounds and methods for modulating plp1
|
US20230235315A1
(en)
|
2020-07-10 |
2023-07-27 |
Horizon Discovery Limited |
Method for producing genetically modified cells
|
WO2022015600A2
(en)
|
2020-07-13 |
2022-01-20 |
Singular Genomics Systems, Inc. |
Methods of sequencing complementary polynucleotides
|
IL300283A
(en)
|
2020-08-04 |
2023-04-01 |
Dicerna Pharmaceuticals Inc |
Systemic administration of oligonucleotides
|
EP4193151A1
(de)
|
2020-08-04 |
2023-06-14 |
Abbott Rapid Diagnostics International Unlimited Company |
Assays zum nachweis von sars-cov-2
|
KR20230066149A
(ko)
|
2020-08-07 |
2023-05-12 |
포티스 테라퓨틱스, 인크. |
Cd46을 표적화하는 면역접합체 및 이의 사용 방법
|
WO2022038521A1
(en)
|
2020-08-18 |
2022-02-24 |
Regenacellx.SL |
Compositions and methods for detecting sars-cov-2 spike protein
|
US20230265214A1
(en)
|
2020-08-31 |
2023-08-24 |
Yale University |
Compositions and methods for delivery of nucleic acids to cells
|
TW202227102A
(zh)
|
2020-09-22 |
2022-07-16 |
瑞典商阿斯特捷利康公司 |
治療脂肪肝病之方法
|
WO2022066847A1
(en)
|
2020-09-24 |
2022-03-31 |
Alnylam Pharmaceuticals, Inc. |
Dipeptidyl peptidase 4 (dpp4) irna compositions and methods of use thereof
|
WO2022070107A1
(en)
|
2020-09-30 |
2022-04-07 |
Crispr Therapeutics Ag |
Materials and methods for treatment of amyotrophic lateral sclerosis
|
TW202229552A
(zh)
|
2020-10-05 |
2022-08-01 |
美商艾拉倫製藥股份有限公司 |
G蛋白-偶合受體75(GPR75)iRNA組成物及其使用方法
|
EP3978608A1
(de)
|
2020-10-05 |
2022-04-06 |
SQY Therapeutics |
Oligomere verbindung zur dystrophinrettung in dmd-patienten während des skipping exon-51
|
CA3194880A1
(en)
|
2020-10-09 |
2022-04-14 |
Carolina E. CAFFARO |
Immuno oncology therapies with il-2 conjugates
|
IL301611A
(en)
|
2020-10-09 |
2023-05-01 |
Synthorx Inc |
Combined immuno-oncology treatment with pairs of IL-2 and pembrolizumab
|
EP4228637A1
(de)
|
2020-10-15 |
2023-08-23 |
Yeda Research and Development Co. Ltd |
Verfahren zur behandlung von myeloidmalignitäten
|
US20240092819A1
(en)
|
2020-10-20 |
2024-03-21 |
Sanofi |
Novel ligands for asialoglycoprotein receptor
|
EP4232581A1
(de)
|
2020-10-21 |
2023-08-30 |
Alnylam Pharmaceuticals, Inc. |
Verfahren und zusammensetzungen zur behandlung von primärer hyperoxalurie
|
EP4232582A1
(de)
|
2020-10-23 |
2023-08-30 |
Alnylam Pharmaceuticals, Inc. |
Mucin-5b (muc5b)-irna-zusammensetzungen und verfahren zur verwendung davon
|
TW202237841A
(zh)
|
2020-11-13 |
2022-10-01 |
美商艾拉倫製藥股份有限公司 |
凝血因子V(F5)iRNA組成物及其使用方法
|
IL302817A
(en)
|
2020-11-18 |
2023-07-01 |
Ionis Pharmaceuticals Inc |
Compounds and methods for modulating angiotensinogen expression
|
WO2022106695A1
(en)
|
2020-11-23 |
2022-05-27 |
Alpha Anomeric Sas |
Nucleic acid duplexes
|
TW202237826A
(zh)
|
2020-11-30 |
2022-10-01 |
瑞士商克里斯珀醫療股份公司 |
基因編輯的自然殺手細胞
|
CA3201452A1
(en)
|
2020-12-01 |
2022-06-09 |
Alnylam Pharmaceuticals, Inc. |
Methods and compositions for inhibition of hao1 (hydroxyacid oxidase 1 (glycolate oxidase)) gene expression
|
EP4259795A1
(de)
|
2020-12-08 |
2023-10-18 |
Alnylam Pharmaceuticals, Inc. |
Gerinnungsfaktor x (f10)-irna-zusammensetzungen und verfahren zur verwendung davon
|
GB2603454A
(en)
|
2020-12-09 |
2022-08-10 |
Ucl Business Ltd |
Novel therapeutics for the treatment of neurodegenerative disorders
|
GB202019692D0
(en)
|
2020-12-14 |
2021-01-27 |
Apterna Ltd |
Aptamer-sirna fusions
|
WO2022140126A1
(en)
|
2020-12-21 |
2022-06-30 |
The United States Of America, As Represented By The Secretary, Department Of Health And Human Services |
Dna vector and uses thereof for detecting hiv and siv
|
WO2022140535A1
(en)
|
2020-12-23 |
2022-06-30 |
Sarepta Therapeutics, Inc. |
Compositions comprising exon skipping oligonucleotide conjugates for treating muscular dystrophy
|
US20240175020A1
(en)
|
2020-12-23 |
2024-05-30 |
Flagship Pioneering Innovations Vi, Llc |
Compositions of modified trems and uses thereof
|
WO2022144632A1
(en)
|
2020-12-30 |
2022-07-07 |
Crispr Therapeutics Ag |
Compositions and methods for differentiating stem cells into nk cells
|
KR20230146008A
(ko)
|
2020-12-31 |
2023-10-18 |
크리스퍼 테라퓨틱스 아게 |
범용 공여자 세포
|
CA3207144A1
(en)
|
2021-01-05 |
2022-07-14 |
Horizon Discovery Limited |
Method for producing genetically modified cells
|
EP4274896A1
(de)
|
2021-01-05 |
2023-11-15 |
Alnylam Pharmaceuticals, Inc. |
Komplementkomponente 9 (c9)-irna-zusammensetzungen und verfahren zur verwendung davon
|
EP4251770A4
(de)
|
2021-02-08 |
2024-05-29 |
Singular Genomics Systems Inc |
Verfahren und zusammensetzungen zur sequenzierung komplementärer polynukleotide
|
AU2022220704A1
(en)
|
2021-02-12 |
2022-08-18 |
Alnylam Pharmaceuticals, Inc. |
Superoxide dismutase 1 (sod1) irna compositions and methods of use thereof for treating or preventing superoxide dismutase 1- (sod1-) associated neurodegenerative diseases
|
TW202302148A
(zh)
|
2021-02-12 |
2023-01-16 |
美商欣爍克斯公司 |
使用il-2接合物和抗pd-1抗體或其抗原結合片段的肺癌組合療法
|
WO2022174101A1
(en)
|
2021-02-12 |
2022-08-18 |
Synthorx, Inc. |
Skin cancer combination therapy with il-2 conjugates and cemiplimab
|
CA3207947A1
(en)
|
2021-02-17 |
2022-08-25 |
Aaron Noyes |
Extracellular vesicle linked to a biologically active molecule via an optimized linker and an anchoring moiety
|
EP4298220A1
(de)
|
2021-02-25 |
2024-01-03 |
Alnylam Pharmaceuticals, Inc. |
Prionprotein (prnp)-irna-zusammensetzungen und verfahren zur verwendung davon
|
BR112023016645A2
(pt)
|
2021-02-26 |
2023-11-14 |
Alnylam Pharmaceuticals Inc |
Composições de irna de ceto-hexoquinase (khk) e métodos de uso das mesmas
|
MX2023010249A
(es)
|
2021-03-04 |
2023-09-15 |
Alnylam Pharmaceuticals Inc |
Composiciones de arni de proteina similar a la angiopoyetina 3 (angptl3) y metodos para usarlas.
|
DE112022001365T5
(de)
|
2021-03-05 |
2024-02-15 |
The Board Of Trustees Of The Leland Stanford Junior University |
In vivo dna zusammenbau und analyse
|
EP4305169A1
(de)
|
2021-03-12 |
2024-01-17 |
Alnylam Pharmaceuticals, Inc. |
Glykogensynthasekinase-3-alpha (gsk3a)-irna-zusammensetzungen und verfahren zur verwendung davon
|
WO2022192038A1
(en)
|
2021-03-12 |
2022-09-15 |
Northwestern University |
Antiviral vaccines using spherical nucleic acids
|
US11884977B2
(en)
|
2021-03-12 |
2024-01-30 |
Singular Genomics Systems, Inc. |
Nanoarrays and methods of use thereof
|
WO2022192671A1
(en)
|
2021-03-12 |
2022-09-15 |
Singular Genomics Systems, Inc. |
Nanoarrays and methods of use thereof
|
CA3214486A1
(en)
|
2021-03-24 |
2022-09-29 |
Genentech, Inc. |
Efficient tcr gene editing in t lymphocytes
|
TW202305134A
(zh)
|
2021-03-29 |
2023-02-01 |
美商艾拉倫製藥股份有限公司 |
杭丁頓蛋白(HTT)iRNA劑組成物及其使用方法
|
EP4314293A1
(de)
|
2021-04-01 |
2024-02-07 |
Alnylam Pharmaceuticals, Inc. |
Prolindehydrogenase 2 (prodh2)-irna-zusammensetzungen und verfahren zur verwendung davon
|
JP2024516168A
(ja)
|
2021-04-22 |
2024-04-12 |
デイナ ファーバー キャンサー インスティチュート,インコーポレイテッド |
がんを治療するための組成物および方法
|
AU2022264478A1
(en)
|
2021-04-26 |
2023-10-12 |
Alnylam Pharmaceuticals, Inc. |
Transmembrane protease, serine 6 (tmprss6) irna compositions and methods of use thereof
|
US11578320B2
(en)
|
2021-04-27 |
2023-02-14 |
Singular Genomics Systems, Inc. |
High density sequencing and multiplexed priming
|
JP2024519293A
(ja)
|
2021-04-29 |
2024-05-10 |
アルナイラム ファーマシューティカルズ, インコーポレイテッド |
シグナル伝達兼転写活性化因子6(STAT6)iRNA組成物およびその使用方法
|
WO2022232478A1
(en)
|
2021-04-30 |
2022-11-03 |
Sarepta Therapeutics, Inc. |
Treatment methods for muscular dystrophy
|
EP4334448A1
(de)
|
2021-05-03 |
2024-03-13 |
Alnylam Pharmaceuticals, Inc. |
Zusammensetzungen und verfahren zur behandlung von transthyretin(ttr)-vermittelter amyloidose
|
WO2022245583A1
(en)
|
2021-05-18 |
2022-11-24 |
Alnylam Pharmaceuticals, Inc. |
Sodium-glucose cotransporter-2 (sglt2) irna compositions and methods of use thereof
|
EP4341405A1
(de)
|
2021-05-20 |
2024-03-27 |
Korro Bio, Inc. |
Verfahren und zusammensetzungen für adar-vermittelte bearbeitung
|
CN115404240A
(zh)
|
2021-05-28 |
2022-11-29 |
上海环码生物医药有限公司 |
制备环形rna的构建体、方法及其用途
|
WO2022251644A1
(en)
|
2021-05-28 |
2022-12-01 |
Lyell Immunopharma, Inc. |
Nr4a3-deficient immune cells and uses thereof
|
WO2022256283A2
(en)
|
2021-06-01 |
2022-12-08 |
Korro Bio, Inc. |
Methods for restoring protein function using adar
|
EP4347826A1
(de)
|
2021-06-02 |
2024-04-10 |
Lyell Immunopharma, Inc. |
Nr4a3-defiziente immunzellen und verwendungen davon
|
TW202317762A
(zh)
|
2021-06-02 |
2023-05-01 |
美商艾拉倫製藥股份有限公司 |
含有類PATATIN磷脂酶結構域3(PNPLA3)的iRNA組成物及其使用方法
|
EP4346903A1
(de)
|
2021-06-03 |
2024-04-10 |
Synthorx, Inc. |
Kopf-hals-krebskombinationstherapie mit einem il-2-konjugat und pembrolizumab
|
IL308743A
(en)
|
2021-06-04 |
2024-01-01 |
Alnylam Pharmaceuticals Inc |
Compositions of human chromosome 9 open reading frame 72 iRNA factor (C9ORF72) and methods of using them
|
WO2022260939A2
(en)
|
2021-06-08 |
2022-12-15 |
Alnylam Pharmaceuticals, Inc. |
Compositions and methods for treating or preventing stargardt's disease and/or retinal binding protein 4 (rbp4)-associated disorders
|
IL308896A
(en)
|
2021-06-11 |
2024-01-01 |
Bayer Ag |
Programmable type V RNA endoclase systems
|
EP4101928A1
(de)
|
2021-06-11 |
2022-12-14 |
Bayer AG |
Programmierbare typ-v-rna-endonukleasesysteme
|
CN117500815A
(zh)
|
2021-06-18 |
2024-02-02 |
Ionis制药公司 |
用于降低ifnar1表达的化合物和方法
|
EP4359527A2
(de)
|
2021-06-23 |
2024-05-01 |
Novartis AG |
Zusammensetzungen und verfahren zur behandlung von hämoglobinopathien
|
US20230016422A1
(en)
|
2021-06-23 |
2023-01-19 |
Crispr Therapeutics Ag |
Engineered cells with improved protection from natural killer cell killing
|
EP4363574A1
(de)
|
2021-06-29 |
2024-05-08 |
Korro Bio, Inc. |
Verfahren und zusammensetzungen für adar-vermittelte bearbeitung
|
US20230194709A9
(en)
|
2021-06-29 |
2023-06-22 |
Seagate Technology Llc |
Range information detection using coherent pulse sets with selected waveform characteristics
|
WO2023278576A1
(en)
|
2021-06-30 |
2023-01-05 |
Alnylam Pharmaceuticals, Inc. |
Methods and compositions for treating an angiotensinogen- (agt-) associated disorder
|
WO2023285431A1
(en)
|
2021-07-12 |
2023-01-19 |
Alia Therapeutics Srl |
Compositions and methods for allele specific treatment of retinitis pigmentosa
|
WO2023003805A1
(en)
|
2021-07-19 |
2023-01-26 |
Alnylam Pharmaceuticals, Inc. |
Methods and compositions for treating subjects having or at risk of developing a non-primary hyperoxaluria disease or disorder
|
AU2022316139A1
(en)
|
2021-07-23 |
2024-01-18 |
Alnylam Pharmaceuticals, Inc. |
Beta-catenin (ctnnb1) irna compositions and methods of use thereof
|
WO2023009687A1
(en)
|
2021-07-29 |
2023-02-02 |
Alnylam Pharmaceuticals, Inc. |
3-hydroxy-3-methylglutaryl-coa reductase (hmgcr) irna compositions and methods of use thereof
|
WO2023014677A1
(en)
|
2021-08-03 |
2023-02-09 |
Alnylam Pharmaceuticals, Inc. |
Transthyretin (ttr) irna compositions and methods of use thereof
|
AU2022324003A1
(en)
|
2021-08-04 |
2024-02-08 |
Alnylam Pharmaceuticals, Inc. |
iRNA COMPOSITIONS AND METHODS FOR SILENCING ANGIOTENSINOGEN (AGT)
|
IL310407A
(en)
|
2021-08-13 |
2024-03-01 |
Alnylam Pharmaceuticals Inc |
Factor XII (F12) IRNA compositions and methods of using them
|
WO2023034870A2
(en)
|
2021-09-01 |
2023-03-09 |
Ionis Pharmaceuticals, Inc. |
Compounds and methods for reducing dmpk expression
|
WO2023034515A2
(en)
|
2021-09-03 |
2023-03-09 |
Sarepta Therapeutics, Inc. |
Delivery of anitsense oligomers by mirror image peptides
|
WO2023034920A2
(en)
|
2021-09-03 |
2023-03-09 |
Singular Genomics Systems, Inc. |
Amplification oligonucleotides
|
EP4144841A1
(de)
|
2021-09-07 |
2023-03-08 |
Bayer AG |
Neue programmierbare rna-endonuklease-systeme mit verbesserter pam-spezifität und deren verwendung
|
WO2023044370A2
(en)
|
2021-09-17 |
2023-03-23 |
Alnylam Pharmaceuticals, Inc. |
Irna compositions and methods for silencing complement component 3 (c3)
|
AU2022345881A1
(en)
|
2021-09-20 |
2024-03-21 |
Alnylam Pharmaceuticals, Inc. |
Inhibin subunit beta e (inhbe) modulator compositions and methods of use thereof
|
WO2023055774A1
(en)
|
2021-09-30 |
2023-04-06 |
Sarepta Therapeutics, Inc. |
Antisense oligonucleotides having one or more abasic units
|
US20230096386A1
(en)
|
2021-09-30 |
2023-03-30 |
Illumina Cambridge Limited |
Polynucleotide sequencing
|
WO2023070086A1
(en)
|
2021-10-22 |
2023-04-27 |
Sarepta Therapeutics, Inc. |
Morpholino oligomers for treatment of peripheral myelin protein 22 related diseases
|
WO2023069603A1
(en)
|
2021-10-22 |
2023-04-27 |
Korro Bio, Inc. |
Methods and compositions for disrupting nrf2-keap1 protein interaction by adar mediated rna editing
|
WO2023076451A1
(en)
|
2021-10-29 |
2023-05-04 |
Alnylam Pharmaceuticals, Inc. |
Complement factor b (cfb) irna compositions and methods of use thereof
|
TW202334418A
(zh)
|
2021-10-29 |
2023-09-01 |
美商艾拉倫製藥股份有限公司 |
杭丁頓(HTT)iRNA劑組成物及其使用方法
|
CA3237769A1
(en)
|
2021-11-10 |
2023-05-19 |
University Of Rochester |
Gata4-targeted therapeutics for treatment of cardiac hypertrophy
|
WO2023086295A2
(en)
|
2021-11-10 |
2023-05-19 |
University Of Rochester |
Antisense oligonucleotides for modifying protein expression
|
GB202117758D0
(en)
|
2021-12-09 |
2022-01-26 |
Ucl Business Ltd |
Therapeutics for the treatment of neurodegenerative disorders
|
WO2023122573A1
(en)
|
2021-12-20 |
2023-06-29 |
Synthorx, Inc. |
Head and neck cancer combination therapy comprising an il-2 conjugate and pembrolizumab
|
WO2023118349A1
(en)
|
2021-12-21 |
2023-06-29 |
Alia Therapeutics Srl |
Type ii cas proteins and applications thereof
|
WO2023118068A1
(en)
|
2021-12-23 |
2023-06-29 |
Bayer Aktiengesellschaft |
Novel small type v rna programmable endonuclease systems
|
WO2023122750A1
(en)
|
2021-12-23 |
2023-06-29 |
Synthorx, Inc. |
Cancer combination therapy with il-2 conjugates and cetuximab
|
US20230212667A1
(en)
|
2021-12-29 |
2023-07-06 |
Illumina Cambridge Limited |
Methods of nucleic acid sequencing using surface-bound primers
|
US11857961B2
(en)
|
2022-01-12 |
2024-01-02 |
Miroculus Inc. |
Sequencing by synthesis using mechanical compression
|
WO2023141314A2
(en)
|
2022-01-24 |
2023-07-27 |
Alnylam Pharmaceuticals, Inc. |
Heparin sulfate biosynthesis pathway enzyme irna agent compositions and methods of use thereof
|
WO2023159189A1
(en)
|
2022-02-18 |
2023-08-24 |
Yale University |
Branched poly(amine-co-ester) polymers for more efficient nucleic expression
|
WO2023168427A1
(en)
|
2022-03-03 |
2023-09-07 |
Yale University |
Compositions and methods for delivering therapeutic polynucleotides for exon skipping
|
WO2023172885A1
(en)
|
2022-03-09 |
2023-09-14 |
The Board Of Trustees Of The Leland Stanford Junior University |
Branched lipid charge-altering releasable transporters for nucleic acid delivery
|
WO2023172665A2
(en)
|
2022-03-10 |
2023-09-14 |
Singular Genomics Systems, Inc. |
Nucleic acid delivery scaffolds
|
WO2023178230A1
(en)
|
2022-03-17 |
2023-09-21 |
Sarepta Therapeutics, Inc. |
Phosphorodiamidate morpholino oligomer conjugates
|
WO2023177866A1
(en)
|
2022-03-18 |
2023-09-21 |
Dicerna Pharmaceuticals, Inc. |
Decarboxylative acetoxylation using mn(ii) or mn(iii) reagent for synthesis of 4'-acetoxy- nucleoside and use thereof for synthesis of corresponding 4'-(dimethoxyphosphoryl)methoxy- nucleotide
|
WO2023194359A1
(en)
|
2022-04-04 |
2023-10-12 |
Alia Therapeutics Srl |
Compositions and methods for treatment of usher syndrome type 2a
|
WO2023212293A1
(en)
|
2022-04-29 |
2023-11-02 |
Broadwing Bio Llc |
Complement factor h related 4-specific antibodies and uses thereof
|
WO2023212294A1
(en)
|
2022-04-29 |
2023-11-02 |
Broadwing Bio Llc |
Angiopoietin-related protein 7-specific antibodies and uses thereof
|
WO2023212298A1
(en)
|
2022-04-29 |
2023-11-02 |
Broadwing Bio Llc |
Bispecific antibodies and methods of treating ocular disease
|
WO2023225665A1
(en)
|
2022-05-19 |
2023-11-23 |
Lyell Immunopharma, Inc. |
Polynucleotides targeting nr4a3 and uses thereof
|
WO2023230201A1
(en)
|
2022-05-26 |
2023-11-30 |
The Board Of Trustees Of The Leland Stanford Junior University |
Small molecule conjugated charge-altering releasable transporters for nucleic acid delivery
|
WO2023231959A2
(en)
|
2022-05-30 |
2023-12-07 |
Shanghai Circode Biomed Co., Ltd |
Synthetic circular rna compositions and methods of use thereof
|
WO2023233339A1
(en)
|
2022-06-01 |
2023-12-07 |
Crispr Therapeutics Ag |
Compositions and methods for differentiating stem cells into nk cells
|
WO2023233342A2
(en)
|
2022-06-01 |
2023-12-07 |
Crispr Therapeutics Ag |
Gene-edited natural killer cells
|
WO2023237587A1
(en)
|
2022-06-10 |
2023-12-14 |
Bayer Aktiengesellschaft |
Novel small type v rna programmable endonuclease systems
|
WO2024006477A1
(en)
|
2022-06-29 |
2024-01-04 |
Life Technologies Corporation |
Multiplex dye compounds
|
WO2024015924A2
(en)
|
2022-07-15 |
2024-01-18 |
Entrada Therapeutics, Inc. |
Hybrid oligonucleotides
|
WO2024015962A1
(en)
|
2022-07-15 |
2024-01-18 |
Pacific Biosciences Of California, Inc. |
Blocked asymmetric hairpin adaptors
|
WO2024026474A1
(en)
|
2022-07-29 |
2024-02-01 |
Regeneron Pharmaceuticals, Inc. |
Compositions and methods for transferrin receptor (tfr)-mediated delivery to the brain and muscle
|
WO2024039776A2
(en)
|
2022-08-18 |
2024-02-22 |
Alnylam Pharmaceuticals, Inc. |
Universal non-targeting sirna compositions and methods of use thereof
|
WO2024044352A1
(en)
|
2022-08-26 |
2024-02-29 |
The General Hospital Corporation |
Methods and compositions for prognosis and treatment of dilated cardiomyopathy and heart failure
|
WO2024050261A1
(en)
|
2022-08-29 |
2024-03-07 |
University Of Rochester |
Antisense oligonucleotide-based anti-fibrotic therapeutics
|
WO2024059165A1
(en)
|
2022-09-15 |
2024-03-21 |
Alnylam Pharmaceuticals, Inc. |
17b-hydroxysteroid dehydrogenase type 13 (hsd17b13) irna compositions and methods of use thereof
|
WO2024056880A2
(en)
|
2022-09-16 |
2024-03-21 |
Alia Therapeutics Srl |
Enqp type ii cas proteins and applications thereof
|
WO2024064237A2
(en)
|
2022-09-21 |
2024-03-28 |
Sarepta Therapeutics, Inc. |
Dmd antisense oligonucleotide-mediated exon skipping efficiency
|
WO2024073440A1
(en)
|
2022-09-27 |
2024-04-04 |
Genentech, Inc. |
Inhibition of genotoxic stress to improve t cell engineering
|
WO2024073040A1
(en)
|
2022-09-29 |
2024-04-04 |
The Board Of Trustees Of The Leland Stanford Junior University |
C-myc-targeting charge-altering releasable transporters as anti-tumor agents for breast cancer therapy
|
WO2024081736A2
(en)
|
2022-10-11 |
2024-04-18 |
Yale University |
Compositions and methods of using cell-penetrating antibodies
|
WO2024091824A1
(en)
|
2022-10-26 |
2024-05-02 |
Ada Forsyth Institute, Inc. |
Differentiation and reprogramming of chondrocyte
|
WO2024094125A1
(en)
|
2022-11-03 |
2024-05-10 |
Shanghai Circode Biomed Co., Ltd. |
Lipid compounds, lipid nanoparticles, and pharmaceutical compositions
|
WO2024098002A1
(en)
|
2022-11-04 |
2024-05-10 |
Regeneron Pharmaceuticals, Inc. |
Calcium voltage-gated channel auxiliary subunit gamma 1 (cacng1) binding proteins and cacng1-mediated delivery to skeletal muscle
|
WO2024102797A1
(en)
|
2022-11-08 |
2024-05-16 |
The Board Of Trustees Of The Leland Stanford Junior University |
Charge-altering nucleic acid transporters with beta-amido carbonate backbones
|
WO2024104914A1
(en)
|
2022-11-14 |
2024-05-23 |
BioNTech SE |
Rna capping efficiency assay
|
WO2024107765A2
(en)
|
2022-11-14 |
2024-05-23 |
Regeneron Pharmaceuticals, Inc. |
Compositions and methods for fibroblast growth factor receptor 3-mediated delivery to astrocytes
|
WO2024105162A1
(en)
|
2022-11-16 |
2024-05-23 |
Alia Therapeutics Srl |
Type ii cas proteins and applications thereof
|